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ABSTRACT

Clostridium difficile infection (CDI) is a serious problem within 
the healthcare environment where the bacterium causes symptoms 
ranging from mild diarrhoea to life-threatening colitis. In addition to 
its principal virulent factors, Toxin A and Toxin B, some C. difficile 
strains produce a binary toxin (CDT) composed of two subunits 
namely CDTa and CDTb that are produced and secreted from the 
cell as two separate polypeptides. Once in the gut, these fragments 
have the potential to combine to form a potent cytotoxin whose role 
in the pathogenesis of CDI is presently unclear. This thesis is a step 
towards understanding structural and functional aspects of the 
binary toxin produced by C. difficile. 
The first half of this thesis (chapter I and II) provides a brief 
introduction to the method of structure determination of proteins 
molecules, i. e. X-ray crystallography and a detailed overview of C. 
difficile and the three known toxins from C. difficile namely – Toxin 
A, Toxin B and the binary toxin. Chapter II further focuses on C. 
difficile binary toxin and other related toxins. These toxins, known 
as the ADP-ribosylating toxins (ADPRTs) form a big family of potent 
toxins which includes Cholera, Pertussis and Diphtheria toxins and 
are capable of transferring the ADP-ribose part of NAD/NADPH to a 
varity of substrates in the target cell which ultimately results in cell 
death. 
The second half of the thesis comprises of experimental 
procedures that were carried out during the course of this study 
and their results. Cloning and expression methods for recombinant 
CDTa and CDTb in bacterial system followed by their purification 
are described with the abnormal behaviour exhibited by CDTb 
(chapter III). We show for the first time that purified CDTa and 
CDTb can combine to form an active CDT which is cytotoxic to Vero 
cells (Chapter IV). The purification processes described yielded 
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milligram quantities of binary toxin fragments of high purity that 
led to the successful crystallisation of the proteins (chapter IV) for 
further functional and structural studies. 
High resolution crystal structures of CDTa in its native form (at 
pH 4.0, 8.5 and 9.0) and in complex with the ADP ribose donors -
NAD and NADPH (at pH 9.0) have been determined (chapter V). The 
crystal structures of the native protein show ‘pronounced 
conformational flexibility’ confined to the active site region of the 
protein and ‘enhanced’ disorder at low pH while the complex 
structures highlight significant differences in ‘ligand specificity’ 
compared with the enzymatic subunit of a close homologue, 
Clostridium perfringens Iota toxin (Ia). These structural data provide 
the first detailed information on protein- donor substrate complex 
stabilisation in CDTa which may have implications in 
understanding CDT recognition. Crystallisation of CDTb yielded 
preliminary crystals. The optimisation of these crystallisation 
conditions is underway. The thesis concludes with some thoughts 
and discussion on future directions of this research. 
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CHAPTER - I 
INTRODUCTION TO MACROMOLECULAR

CRYSTALLOGRAPHY
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Introduction 
Proteins are biomolecules of fundamental importance to any organism 
from unicellular to multicellular composition. They are one of the building 
blocks of the basic unit of life i. e. the cell. Proteins play a vital role in most of 
the cellular events such as cell growth and differentiation, signal transduction, 
providing mechanical strength to tissues, immune protection, storage and 
transport, coordinated motion of muscles and catalysis of metabolism. 
Structure determination of a protein molecule (and other biomolecules) at 
atomic resolution provides insight into its function, mechanism of recognition 
of substrates and the conformational changes they might undergo (Blow, 
2002). The area of protein crystallography is not only of academic relevance 
but it is also an important gateway to structure based drug design or 
development of therapeutics such as engineered antibodies and enzymes to 
alter functional capabilities of biomolecules. 
X-ray crystallography is one of the various scientific methods available 
to determine and study the three dimensional structures of small inorganic or 
organic molecules and large biological macromolecules (Nucleic acids, proteins 
and their complexes). However, amongst all available methods, X-ray 
crystallography is the most favoured method for studying biological 
macromolecular structures because of its unique advantage of providing 
details at almost atomic resolution, its accuracy and reproducibility. 
Why X-rays and Why Crystals 
Biological molecules are very tiny objects with their largest dimensions 
in Å (C-C bond is 1.54 Å, 1 Å = 10-8 cm). In principle, an object can be seen 
only if the wavelength of electromagnetic radiation used to see it is of the order 
of its size. Hence, the atomic details can not be resolved by using visible 
radiations (wavelength of 4000-7000 Å). X-rays have wavelength in the range 
of 100 to 0.1 Å and thus towards the lower side of their spectra, they fulfil the 
above requirement and can be used to visualise molecules up to a resolution 
that is of the order of bond lengths. Typical wavelengths used for X-ray 
crystallography experiments lie in the range of 1.0 to 1.54 Å. 
Direct result of an X-ray crystallography experiment is the diffraction 
pattern of a molecule. The diffraction pattern of any molecule is its 
characteristic property that depends on the number of electrons present, their 
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relative orientation in the molecule and their location in the crystal. Diffraction 
from a single molecule is not strong enough to be detected above the noice 
level on a detector. In a crystal, identical molecules of substance are arranged 
in a regular repetitive fashion and thus they all diffract the incident X-ray 
beam in an identical manner in all directions. Diffraction from millions of 
identical molecules in same direction adds up and the signal can be detected 
easily. In other words, crystals act as an amplifier to amplify diffraction 
intensities of reflected X-rays. 
Steps Involved in Structure Determination 
In principle, the process of structure determination by X-ray 
crystallography is carried out by following a series of steps essentially in an 
order as shown in figure 1.1. 
Figure 1.1: The steps involved in the structure determination process of 
proteins by X-ray crystallography. (Figure partly adopted from 
http://en.wikipedia.org/wiki/X-ray_crystallography). 
However, the process of structure determination is not as simple and 
straightforward as it is illustrated above. An image of the molecule can not be 
drawn directly because of the unavailability of a lens to focus and recollect all 
scattered X-rays from the object which is a must condition (Blow, 2002). 
Therefore, the image of the molecule is generated by indirect methods 
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involving complex mathematical operations with the help of very fast and 
modern computers. Each step involved in the process of crystallographic 
structure determination is explained below in detail. 
Cloning and Expression of Proteins 
The first and foremost requirement in X-ray crystallography is the 
availability of good quality crystals. The process of structure determination by 
means of X-ray crystallography starts with the availability of a large quantity 
of extremely pure (generally > 95 % pure) homogeneous protein. As a rule of 
thumb, the diffraction data quality, up to a large extent, depends on the 
quality of crystals which in turn basically depends on the quality (i. e. purity 
and homogeneity) of the protein in hand. 
Recombinant DNA technology provides excellent tools to produce a 
sufficient amount of protein in a cost and time effective manner. Discovery of 
several enzyme systems (and understanding of their mechanism of action) that 
play a vital role in the ‘essential to survive’ processes of central dogma (DNA, 
RNA and protein metabolism) have made molecular cloning almost a routine 
experiment in the laboratories these days. 
In brief, coding DNA for the target protein can be identified. The DNA 
can be isolated from living cells and amplified in vitro using polymerase chain 
reaction (PCR) with the help of suitable oligonucleotide (primer) sequences and 
DNA polymerising enzymes. As an alternative way, coding DNA sequence for 
any naturally existing or hypothetical peptide sequence can be synthesised 
chemically. Ends of the PCR amplified or commercially synthesized DNA can 
be modified according to the convenience in order to construct suitable 
expression clones. 
With the help of carefully chosen sequence specific restriction enzymes, 
this DNA fragment (called an insert or transgene) can be cut and inserted into 
a vector DNA that has compatible ends. These ends can then be sealed by 
using DNA ligase enzyme to produce a ‘chimeric or recombinant DNA’. 
Positioning of the insert into the vector backbone can be regulated precisely to 
ensure that the inserted DNA is read in the correct reading frame. It is 
necessary to avoid an immature termination of transcription (and translation) 
and therefore, production of a mis-sense or nonsense mRNA (and thus 
protein), in vivo. The recombinant DNA is then inserted into a suitable host 
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organism where it replicates, transcribes and translates itself by exploiting the 
host cell machinery in a ‘semi independent’ manner. 
Vector DNA is defined as a ‘cloning vehicle’ that has a property of self 
replication. Vectors, called expression vectors, are specific to carry out 
expression of the transgene in the host cell. These vectors generally have a 
promoter and other conserved sequences that are necessary for transcription 
of the transgene and translation of the resulting mRNA. Simpler vectors (called 
cloning vectors) can only replicate in the host cell but can not transcribe the 
gene and thus do not result in the expression of desired protein. Unlike 
expression vectors, cloning vectors are used only for in vivo amplification of 
the insert. 
Plasmids are the most widely used cloning vectors. They are double-
stranded, generally circular DNA sequences consisting of an ‘origin of 
replication’ that allows for a semi-independent replication of the plasmid in the 
host. Plasmids have a multiple cloning site (MCS) which consists of various 
restriction enzyme consensus sequences. The MCS provides freedom to choose 
a combination of available restriction sites for cloning purpose with a choice of 
reading frame to read the transgene. 
In addition to plasmids, many other cloning vehicles such as cosmids, 
phasmids, viral vectors, bacterial artificial chromosome (BAC) and Yeast 
artificial chromosome (YAC) are also available and are used when convenient. 
Each type of vector has its own set of advantages and disadvantages over 
others. 
Almost all vectors bear a positive selection marker usually in the form 
of a gene that translates for an antibiotic resistance. This property of a vector 
serves two elementary purposes. Firstly, it acts as a selection pressure on the 
host and only vector bearing cells (positive cells) can survive on a growth 
medium that contains that particular antibiotic. Secondly, in the presence of 
selection pressure (antibiotic containing medium) it becomes mandatory for 
the host to carry and maintain (replicate, transcribe and translate) the vector 
in order to survive against the applied selection pressure. Since the gene of 
interest is also contained by the vector, under favourable conditions, a good 
yield of recombinant protein is produced by the host. 
Expression vectors exhibit diversity in their expression patterns. It can 
either be constitutive (consistent expression) or inducible (expression only 
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under the influence of certain growth conditions or chemicals). Expression 
pattern is a characteristic of the promoter that is present in the vector. 
Inducible expression depends on promoters that respond to specific induction 
conditions. Inducers are added to the growth medium and taken up by the 
host cell in order to start transcription of the inserted gene and hence 
translation of the target protein. 
The next step is to select a suitable host organism for expression of the 
target protein. There are several different host systems available. They can be 
classified as animal cell, plant cell, yeast cells, insect cell and bacterial cell 
systems. It is possible to divert metabolism of the expression host towards 
overexpression of the target protein by providing it specific growth conditions 
such as substrates, aeration, effectors (inducers and enhancers) and 
temperature. However, the growth condition requirements of host systems 
differ from each other. The host system is chosen depending upon the nature 
of target protein. For example, if the target protein is of eukaryotic origin and 
requires heavy posttranslational modifications (an antibody molecule, for 
example), an eukaryotic expression system (animal cell, insect cells or yeast 
cell culture) is chosen whereas if the target protein is simple (for example a 
protein of bacterial origin) and does not require any post translational 
modification machinery, it can be expressed in prokaryotic expression 
systems. 
Plant cell cultures suffer from the disadvantage of very slow growth rate 
and hence are very rarely used systems. Animal cells are commonly used to 
express proteins of eukaryotic origin but respond to a narrow range of growth 
conditions such as substrate, pH and temperature. Bacterial expression 
systems and specially E. coli bacterial cells are the most widely used 
prokaryotic host systems. They are easy to manipulate genetically and provide 
a high expression rate due to their fast metabolism and short doubling time 
which is beneficial to produce a large amount of the target protein in a 
relatively short period of time. 
Generally, proteins are expressed as fusion proteins with a suitable ‘tag’ 
that is of great help in the down streaming processes. Fusion proteins are 
created by joining two or more genes which originally code for two separate 
proteins, one of which is the target protein. Translation of the fusion gene 
results in a single polypeptide with functional properties derived from each of 
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the original proteins. Production of proteins as ‘fusion proteins’ overcomes 
many of the expression-purification associated problems. Fusing the target 
protein to a suitable tag sometime enhances the fusion protein expression and 
may retain the expressed fusion protein in soluble form. Another important 
advantage of the tag is in purification as discussed in the next section. Both of 
the genes (tag and target) can be linked via a linker DNA region that codes for 
a peptide sequence which can be recognised by suitable protease. The fusion 
partner (tag) can then be cleaved off from the target protein by using these 
specific proteases at a carefully chosen suitable step during purification. 
Protein Purification 
As indicated earlier, quality of the protein to start with is one of the 
bottle necks in the process of crystallographic structure determination of 
proteins. No matter what expression system is used to overexpress the target 
protein, it would be expressed along with several of other proteins that are 
normally produced by the host. The aim of the purification process is to isolate 
the target protein from such a crude mixture of proteins. In principle, a 
protein should be more than 95 % pure for crystallisation purpose. 
The overexpressed protein can be released by lysing the host cells and 
purified either from the crude cell lysate (in the case of soluble proteins) or 
from inclusion bodies (aggregated form of proteins). There are several 
techniques available to break open the cells such as mechanical disruption, 
liquid homogenisation, sonication, freeze/thaw and the enzyme mediated cell 
lysis. The choice of cell lysis method depends on how sensitive the protein is, 
the amount to be processed, how sturdy the cells are and the location of the 
target protein (compartmentalisation). After extraction, soluble proteins can be 
separated from cell membranes, DNA and insoluble proteins by centrifugation, 
prior to their purification whereas insoluble proteins (inclusion bodies) need to 
be solubilised first and then refolded prior to or during the purification 
procedure. Sometimes, the target protein is released into the growth media by 
the expression host which is mostly the case with animal cell cultures. 
Ease of the purification process depends on the nature of 
compartmentalisation of the expressed protein as well as on the stability of the 
protein under the chosen physiochemical environment. Different 
physiochemical and biological properties of proteins can be used to develop 
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purification strategies ensuring high recovery of the purest form of 
homogeneous, stable and non-denatured protein. Listed in table 1.1 are four 
most basic properties that can be used. 
Table 1.1: Different properties of proteins that form the basis for different 
purification strategies. 
S. No Property Based on Example 
1 Biological activity specific interaction Affinity 
Chromatography 
2 Charge Net surface charge Ion exchange 
Chromatography 
3 Size Molecular weight Gel permeation 
Chromatography 
4 Solubility Hydrophobic 
interactions 
Reverse phase 
Chromatography 
All of the different chromatography processes described above rely on 
the distribution of target substance (protein) in two phases known as the 
stationary and the mobile phase. The mobile phase with substance (and 
impurities) is passed through the stationary phase where different components 
get separated based on their distribution coefficient between the two chosen 
phases. 
Affinity chromatography takes advantage of the biological activity and 
specificity exhibited by one molecule towards the other such as antibody-
antigen and enzyme–substrate systems. Generally to facilitate the purification 
using affinity chromatography, the target protein is expressed as a fusion 
protein with a tag at the N or the C terminal of the target protein (page 7). The 
most commonly used tags are poly-Histidine tag (His-tag), glutathione S-
transferase (GST) tag and maltose binding protein (MBP). These tags (and thus 
fusion proteins) bind to specific molecules that have been immobilised on a 
stationary support matrix and thus can be trapped. Release of the bound tag 
(or the fusion protein) can then be achieved by altering physiochemical 
conditions of the mobile phase so as to alter its (tag’s) affinity for the 
immobilised material or by using a substrate that competes with the tag to 
bind to the immobilised purification matrix. For example, proteins with a poly-
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Histidine extension (His tag) can be trapped by a nickel chelating matrix and 
the bound proteins can then be released from the matrix by passing imidazole 
through the matrix which competes with the His-tag for binding to nickel ions 
immobilised on the matrix because of the imidazole ring that is present in 
Histidine. 
Ion exchange chromatography exploits the charge property of the 
protein and is based on the coulombic interactions between the protein 
molecules and the stationary phase. Amino acids and hence proteins exhibit 
zwitter ion characterises. The isoelectric point (pI) of a zwitter ion is defined as 
the pH value at which it acquires a net zero charge. At any pH below its pI, the 
zwitter ion possesses a net positive charge whereas at a pH above its pI, it 
possesses a net negative charge. By choosing suitable buffer conditions, 
proteins can be forced to bind to an immobilised matrix of complementary 
charge (negatively charged proteins on a positively charged matrix and vice 
versa). The bound proteins can be released selectively by changing the pH or 
ionic strength of mobile phase and thus can be separated from each other. 
Size exclusion or Gel filtration chromatography (GFC) is a 
separation technique based on the hydrodynamic volume (size in solution) of 
the molecules and hence the separation is achieved on the basis of differences 
in their molecular size. A crude protein sample is passed through a porous 
stationary phase. Larger molecules that can not access the pores exit the 
column more rapidly. Smaller molecules penetrate into the porous structure 
and get trapped according to their size. Retention time of a molecule in the 
pores is indirectly proportional to its molecular weight (size). The smaller the 
molecule, the longer the retention time and thus the later the molecule is 
released from the matrix and vice versa. 
Hydrophobic interaction chromatography is another process, based 
on the hydrophobic interactions between the matrix and the protein molecules 
which can also be used effectively for purification. High pressure can be 
applied to drive the solute faster through a column, thereby improving the 
resolution. The most common form of High Pressure Liquid Chromatography 
(HPLC) (Regnier, 1983) is the “reverse phase” HPLC, where the column 
material is hydrophobic and proteins elute according to their hydrophobicity 
using a gradient of an organic solvent (such as acetonitrile). However, HPLC 
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often causes denaturation of proteins and is sometimes not appropriate for 
molecules that do not spontaneously refold. 
In most of the cases, purification is a multistep process. More than one 
of the strategies listed above are chosen carefully and employed in different 
combinations based on characteristics of the target protein and impurities 
present to achieve highest purity of the target protein. During the process of 
purification, the quality of purified protein is monitored by Sodium Dodecyl 
Sulphate-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) or Western blotting 
analysis from time to time. The quantity of proteins can be monitored by one 
of the several available methods such as absorbance at 280 nm or other 
colorimetric methods like the Bradford’s method or the Lowry’s method. 
Growing Protein Crystals 
The process of crystallisation involves controlled precipitation of the 
protein from its supersaturated aqueous solution such that it does not form 
amorphous aggregates (Rhodes, 2000). The aim of the crystallisation process 
is to produce large diffraction quality crystals. 
Crystallisation of any substance occurs when the concentration of 
substance is higher than that of its saturation limit at that temperature. The 
state of supersaturation is a nonequilibrium state that results in precipitation 
of the substance from solution until the equilibrium state (saturation point) is 
reached. In principle, crystallisation is a two step process: nucleation and 
crystal growth (McPherson, 1999; McPherson, 2004). Nucleation is the step 
where protein molecules start aggregating in a supersaturated protein solution 
by overcoming an energy barrier under given experimental conditions. This is 
then followed by a growth step where more and more protein molecules 
aggregate on the formed nucleus resulting in sufficiently large crystals and the 
entire system attains the state of equilibrium. The process of crystal growth 
can be understood with the help of crystallisation phase diagram (Figure 1.2). 
The phase diagram shows the solubility of a protein in a solution as a 
function of concentration of the protein and the precipitant present. 
Nucleation takes place in the nucleation zone whereas the crystal growth 
occurs in the metastable zone. If the concentration of the protein and/or 
precipitant is not enough for supersaturation to enter in the nucleation zone, 
no crystals would grow. However, if supersaturation is attained too quickly 
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and continues beyond the nucleation zone into the precipitation zone, 
excessive nucleation or an amorphous precipitate may result. To prevent this 
from happening, a careful screening of crystallisation condition variables, such 
as starting protein concentration, crystallising agent (precipitant) 
concentration, pH of solutions and incubation temperature, is needed. This 
process usually requires setting up hundreds of different crystallisation 
conditions. 
Figure 1.2: The crystallisation phase diagram. Zones of undersaturation and 
oversaturations are shown in different colours. 
Though the mechanism of crystal growth is known very well, 
crystallisation is still the key limiting step in the success of structure 
determination process because of the involvement of a large number of 
variables. Each protein requires its own set of conditions to crystallise. Factors 
involved in the process can be classified into two categories. 
1- Controllable parameters – pH, concentration of protein, concentration of 
precipitants, temperature etc. 
2- Uncontrollable parameters – gravity, magnetic and electric field, 
vibrations, kinetics of reaction etc. 
Protein molecules are big in size and have irregular shape. They never 
crystallise without large solvent channels between molecules. The advantage of 
these solvent channels is that their presence provides us an excellent way to 
study ligand binding. Crystals can be soaked with the ligand solution and 
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ligand molecules can diffuse through these channels to the active site and 
bind there. Also, since proteins always remain in contact with the solvent 
while they are in the crystal, the effect of crystal packing is negligible on their 
overall structure and protein structures in crystals resemble their structures 
in free solution. However, the presence of these solvent channels makes 
protein crystals extremely fragile and highly sensitive to their physiochemical 
environment. 
Methods of Protein Crystallisation 
Following are the most commonly used methods of protein 
crystallisation. 
Batch crystallisation method is the most ancient method of 
crystallisation. A large volume of protein is directly mixed with the 
precipitating (crystallising) agent such that the state of supersaturation is 
reached immediately. The system is then left undisturbed for several days to 
achieve slow precipitation of the protein that results in the attainment of 
equilibrium state and thus yields crystals. A variation of this technique known 
as ‘Microbatch’ is also used where a small drop of a mixture of the protein and 
crystallising agent is left undisturbed under a layer of oil. Use of the oil 
prevents evaporation of volatile solvents from the drop. 
In the method of Dialysis, a protein solution is separated from a large 
volume of crystallising agent by the use of a semi permeable membrane. Slow 
movement of solvent through the membrane results in an increase in the 
protein concentration and ultimately leads to the crystal growth. This method, 
however, requires a large quantity of protein in comparison to other 
crystallisation methods. 
Vapour Diffusion technique is the most widely used technique. This 
technique can be used with two variations depending upon the mode of drop 
setting (Figure 1.3) – sitting drop vapour diffusion (SDVD) and hanging drop 
vapour diffusion (HDVD). More common among the two is the hanging drop 
method. A small volume of the protein and precipitant are mixed together and 
suspended over a reservoir of the precipitant in a close system. The precipitant 
concentration in the reservoir is maintained higher than that in the protein 
drop. Due to the concentration difference, the solvent molecules diffuse from 
the protein solution (drop) to the reservoir solution until the vapour pressure 
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of the drop attains equilibrium with the vapour pressure of the reservoir 
solution. This event leads to an increase in the precipitant and the protein 
concentration in the drop and thereby increasing the degree of saturation of 
the protein which, if the physiochemical conditions are chosen optimally, leads 
to the nucleation and then crystal growth. 
Figure 1.3: The two variants of vapour diffusion method of crystallisation – 
hanging drop (left) and sitting drop (right). The arrow shows direction of 
diffusion of vapours in the closed system. 
The process of crystal growth can be explained with the help of a phase 
diagram (Figure 1.2). Crystallisation is set up at point A where the protein and 
the crystallising agent are mixed such that the final protein concentration in 
the drop remains at undersaturation state. As the drop is allowed to 
equilibrate against a large volume of reservoir containing a higher 
concentration of crystallising agent (generally twice of that in the drop), volatile 
solvents start diffusing in the direction from the lower (drop) to the higher 
concentration (reservoir solution). As a result, the concentration of the protein 
and the crystallising agent in the drop starts increasing and the system 
reaches point B which is in the nucleation zone of the supersaturation state. 
This state is a nonequilibrium state and hence the protein molecules start 
aggregating together to form the nucleus for crystal growth. The protein 
concentration in the drop starts decreasing. More and more molecules of 
protein aggregate together to attain equilibrium and soon the system enters 
into the metastable zone where no more nucleation can occur but the protein 
still keeps aggregating on already formed nucleus to attain an equilibrium 
state. As a consequence, the size of the growing crystals increase till the 
protein concentration in the drop drops down to point C where it enters into 
the undersaturation state again and the crystal growth ceases. 
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Since conditions for nucleation and crystal growth phase may differ, 
sometimes seeding becomes necessary to grow protein crystals. The technique 
of seeding has been used successfully when either the condition that results in 
an excessive nucleation does not allow further crystal growth due to protein 
depletion following too much nucleation or to improve crystal quality when the 
originally grown crystals do not diffract up to the mark. A small fraction of 
nucleated crystals is transferred to a new drop under suitable growth 
conditions which may or may not differ from the nucleation condition. 
Depending upon how seeding is performed and the size and the number of 
seeds transferred, the seeding is categorised as macroseeding, microseeding or 
streak seeding. 
Crystals and Symmetry 
Crystals are a regular repetition of objects (protein molecules in this 
case) in three-dimensional space. The smallest unit of a crystal that repeats 
itself throughout the crystal purely by its translation in three dimensions is 
called the unit cell. A unit cell can be defined by six parameters – three edges 
a, b, c and three angles α, β and γ between them. The location of an atom 
within a unit cell is described by a set of three cartesian coordinates (x, y, z) 
with respect to the origin at one of the vertices of the cell. The smallest unit of 
a crystal that repeats itself throughout the crystal by its rotation and 
translation is called the asymmetric unit. The unit cell may contain more 
than one asymmetric unit arranged in patterns that are characteristic of what 
symmetry the crystal possesses. The geometry of the unit cell together with 
the possible symmetry operations defines the space group of the crystal. 
In addition to rotational and translational symmetry, the unit cell of a 
crystal can contain screw axis where the asymmetric unit is not only rotated 
around the axis, but also translated by a fraction of the unit cell length. Screw 
axis is denoted as a subscript number related to the fraction translation of the 
unit cell. For example, 21 is a two-fold rotation axis with a screw 
corresponding to the translation of half of the unit cell length. Furthermore, 
the asymmetric unit may consist of more than one molecule interrelated by 
the non-crystallographic symmetry (NCS). Figure 1.4 below illustrates a two 
dimensional lattice. 
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Figure 1.4: A hypothetical protein sitting in a two dimensional lattice, with a 2 
fold rotational symmetry, along the axis perpendicular to the plane of the paper. 
Each square block represents one unit cell and the shaded part represents the 
asymmetric unit. 
Symmetry poses restrictions on the shape of the unit cell. Crystals can 
be assigned to one of the 7 possible crystal systems which are further divided 
into 14 lattice types depending upon the position of lattice points within the 
unit cell (Figure 1.5 and Table 1.2). Primitive lattices are the crystal systems 
that contain one point at each corner of the unit cell and are designated by 
letter P. The Non-primitive lattices have additional points either at the centre 
of the unit cell faces (designated as face centred – C or F) or at the centre of 
the unit cell itself (designated as body centred – I). The seven primitive lattices 
along with the seven non-primitive lattices are called the Bravais lattices 
(Blundell & Johnson, 1976). 
Figure 1.5: The 7 Crystal systems and 14 Bravais lattices (P – primitive, C – 
centred, I – body centred, F – face centred) (adopted from 
http://perso.fundp.ac.be/~jwouters/DRX/diffraction.html). 
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Table 1.2: The fourteen Bravais Lattices and their associated symmetry point 
groups. 
Name Bravais 
lattice 
types 
Restrictions on unit cell Point 
groups 
Triclinic P a ≠ b≠ c; α ≠ β ≠ γ 1 
Monoclinic P, C a ≠ b≠ c; α = γ = 90° ≠ β 2 
Orthorhombic P, C, I, 
F 
a ≠ b ≠ c; α = β = γ = 90° 222 
Tetragonal P, I a = b ≠ c; α = β = γ = 90° 4, 422 
Trigonal P 
(or R) 
a = b ≠ c; α = β = 90°, γ = 120° 
a = b = c; α = β = γ < 120°, ≠ 90° 
3, 322 
Hexagonal P a = b ≠ c; α = β = 90°, γ = 120° 6, 6222 
Cubic P, I, F a = b = c; α = β = γ = 90° 23, 432 
Owing to the chiral nature of biological macromolecules, not all 230 
possible space groups are allowed for protein crystals as they can not possess 
mirror symmetry or inversion symmetry. Hence the allowed space groups for 
protein crystals are only 65 (Blundell & Johnson, 1976). 
Diffraction and Bragg’s Law 
When a crystal is exposed to a beam of X-rays, the incident beam is 
scattered in all possible directions. This scattering can be of two types-
coherent scattering and non-coherent scattering. Diffraction results from the 
coherent scattering whereas the non-coherent scattering leads to the 
absorption of energy by atoms in the crystal. Coherently scattered (diffracted) 
X-rays interfere constructively (‘in phase’ with each other) in certain directions 
and give rise to the observed diffraction pattern that is recorded on a detector. 
In 1913, the phenomenon of diffraction was explained by W. H. Bragg 
and W. L. Bragg. They considered diffraction as a result of simple reflection 
taking place from a plane mirror. Crystals are made up of several families of 
planes (called lattice planes or Bragg’s planes) passing through the lattice 
points (Figure 1.6). Any family of planes is identified by its Miller indices h, k, 
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and l which are integers representing how many times that particular plane 
repeats itself in a unit cell in all three x, y and z directions respectively. 
Figure 1.6: A representation of different families of Bragg’s planes through a 
two dimensional crystal lattice. 
For example, in figure 1.6, a family of planes shown in blue lines, 
repeats itself twice in the X direction and twice in the Y direction, in the unit 
cell (which is shown in thick lines). Hence, its miller indices will be h = 2, k = 2 
and this particular family of planes will be denoted as (2, 2). 
Braggs proved that for a given angle of incidence (θ) of X-rays on a 
plane, any family of planes would diffract (scatter coherently) the incident X-
rays only and only if the interplanar distance (d) between two consecutive 
planes in the family and the wavelength of incident X-rays obeys the following 
relation. 
2d sinθ = nλ ----------------------- (1) (Where n is an integer) 
Figure 1.7 below is a schematic representation of Bragg’s law. This law 
implies that for a given wavelength of X rays, reflections resulting from the 
diffraction of X-rays from closely spaced families of planes will be at a larger 
angle of reflection and thus will be recorded away from the centre of the 
detector and vice versa. 
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Figure 1.7: A schematic representation of Bragg’s law. D is the interplanar 
distance between two consecutive planes in the family and θ is the angle of 
incidence of X-rays on the plane. 
Reciprocal Lattice and Ewald’s Sphere 
Bragg’s law can give an exact estimation of the angle of diffraction but 
does not provide any information about the position of reflection with respect 
to the origin in 3-dimensional spaces. This piece of information is obtained 
from the reciprocal space concept and the Ewald’s sphere. 
The reciprocal space is an imaginary 3-dimensional space where the 
reflected spots (as a result of diffraction) are assumed to be situated. It is clear 
from the Bragg’s law (equation 1) that for a given wavelength of incident X-ray, 
a family of planes with a narrower interplanar distance would lead to a 
reflection observed at a wider angle on the detector and vice versa. An 
arbitrary origin is chosen and a perpendicular is drawn on any family of 
parallel planes (Bragg’s planes) with an interplanar distance d in the real 
space and a spot at a distance 1/d from the chosen origin is identified on this 
perpendicular. This spot is called reciprocal lattice point corresponding to that 
set of planes. This essentially means that one family of planes in the real 
space lattice produces only one spot in the reciprocal space. The position of 
any spot in the reciprocal space can be given by three indices h, k, l, known as 
Miller indices, which are none other than the indices of the set of planes that 
gives rise to that reciprocal point and hence that particular reflection on the 
detector. All such spots together constitute a reciprocal lattice corresponding 
to the real space lattice. 
The Ewald’s construction (Figure 1.8) is a geometrical representation of 
the reciprocal lattice. It is a sphere of radius 1/λ (where λ is the wavelength of 
incident X-ray) and the crystal is assumed to be situated at the centre of the 
sphere (point A). The origin of the reciprocal space is assumed at the point 
where the direct beam leaves the sphere (point O). 
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Figure 1.8: The Ewald’s sphere and the reciprocal lattice construction (adapted 
from Rhodes, 2000). Direct beam leaves the sphere at O (origin of the reciprocal 
lattice) and the crystal is situated at the centre A. Reciprocal lattice point B is in 
the diffracting condition and line AB shows the direction of the diffracted ray 
whereas the point C can be brought in the diffracting condition by rotating the 
sphere around the origin O. 
It can be shown with the simple laws of geometry and trigonometry that 
when a reciprocal point (point B) falls on the surface of the Ewald’s sphere, it 
fulfils the condition given by the Bragg’s law and thus gives rise to a reflection 
in the direction along the line joining the centre of the sphere to that 
reciprocal point on the surface of the sphere (along the line AB). In figure 1.8 
the reciprocal space point B is in the diffracting condition. 
However, in any particular orientation of the crystal (and thus of the 
reciprocal lattice) not all reciprocal points can be brought on the surface of the 
Ewald’s sphere to give rise to a diffracted reflection. This also means that in 
any particular orientation of the crystal in the beam (which, from Bragg’s law, 
essentially implies that at a particular angle of incidence of X-rays, θ) not all 
families of Bragg’s planes can be brought into the diffracting positions. To do 
so, the Ewald’s sphere has to be rotated with respect to the reciprocal lattice 
keeping the origin fixed in order to make all the reciprocal points fall on the 
surface of the Ewald’s sphere (in diffracting position) in one or the other 
orientation of the reciprocal lattice. This forms the basis of the most commonly 
used method of data collection – ‘the rotation method’. 
The higher the intensity of the incident ray, the more intense will be the 
reflections in the reciprocal space for a given time of exposure. Also, for a given 
intensity of the beam, higher the electron density corresponding to a set of 
planes in the real space, the more will be the number of waves that will be 
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coherently scattered from that particular set of planes and more intense the 
corresponding spot will be. Two pieces of information for any reflection (spot 
on detector) that can be drawn directly from the collected diffraction data are 
the position (h, k, l,) and the intensity (Ihkl) of the reflection. 
X-ray Generators and Detectors 
X-rays of wavelengths in the range of 1.0 – 1.54 Å are usually used for 
crystallography purposes and are obtained from one of the two types of x-ray 
generators. 
In laboratory (or home) sources, a beam of electrons originated at a 
cathode is focused onto a metal anode target through a strong electric 
potential. These high energy electrons cause transitions of the metal atoms at 
anode which result in the production of electromagnetic radiation of a wide 
range of energies and hence of varying wavelength, known as ‘white radiation’. 
This includes some strong characteristic radiations corresponding to the 
excitation of inner cell electrons of the metal. Copper is the most commonly 
used target metal and produces characteristic radiation of CuKα, (1.54 Å 
wavelength) and CuKβ (1.39 Å wavelength). Molybdenum may be used as an 
anode if X-rays of shorter wavelength are required (MoKα and CuKβ, 0.71 and 
0.63 Å wavelengths respectively) (Blundell & Johnson, 1976). Using 
appropriate filters, the white radiation can be converted to a monochromatic 
X-ray beam by removing the weaker (Kβ and other much weaker) radiation. A 
filter made of an element with atomic number Z-1 effectively blocks the Kβ 
radiation produced by a metal of atomic number Z (Ni is an effective CuKβ 
blocker) (Rhodes, 2000). Home sources can again be classified as ‘sealed tube’ 
(stationary anode) and ‘rotating anode’ generators. Although, in-house X-ray 
sources are very convenient and reliable, their use is limited by their low 
intensity beam and inability of tuning the wavelength. 
Tremendous advancements in technology in the past 25 years have 
made data collection much quicker. At synchrotron radiation sources, 
electrons are generated in an electron gun (Figure 1.9) and are accelerated 
with the energy of several giga-volts (Helliwell, 1997). These electrons, moving 
almost at the speed of light, under the influence of an electric field, are fed into 
an outer storage ring (Blow, 2002). In the storage ring, these fast moving 
electrons are forced to revolve in a circular path via a magnetic field and hence 
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to emit electromagnetic radiations in the line tangential to their path (Figure 
1.9). The emitted electromagnetic beam is then carried from the storage ring to 
the experimental area through a high vacuum beamline (Helliwell, 1992) 
collimated by the mirrors and filtered to make it a monochromatic beam. 
Synchrotrons have the advantage of fast data collection using highly intense 
beam. Another major advantage of synchrotron sources is the ability to tune 
the wavelength of the X-ray beam. 
Figure 1.9: A schematic representation of a Synchrotron source and its parts 
(adopted from http://www.warren.usyd.edu.au/bulletin/NO51/ed51art8.htm). 
Detection of the diffracted X-rays is a crucial part of an X-ray 
crystallography experiment. There are several types of detectors available to 
record the diffraction data. Recording the data on X-ray films is now an 
obsolete method. Charged couple device (CCD) detectors are the most 
advanced types of detectors. These detectors are characterised by their fast 
read out time and high noise reduction capability. 
Crystal Mounting and Data Collection 
For mounting in the beam, crystals can be loaded into a glass capillary 
with the crystallisation solution (the mother liquor), and sealed at both the 
ends. Another approach is to loop mount the crystals. Crystals are scooped 
into a tiny loop, made of nylon or plastic, supported by a solid rod and then 
held in the beam. 
The capillary or the loop containing crystals is then mounted on a 
goniometer, which allows it to be positioned accurately within the X-ray beam 
and rotated. Since both, the crystal and the beam are often very small, the 
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crystal must be centred within the beam. The most common type of 
goniometer is the "kappa goniometer", which offers three angles of rotation: 
the ω angle, which rotates about an axis perpendicular to the beam; the κ 
angle, about an axis at ~50° to the ω axis; and, the φ angle about the 
loop/capillary axis. The oscillations (rotation) carried out using the rotation 
method of data collection involve the ω axis only. 
The primary data quality plays an important role since data collection 
(Figure 1.10) is the last experimental step in X-ray crystallography (Dauter, 
1999). While collecting the data one needs to ensure that the collected data is 
complete as much as possible, 
1) – quantitatively, and

2) – qualitatively

Figure 1.10: Arrangement of a typical X-ray crystallographic data collection 
experiment. 
Factors that influence data collection can be classified into two classes. 
Quantitative factors (such as total rotation angle for which the data has to be 
collected and the wavelength of incident beam) ensure that we record as many 
reflections as possible. Quantitative factors basically depend on crystal 
geometry and the experimental set up. 
The wavelength of x-rays can be chosen based upon the nature of the 
experiment. Any wavelength is suitable for native data collection. Usually, a 
higher resolution can be obtained using a shorter wavelength X-rays. Shorter 
wavelength also reduces damage to the crystals due to the absorption of 
radiation, termed as radiation damage. 
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Exposure time affects the intensity of each spot (reflection) in the 
diffraction pattern. A shorter exposure time leads to the loss of high resolution 
weak reflections whereas a longer exposure may result in the saturation of 
low-resolution spots (termed as overloads). Hence, the exposure time should 
be chosen carefully to compensate the both. In addition, a longer exposure 
time increases radiation damage to the crystal. 
One image of the spots is insufficient to reconstruct the diffraction 
pattern of the whole crystal. Hence the crystal is rotated in the beam and 
many images are collected. The total angle of oscillation required to collect a 
complete data set depends on the symmetry of the unit cell. For a crystal 
possessing no symmetry (Triclinic, page 16), at least 1800 rotation data is 
needed to ensure completeness of the collected data. For higher symmetry 
space groups the total angle of rotation required is less, as there are more 
symmetry related reflections. Usually, data over a larger range of oscillation is 
collected to reduce the signal to noise ratio and to improve the redundancy of 
the data (Blundell & Johnson, 1976). The total range of oscillation is achieved 
in several steps of small angle of rotation per image (∆Φ, usually of 10 per 
image for protein crystals). ∆Φ is chosen depending upon the unit cell 
parameters and the arrangement of spots on the image to avoid overlapping of 
the spots or collecting too many of partially recorded spots. 
Crystal-to-detector distance determines the resolution of the collected 
data. The further the detector from the crystal, the lower will be the resolution 
(Figure 1.11) (Evans, 1999). 
Figure 1.11: Effect of the crystal to detector distance on resolution range (the 
larger the θ, the higher will be the resolution). 
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Mosaicity of the crystal refers to the internal disorder of the crystal. 
Ideal crystals are like a brick wall where bricks are arranged regularly. 
However, real crystal lattices can deviate from the ideal and are not the perfect 
lattices. High mosaicity can result in overlapping spots and data loss. High 
mosaicity can easily be detected on a diffraction pattern as broadened spots 
(more like a smear) than circular. 
Another factor that influences the data collection is the movement of 
incident radiation beam. X-rays are never ideally monochromic (single 
wavelength X-rays). This phenomenon is known as the beam divergence. 
Combined effects of the crystal mosaicity and the beam divergence can cause 
a particular reflection to be spread over a range of crystal rotations (same 
reflection appearing over more than 1 image, partially) (Dauter, 1999). 
On the other hand, qualitative factors (such as R factor and signal to 
noise ratio) indicate that the collected data is of the best possible quality 
under the given experimental conditions. These factors depend on the method 
employed in the data collection (Dauter, 1999) and are discussed in the data 
processing section on page 26. 
Cryogenic Data Collection 
The crystallographic data can be collected either at room temperature 
or at lower temperatures. Low temperature (at 100 K) data collection is more 
common. In theory, lowering the temperature increases molecular order in the 
crystal and thus improves the diffraction pattern. However, the crystal is 
soaked in a cryoprotectant before freezing it to avoid the formation of ice 
crystals during the data collection. 
Another advantage of maintaining the crystal at a cryogenic 
temperature is that it prevents diffusion of free radicals from the site of 
primary radiation damage in the crystal and thus saves the crystal from 
further damage called secondary radiation damage. It provides the crystal with 
a longer life span and allows the experimenter to collect more and more data 
without damaging the crystal in the beam. 
Cryogenic data collection, however, has some disadvantages as well. 
Selection of cryoprotectant is a trial and error method. The wrong choice of 
cryoprotectant may lead to cracking or even shattering of the crystal. 
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Sometimes, transferring the crystal to a low temperature may also result in an 
increased mosaicity. 
Concept of Resolution 
The amount of structural information that can be extracted from a 
crystal depends on the resolution to which the crystal diffracts the incident 
beam (Table 1.3). Being able to bring families of planes with narrower 
interplanar distances to the diffracting positions essentially means that being 
able to acquire higher resolution data for the crystal. 
Table 1.3: The structural information obtained from a crystal based on the 
resolution. 
Resolution (Å) Structural information that can be obtained 
6.0 Outline of the molecule and secondary structure features 
(e. g. helices, strands) can be identified. 
3.0 Course of the polypeptide chain can be traced and 
topology of the folding can be established. With the aid of 
the amino acid sequence, it is possible to place the side 
chains within the electron density map. 
2.0 Main chain conformations can be established with great 
accuracy. Details of the side chain conformations, bound 
water molecules, metal ions and cofactors can be 
identified. 
1.5 Individual atoms are almost resolved. It is possible to 
figure out almost all solvent molecules. 
1.0 Hydrogen atoms may become visible. 
A family of closely spaced planes diffracts at a higher angle of diffraction 
(Bragg’s law, θ α 1/λ). Hence, higher resolution spots are always collected far 
from the centre of the detector. Also, Bragg’s law clearly indicates that for a 
given angle of incidence, with a shorter wavelength of incident X-rays, families 
of planes with smaller interplanar distances can also be brought in the 
diffracting positions (d α λ) which means that a higher resolution can be 
obtained. A high resolution data gives information about the finer details of 
the structure. However, low resolution data is equally important for structure 
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determination as it contains information about the overall structure. For 
example, a 6 Å (low resolution) data set can provide information about outlines 
of the molecule and its secondary structure features while individual atoms 
can be easily fitted into higher resolution data (Table 1.3). 
Data Processing 
The crystallographic diffraction data is collected as two dimensional 
images full of diffracted reflections. To determine the structure of the 
molecule, this data needs to be processed. Data processing is a complex multi 
step process which includes – 
(1) - indexing of the data and measurement of cell parameters, 
(2) - refinement of cell and detector parameters, 
(3) - integration of the data, and 
(4) - scaling of the data. 
The first step in data processing is the determination of the unit cell 
dimensions and the crystal system. At this stage, based on the diffraction 
pattern, peaks are picked and indexing of the diffraction pattern is performed 
depending upon the position of peaks (Rossmann and van Beek, 1999). A 
complete search of all possible indices is performed. Finding values (integers) 
for one index (for example, h) for all reflections is equivalent to having found 
one real-space direction of the crystal axis (for example, a). After the search for 
the real space vectors is completed, the program finds three linearly 
independent vectors with minimal determinant (unit cell volume) that would 
index all the observed peaks to determine unit cell dimensions, Bravais lattice 
and the crystal orientation. 
This procedure usually provides with more than one choice for space 
group with their respective distortion coefficient which is an indication of to 
what extent the unit cell parameters for that particular space group have to be 
distorted in order to make it a perfect cell. The selected space group would be 
the one that has highest order of symmetry with lowest distortion coefficient. 
Further processing of the data proceeds using the initial estimates of cell 
parameters for selected space group as reference. Crystal to detector distance, 
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wavelength and oscillation range (phi values), are the input values needed in 
order to complete the process of autoindexing. 
Autoindexing is followed by refinement of cell and detector parameters 
and integration of whole data. Usually, autoindexing is done with only one or a 
few of the recorded images. Integration of data refers to the conversion of 
hundreds of collected images to one file consisting of the Miller indices and 
corresponding intensities for each reflection. 
Scaling is the final step in data processing. A scale factor is applied so 
that the intensities from all images of the data set can be related. The scaling 
of intensities is needed because the diffraction quality of the crystal degrades 
with time as it depends on mosaicity, air and crystal absorption, radiation 
damage etc. The first image usually has a scale factor of 1 and all the 
subsequent images will be scaled up to this (Smyth and Martin, 2000). The 
step of scaling averages the processed data while accounting for errors that 
occur during the data collection. The output of the scaling process is a list of 
reflections with systematic absences that is characteristic of the space group 
that had been chosen during indexing. 
The whole process of ‘processing the data’ produces a list of indices and 
their corresponding scaled intensities for all the recorded reflections and 
provides important statistical information about the quality of data such as 
completeness of data, signal to noise ratio and reliability factor. Each of the 
above steps involves many complex calculations. Therefore the entire process 
is carried out with the help of computer programs using sophisticated 
algorithms. The most frequently used programs are MOSFLM (Leslie, 1992) 
and HKL 2000 / HKL Package (Otwinowski and Minor, 1997). The quality of 
processed and scaled data can be assessed by following statistics: 
Completeness of data is the ratio of the number of unique reflections 
recorded to the total number of unique reflections possible. The higher the 
value, the more information can be obtained from the processed data. 
Rsym is an estimate of disagreement between the measured intensities of 
symmetry related reflections. A low Rsym value indicates less errors in the data 
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collection and hence more precision. If two or more data sets are scaled 
together, the R value is termed as Rmerge. For a typical data set of 2.0 Å, an 
Rsym of 10-12 % is within the acceptable limit (Blow, 2002). 
Signal to noise ratio (I / σI) is the ratio of intensity (I) to the error in 
recording that intensity (σI). This value is indicative of the accepted resolution 
of the data set as reflections with error ratio of (I/σI) < 2.0 can not be 
distinguished from the background noise and may contain errors. 
Redundancy, or multiplicity of the data refers to how many times all 
symmetry related reflections have been recorded. High redundancy is an 
indicative of accuracy in intensity measurement. 
Interpretation of Data – Diffraction to Structure 
Fourier proposed a method called Fourier Transformation (FT) to 
analyse complicated mathematical functions which are repetitive in nature. 
These complicated functions can be represented as a series of functions that 
are an integral multiple of a fundamental function. Since, crystals are also a 
repetitive function of a fundamental function i. e. the unit cell, they also can 
be analysed by applying the Fourier transform on them. More accurately, 
crystals are built from repetitive blocks of electron density. This electron 
density varies from point to point inside the unit cell but if we look at the 
crystal as a whole, this electron density repeats itself again and again in a 
regular fashion. Hence, by applying the Fourier transformation, the electron 
density at any point in a unit cell can be used to determine all its Fourier 
components (in case of waves; the amplitude, frequency and phase). Therefore, 
by working in the opposite direction (known as the inverse Fourier 
transformation) if the amplitude, frequency and phase components of the 
function are known, they can be used to calculate electron density at any 
point in the unit cell. This situation, however, is more complicated because a 
unit cell is a three dimensional object. Furthermore, each spot observed in the 
diffraction pattern appears not as a result of scattering from one electron in 
the unit cell but as a result of the constructive interference between waves 
scattered from all of the electrons present in the unit cell. Therefore, we need 
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to apply the inverse Fourier transform in all 3 directions within the volume of 
the unit cell to calculate the electron density at each and every point in that 
volume. 
The recorded reflections on the diffraction pattern, represent a sum of 
waves, diffracted from atoms on planes in the real space and are known as 
‘structure factors’. A three dimensional wave can be expressed in the following 
form: 
f(xyz) = fhkl e 2πiα ----------------------- (2) 
Where fhkl is the amplitude component of the wave and α is the phase 
component. The h, k, and l are the frequency terms of the wave in all three 
directions respectively i. e. by definition, how many times the wave repeats 
itself per unit cell in all three directions. Hence, the sum of all of the waves 
coherently interfering and producing a reflection in the reciprocal space can be 
represented as: 
F(hkl) = ΣhΣkΣlfhkl e 2π iα ----------------------- (3) 
This equation is known as the ‘structure factor equation’ corresponding 
to the reflection hkl (the Miller indices of that reflection or of the family of 
planes from which that particular reflection is originated). This way, structure 
factors for each and every reflection recorded on the detector can be 
calculated. Since the structure factor is the Fourier transform of electron 
density (ρ), another form of equation (3) can be written as 
F(hkl) =∫v ρxyz e 2 πi (hx+ky+lz) dx.dy.dz ----------------------- (4) 
Where, v is the volume of the unit cell. An inverse Fourier transform of 
equation (4) results in equation (5) -
ρxyz = 1/v ΣhΣkΣlF(hkl) e -2πi (hx+ky+lz) 
= 1/v ΣhΣkΣlf(hkl) e 2π iα e -2πi (hx+ky+lz) ---(5) 
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Equation (5) gives us the value of electron density at any point x, y, z in 
the volume of the unit cell provided that we have estimated all the structure 
factor amplitudes, frequencies and phases. 
Obtaining Phases 
The recorded diffraction pattern of a crystal is the Fourier transform of 
the electron density of its unit cell content. In principle, the Fourier transform 
is reversible and therefore it is possible to reconstruct the electron density in a 
unit cell from its diffraction pattern. However, from the electron density 
equation (equation-5) it is clear that to determine the electron density at any 
particular point in the unit cell (x, y, z) we need to know three parameters – (i)-
the amplitude factor (fhkl), (ii)- the frequency factor (h, k, l) and (iii)- the phase 
(α) components for all the Fourier terms i. e. for all the diffracted waves. 
The amplitude and the intensity of a wave are interrelated (the intensity 
is directly proportional to the square of the amplitude). In the process of data 
collection we only record intensities corresponding to reflections and hence 
amplitudes for all reflections can be easily determined. The frequency terms 
are nothing else but the Miller indices of the reflections. These values for all 
observed reflections have already been determined during the process of 
indexing the data. 
However, the third vital piece of information for each reflection – ‘The 
Phase’, is lost during the process of data collection and needs to be determined 
indirectly. This problem of losing phases in the data collection is termed as the 
Phase Problem. There are three main methods of solving the phase problem 
which can be used depending upon the type of the problem encountered. Any 
of these methods, however, does not provide with the actual and accurate 
phase information. An initial estimate of phases is calculated which is refined 
and improved subsequently (Taylor, 2003). 
Isomorphous replacement is a classical method of solving the phase 
problem. The principle of this method is that the contribution of any atom to 
the structure factor arising from the plane that intersects its position is 
proportional to the number of electrons present in the atom. Proteins are 
formed of C, N, O and S atoms which share almost same number of electrons 
in them. If a heavy atom, with an exceptionally large number of electrons is 
introduced uniformly in the crystal, the intensities of reflections corresponding 
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to the families of planes containing the heavy atom increase because of the 
additional scattering of waves by the heavy metal atom. This ultimately 
increases the amplitude factor of the corresponding structure factor equation 
for that reflection. In this method two different data sets are collected - one for 
the native crystal and the other for the heavy metal derivative crystal (Green et 
al., 1954). 
The condition that applies in this method is that both of the crystals 
should essentially be isomorphous i. e. both crystals should belong to the 
same space group with not more than 5% change in their cell parameters. The 
resulting intensities for both data sets are compared to retrieve phase 
information of heavy metal atom substructure that is present in the crystal. 
Positions of heavy metal atoms in the unit cell can be identified and can 
further be used to build the protein model. In normal practice, more than one 
heavy metal derivative is used and the method is called multiple isomorphous 
replacements. 
The method of anomalous scattering exploits the property of Friedel’s 
law. According to Friedel’s law, each set of planes produces two reflections 
given by hkl and –h-k-l which are equal in their intensities (Ihkl = I-h-k-l) but 
differ in their phases exactly by 1800. This makes all diffraction patterns 
centrosymmetric. Heavy metal atoms are incorporated into the protein crystal 
and the diffraction data is collected at the absorption edge of the incorporated 
heavy atom. This results in the absorption of radiation and Friedel’s law 
brakes down (Ihkl ≠ I–h-k-l). The absorption edge of an atom is defined as the 
wavelength at which the atom absorbs X-rays. 
By comparing the intensities of Friedel’s pairs of native and anomalous 
data (collected at the absorption edge), positions of heavy atoms in the unit 
cell can be determined. The anomalous scattering technique overcomes the 
problem of isomorphism as both, the native and the anomalous data sets can 
be collected from one single crystal by changing the wavelength to the 
absorption edge of the incorporated heavy atom. Usually, data sets are 
collected at several wavelengths in order to maximise the absorption (Taylor, 
2003) and the method of phase extraction is called Multiwavelength 
Anomalous Dispersion (MAD) method (Hendrickson and Ogate, 1997). 
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The use of a combination of above two methods is also becoming 
common. This technique is known as Single Isomorphous Replacement with 
Anomalous Scattering (SIRAS). 
Molecular replacement (Rosmann and Blow, 1962) is a method for 
phase estimation where a similar structure is known (Figure 1.12). Popularity 
of molecular replacement is increasing as more and more structures are being 
deposited in the Protein Data Bank (PDB). The success of molecular 
replacement method depends on the availability of sufficiently homologous 
structure. The higher the primary sequence identity, the higher are the 
chances, that the proteins will assume similar kind of three dimensional fold. 
As a rule of thumb, if the structure to be solved shares more than 30 % 
sequence identity with another protein whose structure is available, the 
molecular replacement method of phase estimation can be applied. 
In principle, this method exploits the property of reversibility of the 
Fourier transform and Patterson synthesis. A suitable protein with known 
structure (and hence known phases) is selected as a model and Patterson 
maps of the model molecule and the target unit cell content are calculated. A 
Patterson map is a Fourier transform of the structure factor amplitudes only 
and does not require phases. It represents all possible atom to atom vectors 
and thus relative positions of atoms with respect to each other. The Patterson 
map of the model is rotated first and then translated (Figure 1.12) within the 
unit cell to obtain the correct orientation of the target in the unit cell relative 
to the origin (Taylor, 2003). 
Figure 1.12: A schematic illustration of the process of molecular replacement. 
The target is similar but not identical to the model. 
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This operation of finding a rotation matrix ‘[R]’ and a translation vector 
‘t’ relates the Patterson map of the model (M) to the Patterson map of the 
target structure (X) according to the flowing equation -
X = [R].M + t 
Phases from the model (called calculated phases) are then associated 
with the observed structure factor amplitudes of the target molecule from 
diffraction data to calculate an initial electron density map according to 
equation – (5). Several computer programmes such as AMoRe (Navaza, 1994), 
MolRep (Vagin and Teplyakov, 1997) and PHASER (McCoy et al., 2007) are 
available to assist the whole operation. 
Model Building and Refinement 
The calculated phases are combined with the observed structure factor 
amplitudes from the diffraction pattern and a starting set of structure factor 
equations is calculated. These structure factor equations are used to calculate 
an initial electron density map of the molecule by using equation-(5). The 
quality of map at this stage depends on the quality of collected data and errors 
in phase estimation. Electron density maps can become biased towards the 
model if phases have been estimated by molecular replacement. This is termed 
as model bias. 
Many rounds of crystallographic model building and refinement are 
then carried out in a cyclic process (Figure 1.1, page 03) aiming to improve the 
agreement between the observed data and the atomic model that has been 
calculated by using phases from the search model. The cyclic process of model 
building and refinement is usually repeated until, ultimately, a model is 
generated which represents the observed data as closely as possible. 
In order to reduce the model biasing of phases, usually a 2Fo-Fc Fourier 
map is calculated. In this map electron density at any point is calculated 
using the structure factor amplitudes equal to a sum of twice the observed 
structure factor amplitudes (|Fobs|), minus the calculated amplitudes (|Fcalc|) 
{(2|Fobs| –|Fcalc|)} in equation-5. This map represents a positive continuous 
density of the model. The structure factor amplitudes of this map are = |Fobs| 
if the model is perfect. This map has a larger contribution of |Fobs| and hence 
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if the model misses parts or is not perfect, this map shows the missing parts 
up with less intensity. 
Another map, known as the Fo-Fc maps is also generated by using a 
sum of the observed structure factor amplitudes, minus the calculated 
amplitudes {(|Fobs| –|Fcalc|)} in equation 5. The electron density 
corresponding to this map is zero if the model is perfect, positive if some parts 
are missing in the model but present in the structure and negative if parts are 
absent in the structure but present in the model. 
In addition to protein molecules, crystals contain water molecules 
which are bonded to the protein by hydrogen bonding and ligands that were 
incorporated during the crystallisation or by soaking the crystal in ligand 
solutions. These molecules also need to be modelled. The electron density 
corresponding to these molecules is visible in the Fo-Fc map. Water molecules 
can be added manually or automatically with the help of computer programs 
used in refinement such as ARP/wARP (Lamzin and Wilson, 1993). Atomic 
coordinates for ligand molecules can be obtained from the database such as 
the HIC-UP server (Kleywegt and Jones, 1998). Alternatively, coordinates for 
ligand can be obtained from the PRODRUG server (Schuettelkopf and van 
Aalten, 2004) or from the Sketcher application of CCP4 (CCP4, 1994). 
Interpretation of electron density maps and model building, however is 
a laborious exercise which has been made easier by the development of several 
softwares such as O (Jones et al., 1991) and COOT (Emsley and Cowtan, 
2004). 
Model building is followed by refinement where adjustments are made 
to bring the calculated structure factors close to the observed structure 
factors. Preliminary progress of refinement is assessed by the reliability factor 
(or the R factor) and improved model geometry. More appropriately, refinement 
is a process that produces the most biologically meaningful structure from the 
experimental data. The model parameters that are refined in each cycle of 
refinement include the position (x, y, z), occupancies and thermal factors (B-
factors) of atoms. Generally used programmes for refinement are REFMAC 
(Murshudov et al., 1997) and CNS (Brunger et al., 1998). 
Refinement can be started at a low resolution in order to reduce the 
model bias and to avoid the entrapment in local minima. The resolution can 
subsequently be increased in one or more steps. This strategy proceeds with 
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the correction of the gross features of the model first and ensures that the 
wrongly assigned details do not bias the model. Initially, the model is refined 
by rigid body refinement in which the protein molecules are refined as if they 
are rigid bodies and no relative movement of different domains is allowed. 
Another basic type of refinement is restrained refinement where some 
freedom of movement within a narrow range of limits is allowed to the 
parameters to be refined. Adding restraints increases the observations to 
parameter ratio and therefore a good technique is to restrain the geometry of 
the protein tightly so that the phases could become more accurate as 
distortions in local geometry cannot be assigned without good phases. 
B-factors are the atomic displacement factors. B factors represent the 
distribution of positions occupied by an atom over a period of time (dynamic 
disorder) as well as variations in the position of an atom between different unit 
cells (static disorder) (McRee, 1993). B factor refinement is an example of 
restrained refinement. Large B-factor values are usually indicative of errors in 
the model coordinates. 
Structure Validation 
Validation is used to access the quality of the refined structure. It is a 
process of checking quality of the structure against basic laws and known 
knowledge of science. The measure of success of refinement process can be 
assessed by several means. 
The R-factor is the primary quality parameter of a structure. At the end 
of every cycle of model building and refinement, the difference between the 
calculated structure factors amplitudes and the observed structure factor 
amplitudes begin to converge and the value of R-factor drops. The R factor is 
calculated as below 
Rcryst = Σ ||Fo| - |Fc|| ----------------------- (6) 
Σ|Fo| 
Another important quality accessing parameter is Rfree. This concept 
was first coined by Brunger (Brunger, 1992). A set of randomly selected 
reflections (known as the test set) is taken out from all the available data and 
not used in the refinement. The rest of the data with which the refinement is 
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carried out is termed as working set. The Rcryst indicates agreement (or 
disagreement) between the observed data (working set) and the calculated 
data. On the other hand, the Rfree is calculated in a similar way but for the test 
set. Since, the Rfree is calculated against the experimental data and not the 
model, there is no model bias in the refinement of the test set. The advantage 
of Rfree is that it indicates about wrongly or over fitted data. 
Root mean square deviation (r.m.s.d) is another statistical parameter 
that helps in assessing the quality of a structure by indicating the deviation of 
covalent bond lengths and bond angles from their ideal values. A low r.m.s.d. 
value indicates that the geometry of the molecule is good and that the 
refinement was carried out properly. Usually an r.m.s.d. value < 0.2 for bond 
angles and <0.02 for bond lengths is considered acceptable. 
Ramachandran plots (Ramachandran et al., 1963) are good indicators 
of accuracy of protein models. A Ramachandran plot indicates whether the 
main chain backbone dihedral angles (Φ – Ψ angles) fall into the allowed range 
to form protein secondary structure elements. PROCHECK (Laskowski et al., 
1993) and MOLPROBITY (Davis et al. 2007) are two useful programs that can 
assist in the assessment of the quality of the structure at various stages of 
refinement. 
Deposition of Atomic Coordinates with the Protein Data Bank 
There is no definitive point when refinement of a structure is completed. 
As a rule of thumb, when the Rcryst and the Rfree stabilise, structure refinement 
is considered to be completed. Refined and validated structures are then made 
available to the public. The protein data bank (at either European 
Bioinformatics Institute, EBI; http://www.ebi.ac.uk/ or with the Research 
Collaboratory for Structural Bioinformatics, RCSB; http://www.rcsb.org/) is a 
global repository for structural information for X-ray crystallographic data. Not 
only the refined atomic coordinates for the protein but the experimental data, 
protein sequence and other parts of information are also deposited through a 
web interface such as AutoDep. The PDB facilitates an open access to all 
structures deposited world wide. 
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CHAPTER - II 
CLOSTRIDIUM DIFFICILE AND

ITS KNOWN TOXINS
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Introduction to Clostridium difficile 
Clostridia are Gram positive, spore forming, anaerobic, rod shaped 
bacteria. They are motile bacteria that are widely distributed in nature with 
their special prevalence in soil. They are commonly found in the 
gastrointestinal track of many animals including humans (Barth et al., 2004). 
Clostridia are closely related to Bacillus genera (Shimizu et al., 2002; Read et 
al., 2003). Along with Bacillus; they are thought to constitute the first bacterial 
population on the earth (Fox et al., 1980). Beside their genetic similarities, the 
two genera are well known for their ability to produce a variety of toxins which 
makes them potent pathogens of eukaryotic cells. 
Figure 2.1: An electron microscopic photograph of Clostridium difficile spores 
(figure obtained from Health Protection agency, U.K.) 
Clostridium difficile (Figure 2.1), originally known as Bacillus difficile 
was described in 1935 for the first time (Hall and Toole, 1935). In 1978, C. 
difficile was isolated from patients undergoing antibiotic treatment. The 
bacterium was soon identified as the primary cause of pseudomembranous 
colitis (Voth and Ballard, 2005). It was found that C. difficile causes disease 
almost exclusively in the presence of exposure to antibiotics. C. difficile is the 
only known anaerobic bacterium that produces toxins in the colon (Bartlett 
and Perl, 2005). 
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Clostridium difficile Infection 
Clostridium difficile is an important nosocomial pathogen. C. difficile 
infection (CDI) is known to be responsible for almost all cases of 
pseudomembranous colitis (PMC) and hospital acquired diarrhoea worldwide 
(Elliott et al., 2007). Elderly people are more at risk. CDI is recognised by a 
wide variety of symptoms ranging from mild self limiting diarrhoea to more 
severe life threatening pseudomembranous colitis. The more serious issue is 
that the infection occurs in hospitalised individuals who have undergone 
antibiotic treatment (Hurley and Nguyen, 2002) and hence the disease is 
called Hospital Acquired Diarrhoea. C. difficile is resistant to several 
antibiotics and antimicrobial agents which give the bacteria a selective 
advantage over other microbes that results in C. difficile associated outbreaks 
in healthcare facilities. 
Reports suggest that almost 3% of healthy and up to 40% of 
hospitalised individuals are colonised with C. difficile (McFarland et al., 1989). 
In healthy individuals, the bacteria remain in spore form under normal 
conditions and only go back to their active – vegetative form, when the normal 
intestinal flora gets disturbed upon exposure to antibiotics (Bartlett and Perl, 
2005). In general, any therapeutic agent, procedure or illness that disturbs the 
normal intestinal flora may give rise to CDI (Riley, 1998). Clindamycin and 
cephalosporins have been considered as significant cause of PMC (Tedesco et 
al., 1974; Gerding, 2004). 
Figure 2.2: The number of reported cases of Clostridium difficile-infection in the 
United Kingdom (Source - Health Protection Agency and Office for National 
Statistics). * - the 2008 data is for 3 quarters (Jan. 2008 – Sep. 2008). 
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A survey report by the Health Protection Agency (HPA), in 2006 revealed 
that there was a 30 fold increment in the reported case of CDI in 15 years 
between 1990 to 2005 (Figure 2.2). In the year 2005, more than 3500 
individuals lost their lives to CDI in the United Kingdom (Figure 2.3). This 
number was more than 8 % of the reported cases of CDI in that year. Although 
the number of reported cases of CDI decreased from 2006 to 2007 (Figure 2.2), 
the severity of infection kept on increasing with a death toll of 6500 in 2006 
and more than 8000 in 2007 (Figure 2.3). 
Figure 2.3: The number of deaths associated with Clostridium difficile infection 
in England and Wales (Source- Office for National Statistics). 
The pathogenesis of C. difficile has been attributed to its three well 
known toxins – Toxin-A (TcdA), Toxin-B (TcdB) and a binary toxin (CDT). All 
three toxins are discussed below in detail. 
Clostridium difficile Virulence Factors 
Toxin-A and Toxin-B (TcdA, 308 kDa and TcdB, 270 kDa) are two 
proteins that have been considered to be the main virulence factors of C. 
difficile (Thelestam and Chaves-Olarte, 2000; Elliott et al., 2007). They along 
with several other closely related Clostridial toxins such as C. sordellii lethal 
toxin (TcsL) and haemorrhagic toxin (TcsH) and C. novyi alpha toxin (Tcn-α), 
constitute a group known as Large Clostridial Cytotoxins (LCT) (Just et al., 
2000). All members of this family are single chain proteins of high molecular 
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weight ranging from 200 to 300 kDa (Rupnik et al., 2003) and are among the 
largest known bacterial toxins. 
TcdA and TcdB from C. difficile have been studied in great detail. Both 
proteins are expressed efficiently by the host during the late log phase or 
stationary phase of growth (Voth and Ballard, 2005). However, the precise 
environmental signal that modulates toxin expression is still unclear. Studies 
suggest that the production of both proteins by C. difficile can be enhanced 
under stress conditions such as in the presence of antibiotics vancomycin and 
penicillin (Dupuy and Sonenshein, 1998). A recent study (Lyras et al., 2009) 
emphasises the essentiality of Toxin-B in C. difficile infection. 
TcdA and TcdB toxins are encoded by two separate genes namely tcdA 
and tcdB. Along with three other genes tcdC, tcdD and tcdE, these toxins form 
a pathogenicity locus (Figure 2.4) which spans over a 19 kb region on the 
genome of the bacterium (Hammond and Johnson, 1995). Translation 
products of these genes (tcdC, tcdD and tcdE) are suspected to be involved in 
the pathogenicity of the organism by regulating the expression of TcdA and 
TcdB and their release from the cell (Hammond and Johnson, 1995). A high 
sequence similarity and functional homology between TcdA and TcdB 
indicates that the two genes may have arisen as a result of gene duplication 
(von Eichel-Streiber et al., 1992). 
Figure 2.4: The arrangement of tcdA and tcdB toxin genes along with their 
regulators (tcdC tcdD and tcdE) in the C. difficile pathogenicity locus and the 
relative position of binary toxin genes (Adopted from McDonald et al., 2005). 
Less prominent is the C. difficile binary toxin (CDT). The pathogenic role 
of CDT in C. difficile infection is still a question of debate. About 6 to 12.5 % 
strains of C. difficile that have been isolated from patients suffering from CDI 
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are found to contain CDT genes (Stubbs et al., 2000; Popoff, 2000; Geric et al., 
2003). CDT is a genome encoded toxin. CDT coding genes are located at an 
unknown position outside the pathogenicity locus (Figure 2.4) (McDonald et 
al., 2005). A recent study has highlighted on an 18 base pair deletion in tcdC 
gene (one of the negative regulators of TcdA and TcdB, Figure 2.4). The 
deletion is found closely associated with the prevalence of C. difficile strains 
carrying CDT encoding genes (McDonald et al., 2005). The importance of this 
deletion and its correlation with the presence of CDT genes is not understood 
yet. It is suggested that the presence of CDT contributes towards the severity 
of infection (Perelle et al., 1997). However, to date, there is no report available 
to evaluate the cytotoxicity effect of complete CDT in isolation. 
Clostridium difficile Binary Toxin (Actin-ADPRT) 
Similar to many other Clostridial binary toxins such as C. perfringins 
iota toxin, C. botulinum C2 toxin, and C. spiroforme toxin, CDT is composed of 
two components – an enzymatically active component (CDTa) and a 
catalytically inert transport component (CDTb) (Barth et al., 2004). Domain 
organisation of CDTa and CDTb is shown in Figure 2.5. 
Figure 2.5: The domain organisation of CDTa and CDTb. CDTa′- mature CDTa 
fragment (without signal peptide), CDTb′- CDTb fragment without signal peptide, 
CDTb″ – fully mature CDTb fragment. 
The enzymatic component of C. difficile binary toxin (CDTa) is a 462 
amino acid protein with a total molecular weight of 49 kDa. The first 42-N 
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terminal residues of CDTa have been predicted to form a transmembrane 
peptide segment that acts as a signal peptide. CDTa gets activated by 
proteolytic cleavage of the signal peptide and the cleavage site has been 
identified at Lys 42-Val 43 (Perelle et al., 1997). Amino acid residues (Arg 295, 
Glu 378 and Glu 380) that are essential for catalytic (ADP ribosylation) activity 
of the enzymatic component of C. perfringens Iota toxin, Ia, the closest 
homologue of CDTa (Perelle et al., 1996; van Damme et al., 1996), are well 
conserved in CDTa. Precursor and mature CDTa share 81% and 84% 
sequence identity with the corresponding lengths of the enzymatic component 
of Iota toxin (Perelle et al., 1997; Voth and Ballard 2005). 
The transport component of C. difficile binary toxin (CDTb) consists of 
876 amino acid residues with a molecular weight of 98.9 kDa (Figure 2.5). The 
protein itself is catalytically inert but plays an important role in transporting 
the enzymatic component (CDTa) into the target cells. The first 42 N terminal 
residues of CDTb have also been predicted to be a signal peptide that displays 
features of a transmembrane segment (Perelle et al., 1993). Precursor CDTb 
shares 81.2 % and 38 % sequence identity with the transport component of C. 
perfringens Iota toxin (Ib) and C. botulinum C2 toxin (C2II), respectively (Barth 
et al., 2004). CDTb undergoes a proteolytic cleavage by chymotrypsin and the 
cleavage site has been proposed to be at Lys 209-Leu 210 (Perelle et al., 1997). 
As a result of cleavage, a 25 kDa N terminal fragment of CDTb falls apart and 
the remaining larger C terminal fragment functions as an active (mature) 
CDTb. The mature CDTb is 82 % identical to Ib and 40 % identical to C2II 
(Barth et al., 2004). 
Clostridial Actin-ADPRTs 
Several species of Clostridium and Bacillus produce binary toxins that 
belong to the ADP ribosylating toxin (ADPRT) superfamily. They all target actin 
molecules in the target cell. These toxins are composed of two subunits 
(components) which are transcribed, translated and secreted out of the cell as 
two separate proteins (Barth et al., 2004) encoded by two distinct genes. The 
G+C content of these genes vary between 27 to 31 % among different 
Clostridial species (Popoff, 2000). A significant difference at the genetic level 
between different Clostridial binary toxins is that C. difficile CDT, C. botulinum 
C2 and C. spiroforme CST are chromosome encoded toxins whereas C. 
perfringens iota toxin is a plasmid encoded toxin (Barth et al., 2004). 
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The smaller component (known as A or I) of Clostridial binary toxins 
possess the enzymatic activity of the toxin (Figure 2.5) and is responsible for 
the covalent ADP ribosylation of monomeric actin molecules in the target cell 
(Aktories and Wegner, 1992). These toxins utilise NAD or NADPH as the ADP-
ribose donor. The larger component (known as B or II) of these toxins is 
enzymatically inactive (Figure 2.5). The B component is responsible for the 
translocation of the A component into the target cell (Ohishi et al., 1980). 
Clostridial binary toxins are further classified into two main classes 
based on their substrate specificity (Schering et al., 1988; Rupnik et al., 2003; 
Barth et al., 2004). Toxins belonging to the Iota family can ADP-ribosylate all 
three isoforms of actin whereas toxins from C2 family are specific for only 
smooth muscle actins (β and γ isoforms of actin) (Vandekerckhove et al., 1987; 
Popoff et al., 1988; Aktories et al., 1986; Mauss et al., 1990). Binary toxins 
produced by different Clostridium species are listed in table 2.1. 
Table 2.1: Classification of costridial binary toxins based on their substrate 
specificity. 
Family Toxin and Components Specificity 
C. perfringens toxin (iota) 
α / β / γ Actins Iota family C. spiroforme toxin (CST) 
C. difficile toxin (CDT) 
C2 family C. botulinum toxin (C2) β / γ Actins 
Another basis of their classification is the sequence identity between 
different binary toxins. Members of the Iota family share more than 80% 
sequence identity in the family, while when aligned against the C2 family 
members, the sequence identity is much less – around 30 to 40% (Barth et al., 
2004).Toxins from one family also show immunological cross reactivity. In 
addition, the transport component of one toxin can transport the enzymatic 
components of other toxins into the target cell and thus can be exchanged 
among different toxins within the family (Rupnik et al., 2003). 
Common Mechanism of Action of Clostridial Actin-ADPRTs 
The B (or the transport) component of these binary toxins is produced 
as an inactive precursor molecule which gets activated on proteolysis by 
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various serine proteases such as furin, trypsin and chymotrypsin (Fernie et 
al., 1984; Klimpel et al., 1992; Perelle et al., 1997; Stiles, 1987). This 
activation results in the loss of about 20 to 25 kDa N terminal fragment from 
the precursor molecule (Figure 2.5). The large C terminal fragment of the B 
component undergoes a conformational change that facilitates the formation 
of a homo-heptameric transport component complex (Barth et al., 2004). 
Figure 2.6: The process of cell intoxication by Clostridial binary toxins. The B 
subunit is activated by chymotrypsin (1, 2) and forms a heptameric pore like 
structure (3) that binds to the unknown cell surface receptors (4). The A 
component (5) then docks on the assembly (6) which then gets endocytosed via 
early endosomal pathway (7). The A component translocates through the pore 
into the cytosol (8) and irreversibly modifies monomeric actin which blocks its 
polymerisation (10). 
The enzymatic component of the toxin then docks on the cell surface 
receptor bound heptameric transport component complex. The N terminal 
domains of both components are believed to be involved in docking on each 
other (Barth et al., 2004). The entire assembly of cell surface bound toxin is 
then translocated into the cytosol via acidified early endosomal pathway 
similar to the single chain diphtheria toxin or multi chain B. anthrcis lethal 
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and edema toxin (Madshus et al., 1991; Friedlander, 1986). Late endosomes 
are not involved in the transport as inhibitors of late endosomes are not found 
to affect the biological activity of C2 or iota toxins on the cells. However, the 
biological activity of C2 or iota toxin can be blocked by bafilomycin-A, which is 
known to inhibit the acidification of early endosome (Barth et al., 2000; 
Blocker et al., 2001; Werner et al., 1984). 
Highly acidic environment of the endosomal compartment (pH < 5.0) 
has been suggested to facilitate membrane insertion of the transport 
component heptamer generating a tunnel through the endosomal membrane. 
The low pH also induces a drastic conformational change in the enzymatic 
component. The enzymatic component is then translocated from the 
ensdosomal compartment into the cytosol via the tunnel. In the cytosol, the 
enzymatic component regains its three dimensional structure and becomes 
catalytically functional again. It is not clear whether the transport component 
heptamer also enters cytosol with the enzymatic component or remains 
attached to the endosomal membrane (Ohishi and Yanagimoto, 1992; Richard 
et al., 2002). A heat shock protein (Hsp90), a well conserved ATPase in 
eukaryotic cells has been thought to be involved in the transportation of 
enzymatic components of iota, CDT and C2 toxins across the endosomal 
membrane but the mechanism is yet to be understood (Haug et al., 2003a; 
Haug et al., 2003b). 
Figure 2.7: Site of cleavage on the NAD molecule by ADPRTs. 
The enzymatic component of these toxins transfers the ADP ribose 
moiety (Figure 2.7) of NADH or NADPH to monomeric actin (G-actin) molecules 
(Aktories and Wegner, 1989; Considine and Simpson, 1991). Monomeric actin 
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(G-actin) is a single peptide chain of 375 amino acid residues. 14 G-actin 
molecules interact together to produce a long thread like structure. Two of 
these strands then produce a right handed double stranded helix known as 
polymeric actin (F-actin). The polymeric form of actin is a polar molecule. 
Polymerisation of actin molecules takes place mainly at one end of the polymer 
known as the barber end (Figure 2.8), whereas depolymerisation occurs at the 
other end of the molecule known as the pointed end (Figure 2.8) at a faster 
rate (Aktories and Wegner, 1992). 
Figure 2.8: A schematic representation of mechanism of actin cytoskeleton 
disruption by Clostridial binary toxins. An irreversible modification of monomeric 
actin at Arg-177 prevents stacking of newly coming momonomeric actin on the 
growing polymeric actin chain. 
All ADP-ribosylating toxins transfer the ADP-ribose of NADH to Arg-177 
residue of monomeric actin (Vandekerckhove et al., 1988). Arg-177 of actin is 
located in the domain of newly entered G-actin molecule which interacts with 
the next coming G-actin (Figure 2.8). In the process of polymerization, Arg-177 
gets buried in the polymer and remains unaccessible to the toxin (Figure 
2.18). Hence, the polymeric form of actin is not a substrate for the ADP 
ribosylation by these toxins (Aktories et al., 1986). 
The irreversible modification of G actin results in disruption of the F-
actin - G-actin equilibrium in the cell as the polymerisation of actin molecules 
ceases (Aktories and Wegner, 1992; Barth et al., 2002). Eventually the cell 
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cytoskeleton, which is totally dependent on this equilibrium, collapses. These 
events result in excessive fluid loss from the cell (Simpson, 1982), increased 
intestinal fluid accumulation (Ohishi, 1983), rounding of the cell (Reuner et 
al., 1987) and finally cell death. 
Research has been carried out to identify cell surface receptors of these 
binary toxins but only a limited amount of knowledge is present in literature. 
Cell surface receptor/s of C. difficile CDT have not been identified. Cell surface 
receptors for C. botulinum C2 toxin have been identified as asparagine linked 
complex/hybrid carbohydrates (Eckhardt et al., 2000; Sugii and Kozaki, 1990) 
whereas the receptors for C. perfringens iota toxin have been found to be 
proteins which are resistant to proteases (Liu and Lappa, 2003; Stiles et al., 
2000; Stiles et al., 2002). 
Bacterial ADPRTs and Their Classification 
Bacterial pathogens utilise a whole range of toxins to modify or kill the 
target cell. ADP ribosylation (Collier and cole, 1969), glucosylation (Sehr et al., 
1998), acetylation (Mukherjee et al., 2006), deamidation (Schmidt et al., 1997) 
and proteolysis (Schiavo et al., 1992) of host proteins are some of the favoured 
methods of cell intoxification. ADP-ribosylation of elongation factor-2 (EF-2) 
was the first covalent modification shown to be performed by any toxin 
(diphtheria toxin) (Collier, 1975). 
ADP ribosylating toxins (ADPRTs) are a large family of potentially lethal 
toxins that transfers the ADP-ribose portion of NAD, covalently, to their targets 
(Deng and Barbieri, 2008). Producers of this family of toxins belong to a vast 
range of bacterial pathogens including Clostridia and Baccilus. These 
organisms are the principal causative agents of several serious diseases 
(Holbourn et al., 2006) such as cholera, diphtheria and hospital acquired 
diarrhoea. Targets of these ADPRTs are the key regulators of cellular functions 
such as small GTPases or Actin. Covalent modification of these proteins by 
toxins results in the serious collapse of key cellular processes and eventually 
cell death (Holbourn et al., 2006). The ADPRTs have been classified in 4 major 
classes based on their domain organisation and target specificity (Table 2.2). 
The AB5 class consists of some of the most well known toxins such as 
cholera, pertussis and E. coli enterotoxin (Figure 2.9). The catalytically active 
subunit (A subunit) of the toxin docks on a doughnut shaped pentamer of B 
48

subunit that comprises the cell binding and translocation domains (Stein et 
al., 1994; Zhang et al., 1995; Gill et al., 1981; Finkelstein et al., 1987; Sixma 
et al., 1991). The hetero-hexamer assembles in the bacterial cell itself prior to 
its secretion (Sandkvist et al., 2000). The A subunit undergoes a proteolytic 
cleavage to release a disulphide linked A1 domain from the rest of the 
complex. The A1 domain is then transported into the target cell where it 
undergoes another activation process in order to become fully functional 
(Holbourn et al., 2006). Targets for this family of toxins are small regulatory G 
proteins (Table 2.2). 
Table 2.2: Different classes of the ADPRTs and their substrates. 
ADPRT 
class 
Toxin 
(PDB ID) 
Bacterium Target 
AB5 Cholera (1XTC) Vibrio cholerae Gs 
Pertussis (1PRT) Bordetella pertussis Gi, Gt and Ga 
E. coli 
Enterotoxin (1LTS) 
Escherichia coli Gs 
AB Diphtheria (1TOX) Corynebacterium 
Diphtheriae 
eEF2 
Pseudomonas 
exotoxinA (1AER) 
Pseudomonas 
Aeruginosa 
A-B VIP (1QS1) Bacillus cereus G-Actin 
binary Iota (1GIQ) Clostridium perfringens 
CDT (2WN4) Clostridium difficile 
C2 Clostridium botulinum 
Single C3bot (1G24) Clostridium botulinum RhoA, B, C 
polypep 
-tide 
C3stau (1OJZ) Staphylococcus aureus RhoA, B, C, E 
and Rnd3 
Diphtheria toxin belongs to the AB class of ADPRTs (Figure 2.9). 
Members of this family are highly potent toxins. Lethal dose of diphtheria 
toxin for humans is as low as 0.1 µg of toxin per kilogram (Deng and Barbieri, 
2008). These toxins are multidomain proteins with their receptor binding, 
translocation and catalytic domain residing on one single polypeptide chain 
(Hwang et al., 1987; Allured et al., 1986; Morris et al., 1985; Sandvig and 
Olsnes, 1980; Collier, 1975; Wilson and Collier, 1992). The substrate for AB 
class of ADPRTs is a diphthamide residue (a His residue that has been 
modified by addition of diphthamide side group) (Van Ness et al., 1980) on 
elongation factor-2 (Table 2.1) (Wilson and Collier, 1992). Interruption of 
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elongation factor-2 (EF2) function disrupts protein synthesis which leads to 
cell death (Collier, 1975). 
Figure 2.9: The structural comparison of all 4 classes of the ADPRTS with 
representative members from each class: A- C3Bot (PDB ID - 1G24) (Han et al., 
2001), B- Iota Toxin (PDB ID - 1GIQ) (Tsuge et al., 2003), C- Cholera toxin (PDB 
ID – 1XTC) (Zhang et al., 1995), D- Diphtheria toxin (PDB ID - 1TOX) (Bell and 
Eisenberg, 1996). The catalytic domains of each protein are shown in red (figure 
adopted from Holbourn et al., 2006). 
The third class of ADPRTs comprises small single domain C3 
coenzymes. An example of this class is C. botulinum C3bot toxin (Figure 2.9) 
(Aktories et al., 1987). This family of ADPRTs targets small GTPases such as 
RhoA, B and C (Table 2.1) at an exposed Arg-41 (Chardin et al., 1989; Sekine 
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et al., 1989). Covalent modification of Rho proteins as a result of ribosylation 
prevents its switching to active GTP bound state and leads to the loss of 
control over the cytoskeleton and eventually to cell death (Wilde and Aktories, 
2001). 
The A-B binary ADPRTs comprise the fourth class of the superfamily. 
This family includes toxins from a wide range of Clostridium species such as C. 
perfringens iota toxin, C. botulinum C2 toxin, C. difficile binary toxin (CDT), 
and vegetative insecticidal protein (VIP2) from Bacillus cereus (Han et al., 
1999; Aktories et al., 1986; Stiles and Wilkins, 1986; Simpson et al., 1989; 
Popoff and Boquet, 1988). As the name suggests, these toxins are binary in 
nature. These toxins are composed of two independently transcribed and 
translated gene products. A larger subunit (B subunit), that is known to form 
a heptameric pore like structure upon proteolytic activation translocates the 
catalytically active A subunit into the cytosol of the target cell. These toxins 
ADP-ribosylate monomeric actin in the target cell and thus are responsible for 
the collapse of the cell cytoskeleton (Aktories and Wegner, 1989). 
Mechanism of Action of C. difficile Toxin A and Toxin B 
TcdA and TcdB toxins from C. difficile utilise a well defined mechanism 
of action. Both the toxins possess glucosyltranferase activity and are capable 
of transferring the glucose moiety of UDP-glucose to small GTPases of the Rho 
superfamily in the target cell (Just and Gerhard, 2004; Just et al., 1995a; Just 
et al., 1995b; Lyras et al., 2009). Rho proteins are the primary regulators of 
actin cytoskeleton (Hall, 1990). Irreversible glucosylation by TcdA and TcdB 
results in the inactivation of these small GTPases and thus disruption of vital 
cell signalling pathways (Just et al., 1995a; Just et al., 1995b) which 
ultimately leads to cell death. 
Internalization of TcdA and TcdB in to the target cell takes place 
through nonproteinaceous cell surface receptor mediated endocytosis (Florin 
and Thelestam, 1983; Mitchell et al., 1987) via acidified endosomal pathway. 
The low pH of the endosome induces conformational changes in the toxin 
structure and exposes a hydrophobic domain (discussed in the next section) of 
the protein that is then inserted into the endosomal membrane (Qa’Dan et al., 
2000). The formation of such channels in the lipid bilayer by TcdB in a pH-
dependent process has indeed been reported (Barth et al., 2001). 
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Structural Organisation of TcdA and TcdB 
Structurally, these proteins are described as ABCD type protein (figure 
2.10) (Jank and Aktories, 2008). The full length protein can be divided into 4 
domains according to their function (Giesemann et al., 2008). 
Figure 2.10: The domain organisation of toxin-A and Toxin-B (ABCD model). A – 
Activity domain, B – Binding domain, C – Cutting domain and D – Delivery 
domain. The amino acid residue numbering is based on toxin-B (figure adopted 
from Jank and Aktories, 2008). 
The N terminal catalytic domain (activity or A domain) possesses full 
biological activity of the molecule (Hofmann et al., 1997; Faust et al., 1998). A 
repetitive oligopeptide sequence (binding or B domain) at the C terminal end of 
the protein has been suggested to be involved in receptor binding (Tucker and 
Wilkins, 1991; Wren, 1991; Frisch et al., 2003; Ho et al., 2005). The cell 
surface receptors of TcdA are carbohydrates in nature including Gal-α1, 3-
Gal-β1, 4-GlcNAc (Krivan et al., 1986; Pothoulakis et al., 1996). 
The central part of the protein constitutes the other two domains. Very 
little is known about its exact function (Giesemann et al., 2008). However, a 
small hydrophobic stretch (delivery or D domain) is suggested to mediate 
membrane insertion during the translocation process (Qa’Dan et al., 2000). 
The fourth functional domain of the protein (cutting or C domain), is 
characterised by its resemblance to a putative catalytic triad of a cysteine 
protease and is thought to be responsible for autoproteolytic cleavage of the 
protein (Pruitt et al., 2009) to facilitate transport of the A domain into the 
cytosol. 
In spite of availability of adequate information about their mode of 
internalization into the target cell as well as their mechanism of action, the 
structural information about C. difficile Toxin-A and Toxin-B is limited. The 
three dimensional structure of full length TcdA or TcdB are yet to be 
determined. The crystal structure of the catalytic domain of Toxin-B at 2.2 Å 
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(Figure 2.11) with its donor substrate UDP-glucose (UDP-Glc) and co factor 
(Mn2+) ion has recently been reported (Reinert et al., 2005). 
Figure 2.11: The crystal structure of the catalytic domain (domain A) of TcdB 
(Reinert et al., 2005) with bound manganese (shown as shphere) and UDP-
glucose (shown in sticks). The two orientations are at 900 to each other (PDB ID -
2BVL). 
The N terminal catalytic domain of TcdB consists of the first 543 amino 
acid residues of the protein. The overall fold of the catalytic domain resembles 
that of the members of glycosyltransferase-A (GT-A) family proteins (Reinert et 
al., 2005). Like other GT-A family proteins, a common D-X-D motif exists in 
TcdA and TcdB which is involved in the binding of Mn2+ ion and glucosyl 
group. As a result of intoxification, only the A domain of the protein is 
translocated into the cytosol of the target cell (Pfeifer et al., 2003; Rupnik et 
al., 2005; Reineke et al., 2007). The Large Clostridial toxins (LCTs) undergo an 
autoproteolysis that has been attributed to a cysteine protease activity located 
in the C domain (also known as cysteine protease domain or CPD) of the 
protein (Figure 2.12) (Egerer et al., 2007). Inositolhexaphosphate (IP6) has 
been suggested to mediate this autoproteolytic process (Reineke et al., 2007; 
Egerer et al., 2007). The crystal structure of C domain of TcdA in complex with 
bound IP-6 at 1.6 Å resolution has been reported (Pruitt et al., 2009). The C-
domain of TcdA spans from residue 543 to 809. The CPD of TcdA is composed 
of 9 stranded β sheet flanked by 5 α- helices (Figure 2.12). A trio of Asp, His 
and Cys have been shown important for autoproteolytic activity of TcdA (Pruitt 
et al., 2009) and TcdB (Egerer et al., 2007). 
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Figure 2.12: The C domain (or Cysteine protease domain or CPD) of TcdA with 
bound IP-6 (shown in sticks) (PDB ID - 3HO6) (Pruitt et al., 2009). 
At least two independent high resolution crystal structures of different 
lengths of the receptor binding C terminal repetitive domain (CRD) of TcdA 
(Figure 2.13) have been determined (Ho et al., 2005; Greco et al., 2006). 
Figure 2.13: LHS – the crystal structure of C terminal repetitive domain (127 
residues) of TcdA (PDB ID - 2F6E) (Ho et al., 2005). RHS – the crystal structure of 
C terminal repetitive domain (255 residues) of TcdA in complex with a synthetic 
derivative of its natural carbohydrate receptor (shown in sticks)(PDB ID - 2G7C) 
(Greco et al., 2006). 
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The presence of repetitive units of 21, 30 or 50 amino acid residues is 
the most striking feature of the C terminal repetitive domain of TcdA and TcdB 
(Dove et al., 1990; von Eichel-Streiber et al., 1990; von Eichel-Streiber et al., 
1992; von Eichel-Streiber et al., 1996). In TcdA, there are 30-38 repeats 
present whereas in TcdB the number of repeats are 19 to 24 (Ho et al. 2005). 
The CRD of TcdA is composed of 32 short repeats (SR) and 7 long repeats (LR) 
with each repeat consisting of a β hairpin followed by a loop (Ho et al., 2005). 
The carbohydrate binding site (Figure 2.13, RHS) in the CRD is a shallow 
trough between a LR and the hairpin turn of the following SR (Greco et al., 
2006). It is suggested that the CRD of these toxins adopts an elongated 
serpentine shape in which all carbohydrate binding sites are presented on the 
same face of the structure. This arrangement allows for a multivalent 
interaction of the toxin on the cell surface (Greco et al., 2006). 
Main Experimental Aims of This Thesis 
Limited information is available for both, the structures and 
mechanistic details of Clostridial binary toxins. The available structures to 
date include a high resolution (1.8Å) structure of the enzymatic component (Ia) 
of Iota toxin (Tsuge et al., 2003) in ligand bound form and a 2.1 Å resolution 
structure of the enzymatic component (C2I) of C2 toxin in native state 
(Schleberger et al., 2006). Both of these toxins belong to two different classes 
of Clostridial binary toxins (Table 2.1) on the basis of their substrate 
specificity which makes comparison of the two available structures difficult at 
the molecular level. 
A partially incomplete structure of the transport component (C2II) of 
C2 toxin in monomeric form has been determined (Schleberger et al., 2006). 
The structure provides limited amount of information due to its poor 
resolution (3.1Å). In addition to that, the C terminal receptor binding domain 
of the protein could not be modelled in this structure. The mature transport 
components of Iota family toxins are about 120 amino acid residues longer 
than the C2 family transport component (Barth et al., 2004). Since it is the 
large C-terminal fragment of the transport component that heptamerises and 
is functionally active; this difference in the length of mature proteins may 
provide some crucial information. It would be interesting to establish the 
functional implications of this extra length of the protein. 
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C. difficile is resistant to commonly used antibiotics and is capable of 
causing infection in their presence. An alternative approach to control C. 
difficile infection can be designed based on targeting its toxins. To do so, it is 
necessary to know the 3-dimensional structure of these toxins. Structural 
details of both components of binary toxin can provide important clues about 
their interaction, mechanism of cell intoxication, about their domains that 
should be targeted to make the toxin ineffective and what kind of molecules 
can efficiently inhibit the function of the toxin. 
In addition, the first 42 N terminal residues in CDTa and CDTb have 
been reported to function as signal peptides (Perelle et al., 1997; Rupnik et al., 
2003). Cleavage of the signal peptide is essential for both components to 
become fully mature and functionally active. It would be interesting to see 
what, if any conformational changes, the absence of the signal peptide and 
further proteolytic cleavage induces in mature CDTa and CDTb. Hence, the 
significance of determining the 3D structure is apparent and this leads to the 
aims of the study expected in this thesis. 
In order to provide a structural basis of the understanding of CDT 
function and to determine its role in pathogenesis, a full scale structure 
function study on CDT was initiated with following specific aims: 
� To establish methods of cloning, expression and purification of both the 
components of C. difficile binary toxin. 
� To assess the cell cytotoxicity potential of complete C. difficile binary 
toxin. 
� To determine and analyze the structure of enzymatic as well as 
transport components of C. difficile binary toxin, and 
� To understand the mechanistic details of binary toxins using protein 
engineering approach. 
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CHAPTER - III 
CLONING, EXPRESSION AND

PURIFICATION OF C. DIFFICILE

BINARY TOXIN
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A - CLONING EXPRESSION AND PURIFICATION OF ENZYMATIC

COMPONENT OF C. DIFFICILE BINARY TOXIN: CDTa

MATERIALS AND METHODS 
Primer Design, PCR Amplification and Subcloning 
A set of primers (Table 3.1) was designed to PCR amplify the coding 
sequences of CDTa without its N terminal signal peptide sequence. This 
protein fragment was named CDTa′ and the corresponding coding DNA was 
named cdtA′. 
Table 3.1: The primer sequences for amplification of cdtA′. 
Fragment Primer Sequence 
cdtA′ F= AGCA GGATCC GAA ATC GTG AAC GAA GAT ATT C 
R= AGCA GTCGAC TTA* ATC CAC GCT CAG AAC C 
F – forward primer, R - reverse primer, In italics - random 5′ overhang, 
underlined - restriction sites, * - stop codon. The amplified DNA product was 
named as cdtA′. 
Table 3.2: The PCR composition and reaction conditions for cdtA′ amplification. 
Fragment Reaction mixture (50 µl) Reaction conditions 
cdtA′ Templet DNA= 2 µl, 
Forward primer=2.5 µl, 
Reverse Primer=2.5 µl, 
10X KOD buffer =5 µl, 
25mM MgSO4= 2 µl, 
8 mM DNTP mix=5 µl, 
5M Betaine=10 µl, 
DMSO=2 µl, 
KOD polymerase=1 µl, 
Water= 18 µl. 
950C– 300 secs, 
[950C – 60 secs, 
480C – 60 secs, -(40 cycles) 
720C – 60 secs] 
A recombinant DNA construct (pPCRscript-cdtA) containing the coding 
region of full length CDTa was kindly provided by our collaborator (Dr. Clifford 
C. Shone, HPA, Porton Down) and was used as template DNA for the 
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amplification reaction. The PCR composition and reaction conditions are given 
in table 3.2. The amplified product was run on a 0.8% agarose gel in Tris 
Acetate EDTA (TAE) buffer at 100 volts for 45 minutes and the product was 
eluted from the gel by using a Promega Wizard SV Gel and PCR Clean-up 
system. 
Three different clones of cdtA′ were prepared with the vector backbones 
of pMAL-HT, pMAL-p2x and pGEX-6p1. The PCR amplified product (cdtA′) and 
each of the vector backbones were double digested (Table 3.3) in separate 
reactions in a total volume of 50µL each, with BamHI and SalI restriction 
enzymes to produce compatible sticky ends. The reaction mixtures were 
incubated at 370C overnight to allow the complete digestion of DNA. 
Table 3.3: Composition of the restriction digestion reactions. 
Ingredient Reaction volume 
50 µl 10 µl 
Substrate DNA 30.0 µl 2.0 µl 
10 X buffer D 5.0 µl 1.0 µl 
BamHI and SalI 2.0 µl and 1.0 µl 0.4 µl and 0.2 µl 
100 X BSA 0.5 µl 0.1 µl 
Nuclease free water 11.5 µl 6.5 µl 
The digested products were run on a 0.8% agarose gel in 1X TAE at 100 
volts for 45 minutes and the desired DNA fragments were eluted from the gel 
using Promega Wizard SV Gel and PCR Clean-up system. 
Table 3.4: Composition of the ligation reaction. 
Ingredient Reaction volume = 10 µl 
Vector DNA 5.0 µl 
Insert 3.0 µl 
T4 DNA ligase 1.0 µl 
10 X ligase buffer 1.0 µl 
In the next step, the double digested insert (cdtA′) was ligated with the 
double digested vector backbones (pMAL-HT, pMAL-p2x and pGEX-6p-1) to 
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produce the desired recombinant constructs (Table 3.4). The reaction mixtures 
were incubated at 40C overnight to allow the ligation reaction to complete. 
Screening of Positive Recombinant Clones 
E.coli DH5α competent cells were transformed separately with the 
ligated products. Transformed cells were then plated on LB agar media (Table 
3.5) supplemented with 100 µg/ml ampicillin and incubated at 370C 
overnight. 
Table 3.5: Composition of different growth media used for protein expression. 
Media Ingredients 
LB broth media Tryptone = 10 gm, Yeast extract = 5 gm, NaCl = 10 
gm, dissolve and make up volume to 1000 ml. 
LB Agar media LB media + 1 to1.5% Agar 
TB broth media Tryptone = 12 gm, Yeast extract =24 gm, Glycerol = 4 
ml, dissolve and make up volume with water to 900 
ml. sterilised and allow to cool. Add 100 ml of 
separately sterilised 10 X TB salts solutions. 
TB salts (10X) K2HPO4 =125.4 gm and KH2PO4 =22.70 gm, dissolve 
and make up volume to 1000 ml. 
On the next day, overnight grown single colonies for each construct 
were selected randomly and inoculated in 10 ml of LB media supplemented 
with 100 µg/ml ampicillin, in separate tubes. The cultures were allowed to 
grow at 370C with continuous shaking at 200 rpm overnight. Plasmids were 
isolated from these cultures using a Promega Wiazrd Plus SV Minipreps DNA 
purification system. 
The isolated plasmids were subjected to double digestion reactions for 
preliminary analysis. The digestion reactions at this step were carried out in a 
total volume of 10 µl each (Table 3.3). The reaction mixtures were incubated at 
370C for 4 hours and analysed on a 0.8% agarose gel in 1X TAE at 100 volts 
for 45 minutes. The isolated plasmid DNA that was cleaved into two fragments 
(vector back bone and insert) of the expected size as a result of digestion were 
selected and the presence of the correct DNA fragments (both, inserts and 
vector back bone) was confirmed in those by sequencing (Eurofins, MWG). 
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Preparation of Expression Host 
The new clones that were prepared for CDTa′ expression were pMAL-HT-
cdtA′, pMAL-p2x-cdtA′ and pGEX-6p1-cdtA′. 20 µl of competent E. coli BL21-
CodonPlus (DE3)-RIPL cells were transformed with all three recombinant DNA 
in separate reactions. The transformed cells were plated on the Luria-Bertani 
agar (LB-agar) media (Table 3.5) containing 100 µg/ml ampicillin. All plates 
were incubated at 370C and cells were allowed to grow overnight. 
Next day, 20 ml of Luria-Bertani (LB) broth (Table 3.5) supplemented 
with 100 µg/ml ampicillin was inoculated with a single overnight grown colony 
from each plate in sepearte flasks and these cultures were allowed to grow at 
370C with shaking at 200 rpm overnight. 500 µl of each of the overnight grown 
cultures were mixed with equal volumes of 30% glycerol and stored at -800C. 
These glycerol stocks were used as seed cultures for the subsequent 
expression trials. 
Expression Trials for New Clones 
Table 3.6 provides the details of three sets of expression trials carried 
out for all three newly constructed clones. The frozen glycerol stocks were 
used to inoculate 20 ml of LB broth supplemented with 100 µg/ml of 
ampicillin in separate flasks. These cultures were allowed to grow at 370C with 
shaking at 200 rpm overnight. The expression experiments for all three clones 
were conducted simultaneously under identical conditions so that the results 
could be compared. 
500 ml of fresh sterile media (Table 3.5) was inoculated with the above 
grown seed cultures in separate flasks giving it a 1% final inoculum. 
Appropriate amount of ampicillin (100 µg/ml) was added to the media prior to 
inoculation. These cultures were incubated at 370C with shaking at 200 rpm. 
For low temperature trials, the incubation temperature was shifted to the 
desired value when the culture OD600 was 0.60 – 0.80. Cultures were induced 
with the Isopropyl β-D-thiogalactoside (IPTG) giving a final concentration of 1 
mM when the culture OD600 was 0.90 to 1.0. Incubation at the set temperature 
was continued up to 20 hours post induction. 
Expression samples were collected at different post induction time 
points to analyse on tris-glycine SDS-PAGE during each expression run. These 
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samples were centrifuged at 10,000 rpm for 10 minutes and cell pellets were 
resuspended in 75 µl of water. 25 µl of 4X SDS-PAGE loading dye was added 
to them. These samples were then heated at 1000C for 5 to 10 minutes and 
stored at 40C till they were analysed on a Tris-glycine SDS-PAGE. 
In addition to that, expression samples of 1 ml volume were collected 
separately and centrifuged at 10,000 rpm for 10 minutes at 40C. Cell pellets 
were resuspended in 500 µl of 1X Bug Buster solution (Novagen) and the 
suspensions were incubated at room temperature for 30 minutes. The 
suspensions were centrifuged at 10,000 rpm for 10 minutes at 40C and 
supernatants were collected. 25 µl of 4X SDS-PAGE loading dye was added to 
75 µl of each collected supernatant and these samples were also run on a 
Tris-glycine SDS-PAGE along with the harvested whole cell samples. 
Table 3.6: Different expression trials carried out for CDTa′ expression in the 
shake flask method using three different DNA constructs. 
Parameters Trial 1 Trial 2 Trial 3 
Media LB LB TB +1X TB salts + 0.5% glucose 
Host E. coli BL21-CodonPlus (DE3)-RIPL 
Incubation Started at 370C, 200 rpm 
Temperature Continued 
at 370C 
Shifted to 200C at OD600 = 0.6 to 0.8 
Induction 1 mM IPTG at OD600 = 0.9 to 1.0 
Harvest 4 hours/ 8 hours / 20 hours post incubation 
Results Visible expression, 
insoluble protein for all 
the 3 clones 
Visible expression, soluble 
protein for all the 3 clones 
10% resolving, 5% stacking Tris-glycine SDS-PAGE gels were run for all 
samples. To ensure loading the same amount of total protein on the gel, 
volume equivalent to the 9/OD600 of each sample was loaded on the gels. All 
gels were run at 200 volts at room temperature till the dye front migrated out 
of the lower end of the gel. Gels were stained with brilliant blue R stain for an 
hour and washed with destaining solution until the protein bands were clearly 
visible. Sample preparation and gel run were carried out essentially in an 
identical manner at all times unless otherwise stated. 
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Large Scale Expression of CDTa′ 
Based on the results of expression trials, clone pMAL-p2x-cdtA′ was 
chosen for the large scale production of the protein which was carried out in 
shake flask method. Seed culture was grown from the glycerol stock in the 
ampicillin containing LB media at 370C with continuous shaking at 200 rpm 
overnight. Sterilised TB media (supplemented with 1X TB salts, 0.5% glucose 
and 100 µg/ml ampicillin) was inoculated with the seed culture to give 1 to 
2% inoculum. The culture was allowed to grow at 370C at 200 rpm. The 
incubation temperature was decreased to 200C when the culture OD600 
reached to 0.6-0.8. The culture was induced with the IPTG to a final 
concentration of 1 mM at OD600 = 0.9-1.0 and continued to grow at 200C. The 
culture was finally harvested at 4 hours post induction time and centrifuged 
at 10,000 rpm at 40C for 10 minutes. The cell pellet was stored at -800C until 
further processing. 
Purification of CDTa′ 
The cell pellet was resuspended in buffer A (Table 3.7) (10 ml/gram of 
cell pellet) and the cells were lysed using a French press in two cycles at 2000 
bar pressure. The cell lysate was centrifuged at 25,000 rpm at 40C for 30 
minutes and the supernatant was collected. A Q sepharose ion exchange resin 
was equilibrated with buffer A and the clear supernatant was loaded onto it. 
The column was washed with plenty of buffer A until the base line was 
reached. The bound protein was then eluted in steps of 10%, 20%, 30%, 40%, 
50% and 100% of buffer B in buffer A (Table 3.7). All elution fractions were 
collected separately and run on a 10% separating SDS-PAGE. The MBP-CDTa′ 
fusion protein was identified on the gel and fractions containing the desired 
protein were pooled for tag cleavage reaction. 
Sufficient amount of factor Xa (1 Unit / 50 µg of fusion protein) was 
added to the protein and incubated at 200C for 24 hours with gentle shaking. 
On the next day, completion of the tag cleavage reaction was confirmed by 
running the reaction product on a 10% Tris-glycine SDS-PAGE. The protein 
was dialysed overnight against a 50 volumes of buffer C (Table 3.7) using a 12-
14 kDa cutoff dialysis tubes. 
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Table 3.7: Composition of buffers used in the CDTa′ purification.

Buffer Composition 
Buffer A 20 mM NaCl, and 5 mM CaCl2 in 50 mM Tris-HCl, pH 
8.0 
Buffer B 1 M NaCl and 5 mM CaCl2 in 50 mM Tris-HCl, pH 8.0 
Buffer C 20 mM NaCl in 50 mM Tris-HCl, pH 8.0 
Buffer D 1 M NaCl in 50 mM Tris-HCl, pH 8.0 
Factor Xa 
cleavage buffer 
100 mM NaCl and 5 mM CaCl2 in 50 mM Tris-HCl, pH 
8.0 
The dialysed protein solution was collected in a fresh tube and 
centrifuged at 10,000 rpm for 10 minutes at 40C to remove the insoluble 
debris and precipitated protein. Clear supernatant was passed through a Q 
sepharose ion exchange resin that was pre-equilibrated with buffer C. Purified 
CDTa′ was collected in the column flow-through. 
The bound uncleaved fusion protein and the cleaved MBP tag were 
eluted from the column in two steps of 10% and 50% of buffer D (Table 3.7) in 
buffer C and were collected separately. The column flow-through and eluted 
fractions were analysed on a 10% Tris-glycine SDS-PAGE to assess the purity 
of the protein. The purified protein was concentrated to 0.5 mg/ml using a 10 
kDa MWCO Millipore concentrator at 4000 rpm at 40C and was stored at -
800C in 1 ml aliquots. 
RESULTS AND DISCUSSION 
Primer Design, PCR Amplification and Subcloning 
The DNA construct (pPCRScript-cdtA) was kindly provided by our 
collaborator. It was commercially synthesised by GENEART (Germany). The 
construct was to facilitate in vivo amplification of the ‘insert’ (CDTa coding 
sequence) for further development of new clones. The coding sequence of full 
length CDTa was inserted in the pPCRScript vector backbone between BamHI 
and SalI restriction sites. The insert was provided with a stop codon 
immediately after the CDTa coding sequence. 
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The Primer set was designed to amplify the desired DNA fragments and 
to clone it into the first reading frame between BamHI and SalI sites. Both, the 
forward and the reverse primers were designed with a 5′ overhang of 4 random 
nucleotides followed by the restriction enzyme recognition sequence. Figure 
3.1 shows the PCR amplified DNA fragment on a 0.8% agarose gel. 
Figure 3.1: The PCR amplified cdtA′ on a 0.8% agarose gel. 
While going for the sticky end cloning with a PCR amplified product 
containing restriction sites at the ends, it is always advantageous to have such 
random 5′ overhangs. It is a well established fact that the restriction enzyme 
recognition sites at the end of the sequence are cut with a poorer efficiency 
than the recognition sites in the middle of the sequence. These 5′ random 
overhang sequences bring the recognition sequences in the middle of the DNA 
fragment and thus provide a better place for the restriction enzyme to latch on 
the DNA and to have a better grip on the DNA to cut it. 
A schematic arrangement of the domains of CDTa is presented below 
(Figure 3.2). The primer set was designed to amplify the DNA fragments (cdtA′), 
without the coding sequence of its signal peptide. CDTa (49 kDa) is produced 
by the bacterium as an inactive precursor which is activated by a proteolytic 
cleavage of the signal peptide (Perelle et al., 1997). The signal peptide of CDTa 
comprises of the first 42 N terminal residues of the full length protein and has 
a molecular weight of about 4 kDa. The expressed protein (CDTa′, ~45 kDa), 
thus lacks the N-terminal signal peptide. 
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Figure 3.2: The domain organisation of CDTa. 
Three different clones – pMAL-HT-cdtA′, pMAL-p2x-cdtA′ and pGEX-6p1-
cdtA′, were prepared at this stage. Preliminary analysis of new recombinant 
DNA clones was performed by double digestion reaction (Figure 3.3). All three 
used expression vectors accept the insert in the first reading frame between 
BamHI and SalI restriction sites. The PCR amplified fragment had its first 
codon immediately after the BamHI recognition sequence. Therefore, we had 
the possibilities of inserting the amplified cdtA′ into all three used expression 
vector backbones to produce the correct fusion protein in the first reading 
frame with the chosen set of restriction enzymes. The Sequence of all 
recombinant constructs producing DNA fragments of the expected size on an 
agarose gel as a result of digestion were subsequently confirmed by 
sequencing (Eurofins, MWG). 
Figure 3.3: Preliminary analysis of isolated plasmids from the selected colonies 
by enzymatic double digestion. The numbers were randomly assigned to 
colonies. DNA No. 73, 77 and 81 were sent for sequencing and were found 
correct. DNA No. 78, 79 and 82 did not have correct insert. 
The pMAL-p2x and pGEX-6p1 vectors were obtained commercially from 
New England Biolabs and GE Healthcare respectively. The pMAL-HT vector is a 
modified version of pMAL-c2x expression vector (New England Biolabs). The 
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original pMAL-c2x vector is designed to produce a fusion protein with a 
cleavable N terminal MBP (Maltose Binding Protein) tag. The pMAL-HT was 
produced by deleting the MBP coding sequence from the commercially 
available pMAL-c2x vector and replacing it with the coding sequence for 6-His 
tag. This modification allowed the construct to produce an N terminal 6-His 
tagged fusion proteins which could be cleaved from the fusion protein with the 
help of factor Xa. 
Expression Trials for New Clones 
The new clones are capable of producing the desired protein fused with 
three different cleavable tags at the N terminal (Table 3.8). Based on the tag 
and its properties, a suitable purification strategy can be developed for 
purification of the fusion protein and finally the target protein i. e. CDTa′. 
All different expression trials (table 3.6) produced the desired fusion 
proteins (Figure 3.4). The expression trial set 1 (Table 3.6) produced insoluble 
fusion proteins in the form of inclusion bodies for all three clones. 
Table 3.8: Details of fusion proteins produced by using different recombinant 
clones for CDTa′ expression. 
Clone Fusion 
Protein 
Molecular Weight 
( Tag + Protein) 
Nature of Tag 
pMAL-HT-
cdtA′ 
6His-CDTa′ 48 kDa 
(1 kDa + 47kDa) 
N terminal, cleavable by 
Factor Xa 
pMAL-p2x-
cdtA′ 
MBP-CDTa′ 92 kDa 
(45 kDa + 47 kDa) 
N terminal, cleavable by 
Factor Xa 
pGEX-6p1-
cdtA′ 
GST-CDTa′ 74 kDa 
(27 kDa + 47 kDa) 
N terminal, cleavable by 
PreScission protease 
The TB media is richer than the LB media and supports a much faster 
growth of the organisms. The higher the growth rate of the organism, the 
higher would be the rate of fusion protein expression and thus higher the 
chances of protein forming inclusion bodies. Therefore, no expression trial in 
TB media was carried out at 370C. 
Few more optimisations of the expression conditions (Table 3.6, trial set 
3) resulted in all three fusion proteins expressed in soluble form. The level of 
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expression of the three fusion proteins under identical conditions was in the 
following order (Figure 3.4). 
MBP-CDTa′ > GST-CDTa′ > HT-CDTa′ 
Figure 3.4: The expression of all 3 fusion proteins in expression trial 3 (Table 
3.6). 0H – pre induction sample, 4H – 4 hours post induction whole cell sample, 
CL – bug buster treated supernatant of 4 hours harvested sample. 
Prolonged post induction incubation for 8 hours or longer did not 
improve the expression of fusion proteins any further. Based on their level of 
expression, clone pMAL-p2x-cdtA′ was selected for the large scale production of 
the protein that was carried out in shake flask method. 
Purification of CDTa′ 
The purification of CDTa′ was completely based on its net surface 
charge distribution. At a pH below its isoelectric point (pI), any given protein 
has a net positive charge on it whereas at a pH above its pI, it has a net 
negative charge. Based on its net charge, proteins bind to an anion or a cation 
exchanger resins from which they can be selectively eluted and thus separated 
from each other. In this particular case, the fusion protein (MBP-CDTa′) and 
the tag (MBP) have their pIs in the range of 5.0 to 5.5, and therefore bear a net 
negative charge at the pH of buffers (i. e. pH 8.0) that are used in purification 
process. The theoretical pI of CDTa′ is 8.9 and hence, it is expected to have a 
net positive charge at pH 8.0. 
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Figure 3.5: Step elution from first anion exchange column. MBP-CDTa′ is 
present in the first elution fraction with 10% elution buffer. 1- crude cell lysate, 
M – marker protein ladder, 2, 3, 4, 5, 6 and 7 – elution steps with10%, 20%, 
30%, 40%, 50% and 00% buffer B in buffer A respectively. 
Out of these three species, only the fusion protein was present in the 
crude cell lysate. Because of its net negative charge at pH 8.0, it bound to the 
Q sepharose anion exchange resin and could be eluted from the column with 
an increased salt concentration in the mobile phase i. e. the elution buffer. 
Elution in steps was carried out to provide an idea of suitable range of the 
concentration of salt needed to elute the fusion protein from the column. Most 
of the desired fusion protein elutes with 10% buffer B which corresponds to 
100 mM of NaCl concentration (Figure 3.5). 
Results of the first anion exchange elution pattern were useful in the 
sense that factor Xa is most efficient in the presence of 100 mM NaCl salt. The 
pH of all buffers (pH 8.0) was also optimum for factor Xa mediated tag 
cleavage reaction to take place (Table 3.7). Factor Xa cleaves the MBP- CDTa′ 
fusion protein (in 24 hours at 200C) into two species (Figure 3.6, lanes 2 and 
3) namely, MBP (~42kDa) and CDTa′ (~45 kDa). 
The dialysed, tag cleaved protein sample (Figure 3.6, lane 4) contains all 
three species – CDTa′, MBP and the uncleaved MBP-CDTa′. The CDTa′ did not 
bind to the second Q sepharose column under the conditions that were 
identical to the loading conditions for the first anion exchange column run 
because of its net positive charge at pH 8.0 and could be collected in the 
column flow-through (Figure 3.6, lane 5) in second Q sepharose run. Whereas, 
the MBP and MBP-CDTa′ along with other impurities bound to the column 
again and thus could efficiently be separated from CDTa′ (Figure 3.6, lanes 6 
and 7). 
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Figure 3.6: Step wise progress of CDTa′ purification process. Lane 1- 10% 
elution fraction, lane 2 and 3 – cleaved protein. Lane 4 - dialised cleave protein, 
lane 5- flow-through from second anion exchange, lane 6 and 7- elution fractions 
(20% and 50% of buffer D in buffer C respectively) from second anion exchange 
column. 
SUMMARY 
Three different recombinant constructs namely – pMAL-HT-cdtA′, pMAL-
p2x-cdtA′ and pGEX-6p1-cdtA′ were prepared for the expression of CDTa 
fragment without its signal peptide. Based on the expression pattern, CDTa′ 
was expressed in soluble form as MBP-CDTa′ fusion protein. The purification 
process yielded a protein (CDTa′) of high purity that was stored at -800C. 
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B - CLONING, EXPRESSION AND PURIFICATION OF TWO DIFFERENT 
CONSTRUCTS OF TRANSPORT COMPONENT OF C. DIFFICILE 
BINARY TOXIN: CDTb′ and CDTb″ 
MATERIALS AND METHODS 
Recombinant DNA Construction 
Two different versions of CDTb were studied in this research. Sets of 
specific primers (Table 3.9) were designed to PCR amplify the DNA fragments 
for coding sequences of both the versions. The first version, cdtB′, was the 
DNA fragment that lacks the coding region for the N terminal signal peptide of 
the protein. We named this protein fragment as CDTb′. The second DNA 
fragment (named cdtB″) was the coding sequence for mature CDTb fragment 
and the expressed protein was named CDTb″. A recombinant construct 
(pPCRscript-cdtB) containing the coding region of full length CDTb was 
provided by our collaborator and was used as template DNA for both of the 
amplification reactions. 
Table 3.9: The primer sequences for the amplification of cdtB′ and cdtB″. 
Fragments Primer Sequence 
cdtB′ F= 
R= 
GTAT GGATCC GTG TGC AAC AC 
AGCA GTCGAC TTA* ATC CAC GCT CAG AAC C 
cdtB″ F= 
R= 
AGTA GGATCC CTG ATG AGC GAT TGG 
AGCA GTCGAC TTA* ATC CAC GCT CAG AAC 
F – forward primer, R - reverse primer, In italics - random 5′ overhang, 
underlined - restriction enzyme recognition sequence, * - stop codon. 
The reaction composition and reaction conditions for both the 
amplification reactions are provided in table 3.10. The amplified products were 
analysed on a 0.8% agarose gel in 1X TAE, at 100 V for 45 minutes and the 
products were eluted from the gel using Promega Wizard SV Gel and PCR 
Clean-up system. 
Both the amplified PCR fragments were then cloned into the pGEX-6p-1 
expression vector (GE Healthcare). The PCR amplified products (cdtB′ and 
cdtB″) and the vector backbone were double digested in a 50µL reaction each, 
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with BamHI and SalI restriction enzymes to produce compatible sticky ends as 
described in the section 3A previously. Further steps of ligation, 
transformation, positive clone selection, plasmid isolation, DNA sequencing, 
preparation of E. coli BL21-CodonPlus (DE3)-RIPL expression host and glycerol 
stocks were also carried out as described in the section 3A. 
Table 3.10: The PCR reaction composition and reaction conditions for cdtB′ and 
cdtB″ amplification. 
Fragment Reaction mixture (50 µl) Reaction conditions 
cdtB′ Templet DNA= 2 µl, 
Forward primer=2.5 µl, 
Reverse Primer=2.5 µl, 
10X KOD buffer =5 µl, 
25mM MgSO4= 2 µl, 
950C– 300 secs, 
[950C – 60 secs, 
550C – 60 secs, -(40 cycles) 
720C – 90 secs] 
cdtB″ DNTP mix (2mM each)= 5 µl, 
5M Betaine=10 µl, 
DMSO=2 µl, 
KOD polymerase=1 µl, 
Water= 18 µl. 
950C– 300 secs, 
[950C – 60 secs, 
510C – 60 secs, -(40 cycles) 
720C – 90 secs] 
Preliminary Expression Trials of GST-CDTb′ and GST-CDTb″ 
The expression trials for both the fusion proteins were conducted 
separately but in a similar way. 200 ml of sterilised TB media (with 1 X TB 
salts, 100 µg/ml ampicillin and 0.5% glucose) was inoculated with an 
overnight grown seed culture to give 1% inoculum and incubated at 370C with 
shaking at 200 rpm. The culture was induced with the IPTG to a 1mM final 
concentration when the culture OD600 was in the range of 0.8 to 1.0. 
Incubation at 370C was continued for the next 4 hours. Samples at different 
post induction time were collected to run on a Tris-glycine SDS-PAGE. Sample 
preparation and gel run was carried out as described previously (section 3A). 
More expression trials were carried out in order to express the desired 
protein in soluble form (Table 3.11). The parameter varied during different 
expression trials was temperature. All other parameters were kept identical. 
The culture was started at 370C in shake flask method at 200 rpm and was 
allowed to grow until the culture OD600 reached to 0.6 -0.8. The temperature 
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was then decreased to the desired value and the culture was induced with 1 
mM of IPTG at OD600 = 0.9 - 1.0. The culture was harvested at 16-20 hours 
post induction, centrifuged at 10,000 rpm for 10 minutes at 40C and the cell 
pellet was stored at -800C. 
Table 3.11: Different expression trials for CDTb′ and CDTb″ using pGEX-6p1-
cdtB′ and pGEX-6p1-cdtB″ clones in E. coli host. 
Parameters Trial set number 
1 2 3 4 5 
Media TB +1X TB salts + 0.5% glucose + ampicillin 
Host E. coli BL21-CodonPlus(DE3)-RIPL 
Method Shake flask 
Incubation conditions Started at 370C, 200 rpm 
Temperatures 370C 300C 240C 200C 160C 
Induction 1 mM / 0.5 mM IPTG at OD600 = 0.9 to 1.0 
Harvest 4 hours/ 8 hours / 20 hours post incubation 
Results overexpreesed protein seen at expected position 
on SDS-PAGE 
Location of protein Inclusion bodies Soluble form 
A small sample (1ml) of harvested culture was collected separately and 
centrifuged as above. The pellet was resuspended in buffer F (150 mM NaCl in 
50 mM Tris-HCl, pH 7.5) and was sonicated in 3 cycles of 10 sec on 20 
seconds off. The sonicated sample was centrifuged at 10,000 rpm for 10 
minutes at 40C and the supernatant was run on a 10% separating Tris-glycine 
gel along with the uninduced and induced (hourly) whole cell samples to 
confirm the presence of overexpressed protein in soluble form. 
Large scale Expression of GST-CDTb′ and GST-CDTb″ 
The large scale expression of both of the fusion proteins (GST-CDTb′ 
and GST-CDTb″) in soluble form was carried out in identical manner using a 
BIOFLO 3000 bioreactor (NewBrunswik). TB media supplemented with 1X TB 
salts, 100 µg/ml ampicillin and 0.5% glucose was inoculated with 1% (v/v) of 
the overnight grown seed culture at 370C. The incubation temperature was 
lowered down to 160C when the culture OD600 reached to 0.6 - 0.8, and the 
73

culture was induced with the IPTG to a final concentration of 1 mM at OD600 = 
0.9 to 1.0. 
The temperature of the bioreactor was maintained at a set value by 
running hot/chilled water into the vessel jacket. A mixture of air and oxygen 
was sparged continuously in a ratio of 40:60 (air to oxygen) at 0.5 bar 
pressure each into the bioreactor to maintain a minimum of 60% dissolved 
oxygen (DO) at all times. The pH of the culture was maintained at 7.0 
throughout the process with intermittent addition of 10% orthophosphoric 
acid and 10% ammonium hydroxide, as and when required. An agitation rate 
of 150 rpm was also maintained during the run. The pH, DO and the 
temperature of the bioreactor were controlled in proportional-integral-
derivative (PID) manner. Incubation at 160C was continued and the culture 
was harvested at 20 hours post induction time. The harvested culture was 
centrifuged at 10,000 rpm for 10 minutes at 40C and the cell mass was stored 
at -200C. 
Afinity Purification and Tag Cleavage of CDTb′ 
The cell pellet was resuspended in lysis buffer (Table 3.12) and the cell 
suspension was sonicated in 5 cycles of 20 second on, 40 second off. The cell 
lysate was centrifuged at 25,000 rpm for 30 minutes at 40C and the clear 
supernatant was loaded onto a GST affinity column pre-equilibrated with lysis 
buffer. 
Table 3.12: Composition of the lysis buffer. 
Buffer Composition 
Lysis 150 mM NaCl, 2 mM DTT and 1 mM EDTA in 
buffer 50 mM Tris-HCl, pH 7.5 
The column was washed with plenty of lysis buffer until the base line 
was reached and the bound protein was eluted with 20 mM reduced 
glutathione in lysis buffer. The eluted protein was run on a 10% Tris-glycine 
SDS-PAGE to analyse the quantity and quality of the eluted protein. 
To cleave the GST tag, sufficient amount (1 Unit / 100 µg of fusion 
protein) of PreScission protease (GE Healthcare) was added to the fusion 
protein solution and the reaction mixture was incubated at 40C, overnight with 
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continuous stirring. The cleavage reaction product was analysed on a 10% 
resolving Tris-glycine SDS-PAGE in parallel with the uncleaved protein. 
Gel Filtration 
The affinity purified fusion protein (GST-CDTb′) was loaded onto a 
Superdex-200 gel filtration column pre-equilibrated with lysis buffer (Table 
3.12). Elution fractions of 1 ml each were collected and fractions 
corresponding to the eluted peak were analysed on a 10% resolving Tris-
glycine SDS-PAGE. Three different gel filtration runs at a flow rate of 1.0 
ml/minute, 0.5 ml/minute and 0.2 ml/minute were carried out in order to 
achieve best separation. 
Effect of the Cell Lysis Method on Fusion Protein 
The affinity and gel filtration procedures described above did not 
produce satisfactory results and were associated with a severe protein 
degradation problem. Hence, an extensive search for an appropriate 
purification strategy was carried out starting from the cell lysis method. The 
cell pellet was resuspended in lysis buffer (Table 3.12) as described before and 
cells were lysed using homogenizer at 400 bar pressure in 2 cycles. The cell 
lysate was centrifuged at 25,000 rpm for 30 minutes at 40C and the clear 
supernatant was collected. An affinity purification step was carried out in an 
identical way as it has been described before. At a different occasion, cell lysis 
using a French press at 2000 bar pressure was also tried. 
Search for Suitable Purification Strategy 
The affinity purified, tag cleavage reaction product was loaded again 
onto a GST affinity resin pre-equilibrated with lysis buffer (Table 3.13). The 
column flow-through was collected and was dialysed against 50 volume of 
dialysis buffer (Table 3.13) at 40C overnight. The dialysed protein was 
centrifuged at 10,000 rpm for 15 minutes at 40C to remove any particulate 
material and precipitate present. The clear supernatant was collected and 
loaded onto a Q sepharose column pre-equilibrated with dialysis buffer (Table 
3.13). The loaded column was washed with plenty of dialysis buffer and the 
bound protein was eluted with 100 ml of 0 to 100% gradient starting with 
dialysis buffer and ending with elution buffer (Table 3.13). Fractions 
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corresponding to the eluted peak were analysed on a 4-12% Bis-Tris SDS-
PAGE. Fractions containing the desired protein (CDTb’) were pooled. 
A need for further purification of the pooled protein was felt. Several 
different strategies from this point onwards were employed to serve the 
purpose. A flow chart shown in figure 3.7 explains some of the applied 
strategies. Composition of all the buffers that were used at different steps is 
provided in table 3.13. 
Figure 3.7: A flow chart of different purification strategies employed. 
It became clear that several steps of dialysis were needed to be 
incorporated at the different stages of purification to keep the protein in an 
appropriate buffer to match the physiochemical conditions suitable for loading 
the protein onto a given particular purification resin. All the dialysis steps 
were carried out using 12-14 kDa cut off dialysis tubes at 40C overnight with 
continuous stirring. 
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Table 3.13: Composition of buffers used at different steps of purification.

Step Buffer Composition 
Lysis / affinity 
purification 
and tag 
Lysis buffer 150 mM NaCl, 2 mM DTT and 1 
mM EDTA in 50 mM Tris-HCl, pH 
7.5 
cleavage Elution buffer 20 mM reduced Glutathion in 
lysis buffer 
Q sepharose 
Anion 
exchange / 
Dialysis / 
Equilibration buffer 
50 mM NaCl, 2 mM DTT and 1 
mM EDTA in 50 mM Tris-HCl, pH 
7.5 
MonoQ anion 
exchange 
Elution buffer 1 M NaCl, 2 mM DTT and 1 mM 
EDTA in 50 mM Tris-HCl, pH 7.5 
SP sepharose 
cation 
exchange 
Dialysis / 
Equilibration buffer 
20 mM NaCl, 2 mM DTT and 1 
mM EDTA in 50 mM Succinate 
buffer , pH 5.5 
Elution buffer 1 M NaCl, 2 mM DTT and 1 mM 
EDTA in 50 mM Succinate buffer, 
pH 5.5 
P sepharose 
hydrophobic 
Dialysis / 
Equilibration buffer 
1M NaCl, 2 mM DTT and 1 mM 
EDTA in 50 mM Tris-HCl, pH 7.5 
exchange Elution buffer 2 mM DTT and 1 mM EDTA in 50 
mM Tris-HCl, pH 7.5 
Hydroxyappatit 
e column 
Dialysis / 
Equilibration buffer 
10 mM Sodium di hydrogen 
phosphate, pH 7.0 
Elution buffer 250 mM Sodium di hydrogen 
phosphate, pH 7.0 
Gel filtration Equilibration buffer 150 mM NaCl, 2 mM DTT and 1 
mM EDTA in 50 mM Tris-HCl, pH 
7.5 
A More Efficient Purification Strategy for CDTb′ 
Different purification strategies employed to solve the problem of 
degradation did not bring any significant improvement in the final purity of 
CDTb′. Therefore another method was employed. The cell lysis and affinity 
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purification steps were carried out in lysis buffer (Table 3.14) as it has been 
stated before. 
Table 3.14: Composition of buffers used in the alternative strategy for CDTb′ 
purification. 
Step Buffer Composition 
Lysis/affinity 
purification/tag 
Lysis buffer 150 mM NaCl, 2 mM DTT and 1 mM 
EDTA in 50 mM Tris-HCl, pH 7.5 
cleavage Elution buffer 20 mM reduced Glutathione in lysis 
buffer 
MonoQ anion 
exchange 
Dialysis buffer 50 mM NaCl, 2 mM DTT and 1 mM 
EDTA in 50 mM Tris-HCl, pH 7.5 
Elution buffer 500 mM NaCl, 2 mM DTT and 1 mM 
EDTA in 50 mM Tris-HCl, pH 7.5 
Concentration Concentration 
buffer 
200 mM NaCl, 2 mM DTT and 1 mM 
EDTA in 50 mM Tris-HCl, pH 7.5 
The affinity eluted fraction (fusion protein) was then directly loaded onto 
a MonoQ anion exchange column pre-equilibrated with lysis buffer. The loaded 
column was washed with plenty of lysis buffer and the bound protein was 
eluted with a 0 to 100% gradient starting with lysis buffer and ending with 
elution buffer (Table 3.14). All the fractions were analysed on a 4-12% Bis-Tris 
SDS-PAGE and fractions containing the desired fusion protein were collected 
and pooled. Sufficient amount of PreScission protease (1 Unit / 100 µg of 
fusion protein) was added to the pooled fusion protein solution and left 
overnight at 40C with gentle shaking to cleave the GST tag. 
The cleavage reaction product was once again passed through a GST 
affinity column pre-equilibrated with lysis buffer following a brief spin at 
10,000 rpm for 15 minutes at 40C to remove any particulate material and 
precipitate present. The column flow-through was collected and dialysed 
against 50 volume of dialysis buffer (Table 3.14) overnight at 40C. The dialysed 
protein was loaded onto a MonoQ column pre-equilibrated with dialysis buffer 
and the bound protein was eluted in 0 to 100% gradient starting with dialysis 
buffer and ending with elution buffer (Table 3.14). Fractions containing the 
free CDTb′ protein were identified by Bis-Tris SDS-PAGE and pooled. 
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Routine Quality Check and Mass Spectrometric Analysis of CDTb′ 
The protein was concentrated to 7 mg/ml using 10 kDa MWCO 
concentrators. The protein quantity was estimated by recording absorbance at 
280 nm and the concentrated protein was stored at -800C. The stored protein 
sample was run on a 10% Tris-glycine SDS-PAGE after a week’s time for 
routine analysis. 
For mass spectroscopy analysis, the protein was buffer exchanged into 
water using a concentrator of 30 kDa MWCO, at 40C and 2000 rpm. The buffer 
exchanged protein was run on a 10% Tris-glycine SDS-PAGE along with the 
original concentrated sample under reducing as well as non-reducing 
conditions. The protein was analysed by mass spectroscopy facility at the 
Department of Chemistry, University of Bath. 
Final Purification of CDTb′ and CDTb″ 
The cells were lysed by homogenisation in buffer F (Table 3.15) and the 
cell lysate was centrifuged as explained before. The clear supernatant was 
loaded onto a GST affinity column and the column was washed with plenty of 
buffer F until the base line was reached. The bound protein was eluted with 
20 mM of reduced glutathione in buffer F. 
Table 3.15: Composition of buffers used for final purification of CDTb′. 
Buffer Composition 
Buffer F 150 mM NaCl and 2 mM DTT in 50 mM Tris-HCl, pH 7.5 
Buffer G 1000 mM NaCl, 2 mM DTT in 50 mM Tris-HCl, pH 7.5 
Buffer H 50 mM NaCl, 2 mM DTT and 0.2% tween-20 in 50 mM 
Tris-HCl, pH 7.5 
Buffer I 1000 mM NaCl, 2 mM DTT and 0.2% tween-20 in 50 mM 
Tris-HCl, pH 7.5 
The eluted fusion protein was loaded onto a MonoQ anion exchange 
column pre-equilibrated with buffer F followed by extensive washing of the 
column with plenty of buffer F. The bound protein was eluted in a 0 to 60% 
gradient of buffer G (Table 3.15) in buffer F. All of the fractions containing the 
desired fusion protein were collected and pooled based on a 4-12% Bis-Tris 
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SDS-PAGE result. Sufficient amount of PreScission protease (1 Unit / 100 µg 
of fusion protein) was added to the pooled fusion protein solution and left at 
40C overnight with gentle shaking for the tag cleavage reaction to take place. 
The cleavage reaction product was dialysed against 50 volume of buffer 
H (Table 3.15) overnight at 40C. The dialysed protein was centrifuged at 
10,000 rpm for 15 minutes at 40C and the supernatant was passed through a 
GST affinity column pre-equilibrated with buffer H and the column flow-
through was collected. The collected flow-through was then loaded onto a 
monoQ column pre-equilibrated with buffer H and the bound protein was 
eluted in a 0 to 60% gradient of buffer I (Table 3.15) in buffer H. Fractions 
containing the free CDTb′ (or CDTb″) protein were identified on a 4-12% Bis-
Tris SDS-PAGE and pooled. The pooled protein was stored at -800C. 
Quality Analysis and Quantification of Protein 
The quality of proteins (CDTb′ and CDTb″) was assessed by running 
protein samples on a freshly casted 10% resolving Tris-Glycin-SDS-PAGE in 
Tris-Glycin buffer using a standard protocol. In addition to that, two different 
commercially available SDS-PAGE systems – a 4-12% NuPAGE Novex Bis Tris 
Gels (BT gels) in MES buffer and a 4-20% Novex Tris Glycine gels (TG gels) in 
Tris Glycine buffer were also employed for the analysis of both the proteins. 
Both the gel systems and running buffers were purchased from Invitrogen and 
were used as per the instructions provided by manufacturers. 
The protein quantity in all the samples except the crude cell lysates was 
estimated by recording the absorbance at 280 nm wavelength. Theoretical 
absorbance (for 1 mg protein per ml sample) was calculated by submitting 
protein sequence to the ProtParam application of Expasy proteomic server 
(http://www.expasy.org). 
RESULTS AND DISCUSSION 
Recombinant DNA Construction 
The primers were designed to amplify the desired DNA fragments and to 
clone it into the first reading frame between BamHI and SalI sites. The 
amplified DNA fragments (cdtB′ and cdtB″) code for two different versions of 
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the transport component of C. difficile binary toxin, named CDTb′ and CDTb″ 
respectively. All sets of primers were designed with a random 4 nucleotides 
overhang followed by the restriction enzyme recognition site at the 5′ end of 
the coding sequence for the reasons that have been explained before (section 
3A). The PCR amplified cdtB′ fragment is shown in figure below (Figure 3.8) 
Figure 3.8: The PCR amplified cdtB′ (left) and double digestion of positive 
pGEX-6p1-cdtB′ clone (right). 
Positive colonies were successfully grown on LB-agar plate for both of 
the desired clones namely pGEX-6p1-cdtB′ and pGEX-6p1-cdtB″. A preliminary 
analysis of these clones by double digestion method yielded DNA fragments of 
the expected size on an agarose gel (Figure 3.8). Sequencing of both 
recombinant constructs confirmed the presence of the correct vector backbone 
and insert in the correct orientation and position. 
Expression of Proteins 
The transport component of C. difficile binary toxin, CDTb (99 kDa) is 
produced as an inactive precursor molecule with an N-terminal signal peptide 
of 42 residues. Figure 3.9 shows the domain organisation of CDTb. CDTb′ is 
the name given to the fragment of CDTb that lacks the N-terminal signal 
peptide. 
However, to transport the enzymatic component (CDTa) into the target 
cell, CDTb has to be activated by a proteolytic cleavage (Perelle et al., 1997) 
mediated by chymotrypsin. As a result of chymotrypsin mediated activation, a 
25 kDa N-terminal fragment of precursor CDTb is cleaved from the protein 
and the remaining C-terminal large fragment (75 kDa) has been suggested to 
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oligomerise to form a heptameric pore like structure (Barth et al., 2000; 
Blocker et al., 2001). 
Figure 3.9: The domain organisation of CDTb. 
This essentially means that the expressed CDTb′ requires a proteolytic 
activation by chymotrypsin to become fully functional protein whereas the 
expressed CDTb′′ should be a fully active (mature) fragment of CDTb (Figure 
3.9). With an N-terminal GST fusion partner (27 kDa), expected molecular 
weight of both of the expressed fusion proteins (GST-CDTb′ and GST-CDTb′′) 
are 122 kDa (Figure 3.10) and 102 kDa respectively. 
Figure 3.10: The expression samples of GST-CDTb′ fusion protein on a 10% 
Tris-glycine SDS-PAGE. 
Affinity Purification and Tag Cleavage of CDTb′ 
The gel analysis revealed that the affinity eluted fraction consisted of 
two major proteins bands (Figure 3.11, lane 1). The upper observed band 
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present at about 120 kDa corresponded to the expected molecular weight of 
GST-CDTb′ fusion protein. The lower major band on the gel was observed at 
about 97 kDa marker protein. The expected molecular weight of GST tag is 27 
kDa and it was initially thought that the tag had been cleaved off the fusion 
protein in solution to give free CDTb′. It could be confirmed by any of the 
following two methods. 
Figure 3.11: The affinity purified GST-CDTb′ protein and the tag cleavage 
reaction results. 
The first method exploits the biological specificity by western blot 
analysis of eluted fraction against anti-GST antibody. If the lower band 
present on gel (Figure 3.11, lane 1) was tag cleaved free protein, it should not 
be detected by the anti-GST antibody on the blot. The second method was to 
perform a tag cleavage reaction. This method takes advantage of the size of the 
tag. If the lower band was the tag cleaved protein, no observable shift in the 
position of the band on SDS-PAGE should be detected. However, there should 
be a position shift for the upper 120 kDa band yielding two bands on SDS-
PAGE – one corresponding to the free CDTb′ at 95 kDa and the other 
corresponding to GST tag at 27 kDa. In the absence of anti GST-antibody, the 
method of tag cleavage was employed. 
A shift in positions of both the protein bands was observed. Three 
bands were clearly visible on SDS-PAGE (Figure 3.11, lane 2). The top most 
protein band at 95 kDa (CDTb′) and the bottom most band at 27 kDa (GST 
tag) of lane 2 of Figure 3.11, were generated from the upper GST-CDTb′ fusion 
protein band (120 kDa) of lane 1 (Figure 3.11). However, the middle band at 
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about 66 kDa (Figure 3.11, lane 2) is the tag cleaved product of the lower band 
in the affinity purified fraction (Figure 3.11, lane 1). The result clearly 
indicated that the lower band in the affinity purified fraction was not the tag 
free CDTb′ as it was thought resulting from auto-tag cleavage in solution. 
What does the presence of the lower band in affinity purified fraction 
(Figure 3.11, lane 1) imply? This protein band results from the degradation of 
the fusion protein. The GST tag is at the N-terminal of the fusion protein and 
is intact in both the major components of the elution fraction (Figure 3.11, 
lane 1) and we could still see a position shift for both the protein bands (Figure 
3.11, lane 1) as a result of tag cleavage reaction (Figure 3.11, lane 2). Hence, 
this degradation of the protein must be taking place at the C terminal end. 
Since it is the large C terminal fragment that becomes functionally active on 
chymotrypsin mediated activation; this degradation somewhere at the C 
terminal end defeats the whole purpose of purification process completely. 
Several other pilot purification trials in the presence of different 
concentrations of protease inhibitor solutions / PMSF / DTT and/or EDTA did 
not yield any improvement. 
Gel Filtration 
The gel image (Figure 3.11) provides a fair idea of the molecular weight 
difference between the fusion protein and its degraded companion which is 
about 25 to 30 kDa. 
Figure 3.12: Results of the Gel filtration run. Lanes 1 to 4 are the early to late 
fractions of elution at a flow rate of 0.2 ml / minute. 
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The gel filtration chromatography separates proteins on the basis of 
their molecular weight (size) and could have been a method of choice to 
remove the contaminating protein from the protein of interest. The separation 
pattern of all the three gel filtration runs at different flow rates was similar to 
each other (Figure 3.10). There is a variation in the ratio of higher to lower 
band intensity as we proceed from lane 1 to 4 (early to late fractions of 
elution). This pattern was expected as the high molecular weight protein elutes 
first from the column. None of the run, however, could separate the two 
proteins efficiently. 
Effect of Cell Lysis Method on Fusion Protein 
The first change that was incorporated in the purification protocol was 
the use of homogeniser replacing sonicator for the cell lysis. A drastic decrease 
in the amount of the lower molecular weight protein in the affinity elution 
fraction was observed on SDS-PAGE (Figure 3.13, lanes 1 and 3). 
Figure 3.13: Comparison of the affinity eluted protein using sonication (lane 1) 
and homogenisation (lane 3) as the method of cell disruption. Lane 2 - Crude cell 
lysate. 
Homogenisation is a milder method of cell disruption. It is based on 
mechanical shearing. In homogenization, the cell suspension is passed 
through a small orifice and made to strike against a metallic O ring at a very 
high speed causing rapture of the cell wall. On the other hand, in sonication, 
the cell disruption is carried out by using the energy of ultrasonic waves which 
produces a significant amount of heat during the process that may result in 
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denaturation and degradation of the protein. Cell lysis using another method 
(French press), also did not prove effective (data not shown). 
Search for Suitable Purification Strategy 
Having found a suitable method for cell lysis, further attempts to purify 
the protein were continued. None of the various strategies employed (Figure 
3.7) produced crystallisation quality protein. The best quality (purity) of 
protein was produced by following the strategy shown by shaded path in the 
following flow chart (Figure 3.14). Protein from the first Q sepharose anion 
exchange looked pretty much clean and promising when it was run on a 4-
12% Bis-Tris SDS-PAGE (Figure 3.14). 
Figure 3.14: The best protein producing strategy (shaded) and the quality of 
the protein after first Q sepharose anion exchange. 
Further purification of the protein shown (Figure 3.14), however, was 
not successful. The second anion exchange step on a MonoQ column removed 
many more impurities and concentrated the desired protein to a small volume. 
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The MonoQ sepharose is an anion exchanger with much finer particle size and 
hence provides an improved resolution and separation of proteins as 
compared to other Q sepharose resins. It was this stage, where impurities still 
present in the sample were also concentrated and became visible on the gel 
(Figure 3.15, lanes 4 to 26). 
The elution fractions highlighted in the rectangle (Figure 3.15), 
consisted of highly concentrated protein. However, this protein was not 
considered suitable for crystallisation trials, and hence, further attempts were 
made to purify the protein. 
Figure 3.15: The quality (purity) of protein at the end of the shaded strategy in 
figure 3.14. 1- monoQ load, 2- monoQ flow-through , 3- protein marker, 4 to 26 – 
eluted protein fractions. 
Purification, Concentration and Storage of CDTb′ 
A different purification strategy based on the difference in pI of the two 
proteins i.e. fusion protein (GST-CDTb′) and tag cleaved free CDTb′, was 
tested. Theoretical pI values for these two proteins are in the range of 4.8 to 
5.0 and differ from each other only by 0.12 pH unit. It indicated that it would 
be almost impossible to separate them from each other on an ion exchange 
column and both of them would elute over the same range of salt 
concentration from the column. However, it was found that the fusion GST-
CDTb′ protein elutes at about 200-250 mM of salt while the free CDTb′ elutes 
at about 150-200 mM of salt concentration in the elution buffer from the 
MonoQ anion exchange column under identical conditions (Figure 3.16). 
This difference in elution pattern was not observed using ordinary Q 
sepharose resin due to the lack of resolution. However, this difference could be 
used in purification to improve the purity of the protein. Hence, the 
purification method used at this stage was as follows (Figure 3.17). 
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Figure 3.16: The final purification strategy used for CDTb′ purification.

Figure 3.17: The CDTb′ purification strategy based on the pI difference. 
In the first anion exchange, the elution fractions corresponding to 200-
250 mM salt (containing GST-CDTb′) were collected to get rid of the impurities 
that were eluted at 150-200 mM salt. In the second mono Q run, fractions 
containing the desired free protein (CDTb′) were collected corresponding to 
150-200 mM salt concentration. The impurities that were eluted with the 
fusion protein in the first anion exchange step and remained unmodified 
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would still elute at the same 200-250 mM salt concentration under identical 
conditions of protein loading and elution and thus can be separated from the 
target protein i. e. CDTb′, in the second anion exchange step. 
Figure 3.18: The purified CDTb′. A – purified (pooled) CDTb′ from 3 different 
purification batches. B – concentrated CDTb′ protein. 
The eluted fractions were analysed on a gel and fractions containing 
CDTb′ were collected and pooled. Figure 3.18 A shows purified CDTb′ from 3 
different batches on a 4-12% Bis-Tris SDS-PAGE. Protein quality from all 
three batches does not seem to differ from each other. Though the protein is in 
diluted form, it was certainly much better than the protein purity that was 
achieved by means of any other purification strategy used until then (Figure 
3.15). Figure 3.18 B shows concentrated CDTb′ protein on an SDS-PAGE. A 
direct comparison of Figure 3.18 B with Figure 3.15 clearly shows the 
improvement in the quality of purified protein. 
Routine Quality Check and Mass Spectroscopic Analysis of CDTb′ 
The concentrated protein, stored at -800C was analysed on 10% Tris-
glycine SDS-PAGE after one week of purification. On the gel, CDTb′ looks 
degraded resulting in a major protein band at around 65 kDa molecular 
weight (figure 3.19). Looking at the molecular weight difference of CDTb′ and 
the degraded product on the gel, it was suspected that it was the same 
degradation at the C terminal of the protein that occurred during the cell lysis 
step by sonicating the cell suspension. 
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Figure 3.19: Assessment of the protein (CDTb′) quality on buffer exchange into 
water. NR- non reducing condition, R- reducing condition. 
Figure 3.20: The mass spectroscopy results for CDTb′. 
To find out the molecular weight of the degraded product, mass 
spectroscopic analysis of the protein sample was carried out. The protein was 
stored in 50 mM Tris-HCl containing 200 mM NaCl. Tris is not a 
recommended buffer for mass spectroscopy and hence, the protein was buffer 
exchanged into water prior to its mass spectroscopic analysis. The buffer 
exchanged protein was run on a 10% Tris-glycine SDS-PAGE along with the 
original concentrated sample. Buffer exchange into water did not cause any 
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observable change in the quality of the protein under reducing as well as non-
reducing conditions (Figure 3.19). 
The mass spectrometric analysis did not show any peak at or around 65 
kDa molecular weight. A peak at 47 kDa was detected (Figure 3.20). However, 
there was no protein band detected on the gel at 47 kDa (Figure 3.20). The 
analysis was conducted within few hours of buffer exchange to avoid any 
ambiguity in the results. 
There are several examples of proteins which do not appear at their 
theoretical molecular weight on SDS-PAGE. The TcdC protein from C. difficile 
is one such protein. It has a molecular weight of 27 kDa but appears at about 
34 kDa on Tris-glycine SDS-PAGE (Govind et al., 2006; and unpublished data 
from our laboratory). No other reason could be thought for the absence of a 
peak at 65 kDa when we have most intense band on SDS-PAGE at that 
position Figure 3.19). However, whether it is the 47 kDa molecular weight 
protein that appears at 65 kDa on Tris-glycine gel was not clear. 
Final Purification of CDTb′ and CDTb″ 
Both of the target proteins (CDTb′ and CDTb″) were purified 
successfully (Figure 3.21). Addition of 0.2% Tween 20 enhanced the purity of 
both the proteins. 
Figure 3.21: The purified CDTb′ and CDTb″ on the Bis-Tris SDS-PAGE system. 
Lane 1- 3rd day CDTb′′ stored at -200C, lane 2- 3rd day CDTb′′ at -800C, lane 3 -
11th day CDTb′ stored at -200C, lane 4 - 11th day CDTb′ stored at -800C. 
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The storage concentrations of CDTb′ and CDTb″ were about 0.20 mg/ml 
and 0.15 mg/ml respectively. The purified protein was tested on Bis-Tris SDS-
PAGE over a period of several days to analyse the degradation of protein over 
long term storage and to check the effect of freeze-thaw process on protein 
quality. No observable difference in the protein quality was detected on the gel 
(Figure 3.21). 
Abnormal Behaviour of CDTb′ 
The purity of proteins was regularly checked on SDS-PAGE during the 
process of purification and storage. To understand the ambiguous results 
obtained for SDS-PAGE analysis and mass spectrometry, for CDTb′, two 
different types of SDS-PAGE systems (Bis-Tris system and Tris-glycine system) 
were tested. Figures 3.22 A and 3.22 B compare identical protein samples of 
CDTb′ and CDTb′′ along with the purified CDTa′ on both types of the gel 
systems following multiple cycles of freeze-thaw. Both of the gels were run 
simultaneously to avoid any ambiguity in comparing results. 
Figure 3.22: The purified CDTb′ and CDTb″ (A)- on the Bis-Tris SDS-PAGE 
system, (B) - on the Tris-Glycine SDS-PAGE system. Lane 1- CDTa′, 2- 3rd day 
CDTb′′ stored at -200C, 3- 3rd day CDTb′′ at -800C, lane 4 - 11th day CDTb′ stored 
at -200C, lane 5 and 6- 11th day CDTb′ stored at -800C. 
The degradation of free CDTb′ was observed only on Tris-Glycine SDS-
PAGE (Figure 3.22B, lanes 4, 5 and 6) whereas the protein appeared to be 
perfectly fine on a Bis-Tris SDS-PAGE system (Figure 3.22 A, lanes 4, 5 and 6) 
even after multiple cycles of freeze-thaw. The other two proteins, CDTa′ (Figure 
3.22 A and B, lane 1) and CDTb′′ (Figure 3.22 A and B, lanes 2 and 3) appear 
as a single band at the correct position on both types of the gel systems and 
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hence were used as controls. The protein bands in the protein standard used 
(SeeBlue plus2, from Invitrogen) appear to have different mobility on both 
types of gel systems. Therefore, all three tested proteins (CDTa′, CDTb′ and 
CDTb″) appear at different positions with respect to the standard used on the 
two gel systems. 
An excellent study by Hachmann and Amshey (Hachmann and Amshey, 
2005) helps in understanding the abnormal behaviour of proteins on SDS-
PAGE systems. The authors have suggested that in general, proteins are more 
prone to degradation on a Tris-Glycine gel than on a Bis-Tris gel for the 
reasons such as pH-dependent modifications in proteins, modification of 
sulphydryl groups and formation of acrylamide adducts to sulphydryl groups 
or amino groups on the protein. These effects are expected to be high at a 
higher pH which is a condition for Tris-Glycine gel. Hydrolysis of aspartate-
proline (DP) bonds has been reported to occur when traditional Laemmli 
method of sample preparation is employed (Tang, 1997; Kubo, 1994). 
However, it is also worth noting that not all DP bonds are liable to 
hydrolysis under these conditions and this is not the only mode of peptide 
bond cleavage under these particular conditions. Thus, it is possible that the 
local environment of a DP bond is responsible for its hydrolysis. As a result of 
these modifications, the peptide band may not be recognized and the protein 
could appear as multiple bands on the gel (Hachmann and Amshey, 2005) 
(Figure 3.22 B, lanes 4, 5 and 6). 
A closer look of the protein sequences reveals that CDTa′ (appendix I) 
lacks DP bonds and no abnormality was observed for CDTa′ on the two tested 
gel systems. However, presence of 7 such potential sites in CDTb′ (appendix I) 
makes this protein highly prone to the above stated modifications. Five of 
these DP bonds are present in CDTb′′ too (appendix I). The CDTb′′ did not 
show any abnormal behaviour (Figures 3.22 A and B, lanes 2 and 3). It is 
possible that these DP bonds present in CDTb′′ are the less labile sites for 
modification. We can also not rule out the possibility that this abnormal 
behaviour of CDTb′ (Figures 3.22 B, lanes 4, 5 and 6) could be a result of a 
more complex modification process. 
Another important point to make here is that, this abnormal behaviour 
of CDTb′ was observed only when the GST tag was removed from the protein. 
The GST-CDTb′ fusion protein was prone to degradation by sonication (Figure 
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3.11) but did not show such abnormal behaviour. The fusion protein appeared 
as a single thick band on Tris-Glycine gel (Figure 3.10). How the fusion 
partner (GST) protected the protein (CDTb′) from showing abnormal behaviour 
is also not clear. 
The observed difference in the gel pattern of CDTb′ on different SDS-
PAGE systems was in agreement with mass spectrometry results (Figure 3.20) 
for the protein where no peak was detected in the range where degraded 
product (lower protein band) was present (i.e., at 65 kDa (Figures 3.19 and 
3.22B, lanes 4, 5 and 6) as observed on the Tris-Glycine gel. 
CDTb is the transport component of CDT which corresponds to Ib of C. 
perfringens iota toxin and C2II of C. botulinum C2 toxin. The crystal structure 
of C2II has been published along with its purification method (Schleberger, 
2006). In terms of sequence, closest members to CDTb, is the transport 
component of iota family binary toxins. Such abnormal behaviour has not 
been reported for C2II and Ib despite the presence of such potential DP sites 
for modification. 
SUMMARY 
Two different constructs of CDTb were cloned into pGEX-6p1 system. 
Both the constructs were overexpressed in soluble form as GST fusion 
proteins. CDTb′ protein was found to be sensitive to the method of cell lysis. 
Furthermore, the protein (CDTb′) exhibits abnormal behaviour on a Tris-
glycine SDS-PAGE which made its purification a time consuming task. 
Purification of CDTb″ was relatively easy once a method for CDTb′ purification 
was established. 
94

CHAPTER – IV 
CHARACTERISATION AND

CRYSTALLISATION

OF C. DIFFICILE BINARY TOXIN
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MATERIALS AND METHODS 
Chymotrypsin Mediated Activation of CDTb′ 
Chymotrypsin and trypsin inhibitor from hen egg white (both from 
Sigma) were dissolved in buffer F (Table 3.15) at 1 mg/ml concentration. 
Chymotrypsin was added to the protein (CDTb′) to yield 1:10 (chymotrypsin to 
protein) ratio. The mixture was incubated at room temperature (250C) and 
samples were taken at 10, 15, 20, 25, 30, 40, 50 and 60 minutes time points. 
Trypsin inhibitor was added to the samples to give a 1:2 ratio 
(chymotrypsin to trypsin inhibitor). 4X NuPage gel loading dye (Invitrogen) was 
added to the samples followed by heating of the samples for 5 minutes at 95ºC. 
The samples were analysed on a 4-12% Bis-Tris SDS-PAGE system in MES 
buffer. Suitable heated and non heated control protein samples (CDTb′) were 
also run in parallel. The resulting activated fragment of CDTb′ was named 
CDTb′#. 
Vero Cell Culture 
Vero cells (kidney epithelial cells extracted from African green monkey) 
were grown in complete Dulbecco's Modified Eagle Medium (DMEM, 
supplemented with 10% heat inactivated fetal calf serum (FCS) and 2 mM 
glutamate) at 370C in the presence of 5% CO2 in air. Cells were routinely 
trypsynised and passaged twice a week. For the cytotoxicity assay, cells were 
trypsinised and used to coat 96 well plates in a total volume of 200 µl of 
complete DMEM (medium supplemented with FCS and glutamate). The plates 
were incubated as above for 16-24 hours to allow the formation of a confluent 
monolayer. To perform the cytotoxicity assay, the medium was removed gently 
from the wells without disturbing the cell layer and the cells were washed 
twice with Dulbecco’s phosphate buffered saline (DPBS). 100 µl of serum free 
DMEM was added to the wells and the cells were incubated at 37ºC in the 
presence of 5 % CO2 in air. 
Cytotoxicity Effects of Complete CDT 
To assess the cytotoxic potential of CDT, both components of CDT 
were added to Vero cell monolayers. In the first set of cytotoxicity assays, the 
cells were incubated with CDTa′+CDTb′ and CDTa′+CDTb″ (250ng + 250ng) at 
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370C. Suitable buffer and protein controls were also set up by incubating the 
cells with buffer, CDTa′, CDTb′ and CDTb″ (250 ng each) alone, under identical 
conditions. A positive control with 50 ng/ml of C. difficile Toxin A was also set 
up. All experiments were set up in duplicate in a total volume of 200 µl each 
and the cells were examined at 4 hours post incubation time using an 
Olympus CK2 inverted microscope. 
In the second set of experiments, Tween-20 was completely removed 
from CDTb′ and CDTb″ protein stocks before testing the proteins on the cells. 
Proteins were dialysed against 50 volume of buffer P (50 mM NaCl in 50 mM 
Tris-HCl, pH 7.5) overnight. Each dialysed protein was loaded onto a Q 
sepharose column and the column was washed with buffer P until the base 
line was reached. Bound protein was eluted in one step with buffer Q (600 mM 
NaCl in 50 mM Tris-HCl, pH 7.5). An equal volume of 50 mM Tris-HCl, pH 7.5 
was added to the protein to bring the final salt concentration to 300 mM and 
the protein was stored at -800C. 
Varying amounts of CDTa′ (50, 100, 150, 200 and 250 ng) were 
mixed with equal amounts of CDTb′ or CDTb″ in different combinations in a 
total volume of 100 µl of serum free DMEM and added to the monolayers in 
separate wells. A set of tests with identical amounts of CDTa′, but with 
chymotrypsin activated CDTb′ and CDTb″ (named as CDTb′# and CDTb″#) were 
also prepared. Suitable negative controls with individual proteins CDTa′, 
CDTb′, CDTb″, CDTb′# and CDTb″# (250 ng each) and positive controls with C. 
difficile Toxin A (50 ng/ml) and Toxin B (0.5 ng/ml) were also set up under 
identical conditions. All the experiments were performed in duplicate and the 
cells were incubated at 37ºC in the presence of 5 % CO2 in air. Cells were 
examined for evidence of cytotoxic effect after 24 hours incubation using an 
Olympus CK2 inverted microscope. 
CDTb Oligomerisation in Solution 
Eight different buffer systems (MIB pH 4.0, MMT pH 4.0, SPG pH 4.0, 
Na-Acetate pH 4.0, Bis-Tris pH 5.5, Bis-Tris pH 6.5, Tris-HCl pH 7.5 and Tris-
HCl pH 8.5) were screened for CDTb oligomerisation experiment. CDTb′ was 
treated with chymotrypsin to produce an activated CDTb fragment. 
Chymotrypsin was deactivated by adding trypsin inhibitor to the reaction 
mixture as described before. 20 µl of chymotrypsin activated protein was 
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mixed with 2 µl of 1 M of each buffer in separate reaction tubes and incubated 
at 4 ° C overnight. On the next day, 5 µl of NuPAGE gel loading dye was added 
to all samples. The samples were analysed on a 4-12% Bis-Tris SDS-PAGE in 
MES buffer. 
Concentration and Crystallization of CDTa′ 
The protein (CDTa′) was concentrated further to 10 mg/ml using a 10 
kDa molecular weight cutoff (MWCO) concentrator (Millipore) at 4000 rpm at 
40C. Primary crystallisation of CDTa′ was set up with the help of Phoenix 
crystallisation robot using five different commercially available crystallisation 
screens from Molecular Dimensions Limited, namely: (i)- Structure Screens I 
and II, (ii)- Clear Strategy Screen I, (iii)- Clear Strategy Screen II, (iv)- Pact 
Premier Screen and (v)- JCSG plus Screen. Detailed composition of each 
screen is provided in appendix II. 
Table 4.1: Some of the crystallisation conditions from commercial screens that 
produced preliminary CDTa′ crystals. 
Screen Condition number (appendix II) 
Structure Screen 1 & 2 C7, D1 
Clear Strategy Screen 1 E4, G1, G5, 
Clear Strategy Screen 2 F3, 
Pact Premier Screen A3, A4, A5, A6, B2, B3, B4, B5, B6, C3, C4, 
C5, C6, C7, C8, C9, D1, D3, D4, D5, D6, 
D7, D8, D9, E1, E7, E10, F1, F10, G1, G6, 
G7, G10, H1, H6, H7, H10 
JCSG plus Screen A10, C6, D1, D12 
Each screen comprises 96 conditions and hence in total 480 different 
conditions were set up using the sitting drop vapour diffusion (SDVD) method. 
150 nl of crystallisation solution was added to an equal volume of protein and 
allowed to equilibrate against a reservoir of 50 µl at 160C. 
Eight, out of the many conditions (Table 4.1) that produced primary 
hits for the crystallisation were selected for further optimisation. Crystals were 
reproduced in a 2 µl drop containing the protein and the reservoir solution in 
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a 1:1 ratio using the hanging drop vapour diffusion (HDVD) method in 24 well 
plates under identical incubation conditions. 
Final crystals for native CDTa′ were grown in three different conditions 
(Table 4.2) using the HDVD method by streak seeding the drops. Reservoir 
solution was added to an equal volume of the protein at 4 mg/ml 
concentration and allowed to equilibrate against a reservoir of 500 ul for 60 to 
90 minutes at 160C. The equilibrated drops were then streak seeded with thin 
plate crystals that were grown previously under identical conditions. 
To grow CDTa′ crystals in complex with NAD and NADPH, ligand 
solution at 100 mM was added to the protein at 5 mg/ml and diluted with 
CDTa concentration buffer (20 mM NaCl in 50 mM Tris-HCl pH 8.0) in such a 
way that the final concentration of the ligand was 10 mM and that of the 
protein was 4 mg/ml. Crystallisation was set up using the HDVD method 
under the condition containing 20% PEG 1500 in 0.1 M MIB buffer pH 9.0 
(Table 4.2) by streak seeding the drops as described for the crystallisation of 
native protein above. 
Table 4.2: The CDTa′ final crystal growth conditions. 
Crystal name Composition of crystallisation condition 
CDTa-8.5 0.2 M Potassium Thiocyanate, 0.1 M Tris pH 8.5, 
20% PEG 2K MME 
CDTa-9, 
CDTa+NAD and 
CDTa+NADPH 
0.1M MIB buffer pH 9.0, 20% PEG 1500 
(MIB = sodum malonate, imidazole, boric acid 
buffer) 
CDTa-4, 0.1M MIB buffer pH 4.0, 20% PEG 1500 
Concentration and Crystallisation of CDTb′ and CDTb″ 
CDTb′ and CDTb″ were concentrated to 7 mg/ml with the help of 
Millipore 10 kDa MWCO concentrators at 4000 rpm at 40C. As mentioned 
before, both of the proteins were stored in a buffer containing 0.2 % Tween-20. 
Initial set of crystallisation trials for each protein was set up in the presence of 
Tween-20 using all five commercially available crystallisation screens from 
Molecular Dimensions Limited in identical manner as described for CDTa′. 
An additional set of crystallisation trials for CDTb′ was also set up in 
the absence of tween-20. Tween-20 was removed from the protein as descried 
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before. Table 4.3 below provides a list of crystallisation conditions that 
produced primary hits for all different crystallisation trials. 
Table 4.3: the primary crystallisation hits obtained for CDTb′ (with and without 
tween-20) and CDTb″ (with tween-20) using commercial screens. 
Screen Condition number (appendix II) 
CDTb′ 
(with tween-20) 
CDTb″ 
(with tween-20) 
CDTb′ (without 
tween-20) 
Structure 
Screen 1 & 2 
B10, B12, C3, 
C9, C11, D9, E2, 
B10, C9, H6 G6 
Clear Strategy 
Screen 1 
C8, D9, E3, E9, 
F3, F9, G2, G3, 
G9, H3, H8, H9, 
D8, E3, E9, F3, 
F9, G2, G8, G9, 
H3, H8, H9, 
F9, F10, G10, 
H10, 
Clear Strategy 
Screen 2 
E2, E2, G2, --
Pact Premier 
Screen 
C9, C10, D10, C10, D10, E10, 
JCSG plus 
Screen 
B10, D2, D3, D6, 
D7, F5, G5, 
D6, F5, C4, 
The primary hits obtained for CDTb′ and CDTb″ crystallisation in the 
presence of tween-20 were then optimised using the HDVD and SDVD 
methods in 24 well plates. 1 µl of the protein was mixed with an equal volume 
of reservoir solution and allowed to equilibrate against a 500 µl volume of 
reservoir solution at 160C. Optimisation of CDTb′ crystallisation primary hits 
in the absence of tween-20 were also performed in 24 well plates using the 
HDVD as well as SDVD method. 
The primary hit that produced the best looking crystals (Pact premier 
screen – E10) for CDTb′ crystallisation in the absence of Tween-20 was also 
optimised further using the additive screen from Hampton Research Limited in 
a 96 well plate with the help of crystallisation robot. Table 4.4 lists all crystal 
producing conditions from the additive screen (for detailed composition please 
see appendix II). The obtained hits were then optimised manually using HDVD 
method. 
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Table 4.4: CDTb′ crystallisation hits using the additive screen with Pact Premier 
E10 condition as the basic condition. 
CDTb′ (without Tween-20 – Additive Screen 
Basic condition Additive Screen condition number 
20% PEG 3350 A8, B7, B8, C1, E11, F2, G1 
RESULTS AND DISCUSSION 
Chymotrypsin Mediated Activation of CDTb 
Available literature and experimental evidence suggest that transport 
components of Clostridial binary toxins have to be activated by tripsin or 
chymotrypsin to become fully functional (Perelle et al., 1997; Fernie et al., 
1984). Activation of the transport component of C. botulinum C2 toxin (C2II) by 
trypsin has been reported (Ohishi, 1987). At least two different studies 
(Blocker et al., 2001; Gluke et al., 2001) describe activation of the transport 
component of C. perfringens iota toxin (Ib) by chymotrypsin under the 
conditions of temperature, pH and incubation time similar to that reported for 
C2II. 
Figure 4.1: The chymotrypsin mediated activation of CDTb′ on Bis-tris SDS-
PAGE. Lane 1 and 2- non-heated CDTb′, lane 3- 5 minute heated CDTb′, lane 5, 
6, 7, 8, 9, 10, 11 and 12- 10, 15, 20, 25, 30, 40, 50 and 60 minute 
chymotrypsin treated, heated samples. 
Figure 4.1 shows the control protein, CDTb′ (lanes 1, 2 and 3) and the 
chymptrypsin activated CDTb fragment (lanes 5 to 12) on a Bis-Tris-SDS-
PAGE. A gradual decrease in the amount of precursor protein (CDTb′) can be 
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seen which completely disappears between 20 and 30 minutes time under the 
tested conditions. The reaction was continued for 60 minutes and no further 
cleavage or degradation of the activated fragment was observed in spite of the 
presence of chymotrypsin in the mixture. Chymotrypsin is a non specific 
protease and is known to cleave its substrate at random sites. However, 
successful production of the protein fragment of the correct size is strong 
evidence that activation of the transport component of C. difficile binary toxin 
by chymotrypsin is a highly specific process. These results also indicate that 
the expressed and purified protein (CDTb′) is correctly folded. 
Cell Cytotoxicity Effects of Complete CDT 
The first set of cytotoxicity experiments was conducted with CDTb′ and 
CDTb″ protein samples that were stored in a buffer containing 0.2% Tween-20. 
Previous data produced in our laboratory showed that Tween-20 has a lethal 
effect on growing Vero cells. 
Figure 4.2: The effect of Tween-20 on growing Vero cells in 4 hours time. 
Figure 4.2 demonstrates the effect of Tween-20 on growing Vero cells at 
4 hours post incubation time. CDTb is the transport component of the binary 
toxin and possesses no catalytic activity. The observed cell death in CDTb′ and 
CDTb″ alone controls was due to the presence of Tween-20 in the used protein 
samples (Figure 4.2). CDTa is the catalytic component of the binary toxin. It 
102

requires CDTb as its translocation partner to access entry into the target cell. 
CDTa′ alone controls did not show any cell death (Figure 4.2). 
Due to the lethal effect of Tween-20 on growing cells, it was necessary 
to remove it from the stored protein samples. Figures 4.3, 4.4 and 4.5, below 
summarise the results of the second set of cytotoxicity experiments showing 
the effect of toxins on the cells at 24 hours time point. Observations were not 
made post 24 hours incubation as the cells were maintained in serum 
depleted medium. 
Figure 4.3: Controls for the cell cytotoxicity test. (A) – Blank (buffer control), (B) 
– CDTa′ alone control (250 ng), (C) – CDTb′ alone control (250 ng), (D) – CDTb″ 
alone control (250 ng), (E) – CDTb′# alone control (250 ng), (F) – CDTb″# alone 
control (250 ng),in a total volume of 200 µL. 
No cell death was observed in the buffer control (Figure 4.3 A) and in 
the presence of individual toxin components CDTa, CDTb′, CDTb′′, CDTb′# and 
CDTb′′# (Figures 4.3 B, C, D, E and F). These observations proved that the 
individual components of CDT are not cytotoxic. Healthy cells in CDTb′# and 
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CDTb′′# controls indicate that the chymotrypsin was inactivated completely by 
trypsin inhibitor. Toxin A and Toxin B are the best characterized toxins from 
C. difficile and were used as positive controls for Vero cell cytotoxicity in this 
study (Figures 4.3 G and H). 
Figure 4.4: The effect of binary toxin on growing Vero cells. (G) – Toxin A control 
(5ng), (H) – Toxin B (0.5 ng), (I) – CDTa′ + CDTb′# (10 ng+50 ng), (J) – CDTa′ + 
CDTb′ (250ng+250 ng), (K) – CDTa′ + CDTb′# (50ng+250 ng), (L) – CDTa′ + CDTb′# 
(250ng+250 ng), in a total volume of 200 µL. 
No cell death was observed in any of CDTa′+CDTb′ mixture test cases 
(Figure 4.4 J). CDTb′ is the recombinant inactive precursor fragment of CDTb. 
It requires chymotrypsin mediated activation to become fully functional. Vero 
cells are kidney epithelial cells and are not known to produce chymotrypsin 
which is necessary to activate CDTb′. In all previously reported studies on 
different Clostridial binary toxins (Gluke et al., 2001; Blocker et al., 2001; 
Ohishi et al., 1980; Kaiser et al., 2006), the corresponding transport 
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components activated by trypsin or chymotrypsin have been used. Cell death 
was observed for CDTa′ in the presence of CDTb′# test cases (Figures 4.5 P, Q 
and R). Cell death was recorded for all CDTa′+CDTb′′ cases but to a 
considerably lower extent (Figures 4M and 4N) when compared with its 
chymotrypsin activated product, CDTb′′# (Figures 4.5 M and O). 
Figure 4.5: The effect of various concentrations of binary toxin components on 
growing Vero cells. (M) – CDTa′ + CDTb″(50ng+250 ng), (N) – CDTa′ + 
CDTb″(250ng+250 ng), (O) – CDTa′ + CDTb″# (50ng+250 ng), (P) – CDTa′ + CDTb′# 
(50 ng+50 ng), (Q) – CDTa′ + CDTb′# (50ng+150 ng), (R) – CDTa′ + CDTb′# 
(50ng+250 ng), in a total volume of 200 µL. 
A five-fold variation in the concentration of CDTa and CDTb was 
screened in different combinations. However, it was observed that variation in 
CDTa′ amount from 50 to 250 ng, keeping CDTb′# concentration constant, did 
not increase cell death significantly (Figures 4K and 4L). No significant 
difference in cell death was observed when CDTb′# concentration was varied 
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keeping that of CDTa′ fixed (Figures 4P, 4Q and 4R). However, our 
experimental results are insufficient to show conclusively whether the amount 
of activated CDTb or the concentration of CDTa present is the rate 
determining step in binary toxin mediated cell death. 
Previously, the cytotoxicity effect of CDTa has been studied by Gluke 
and co-workers using the transport component of iota toxin (Ib) to mediate the 
cell entry of CDTa because CDTb could not be well expressed (Gluke et al., 
2001). Hence, their study could not provide a definitive answer as to whether 
full length CDT (CDTa+CDTb) is cytotoxic. Our study presented here, provides 
a clear picture as we have used both components of CDT and have 
conclusively shown that the complete C. difficile binary toxin is capable of 
killing cells at as low as 50 ng/ml of CDTa′ and 250 ng/ml of CDTb′# (Figure 
4.4 I) (at the tested amount of CDTa (Gluke et al., 2001) and iota toxin 
(Blocker et al., 2001) reported in previous studies). 
Perelle and co-workers have demonstrated the cell cytotoxicity of 
complete CDT on Vero cells. In their experiments, Vero cells were incubated 
with the binary toxin producing C. difficile bacterial cell culture supernatant 
(Perelle et al., 1997). The culture supernatant contained Toxin A and Toxin B 
in addition to CDT. Authors suggest that incubation of the culture 
supernatant at -200C deactivated both C. difficile main toxins. However, the 
purified Toxin A and Toxin B that have been used in our study as positive 
controls, were always stored at -200C and no deactivation of either toxin was 
observed as both toxins were still capable of killing cells (Figures 4.4 G and H). 
In our study, both components of CDT were expressed recombinantly and 
purified. Hence, our results leave no ambiguity about cell death mediated by 
the complete CDT. Our report is the first report on CDT mediated cell 
cytotoxicity in isolation. 
Formation of CDTb Oligomer in Solution 
Binary toxins from various Clostridial and bacillus species follow a 
similar mechanism of cell entry. Transport components of these toxins form a 
heptameric pore like structure upon activation by 
trypsin/chymotrypsin/furin. Transport components from two different 
Clostridial actin modifying binary toxins have been studied in this regard. 
However, the two studied toxins belong to two different classes of Clostridial 
106

actin-ADPRTs (Table 2.1) and the physiochemical conditions of heptamer 
formation vary among them. C2II from C. botulinum has been reported to form 
an SDS resistant heptamer whereas the Ib heptamer (from C. perfringens) was 
found susceptible to SDS (Blocker et al., 2001). 
The protein (CDTb′) was activated by chymotrypsin in a buffer 
containing 50 mM Tris-HCl pH 7.5 and 300 mM NaCl, as described previously. 
8 different buffer systems of different pH were screened for the oligomerisation 
of CDTb. Figure 4.6 below shows all samples on a Bis-Tris SDS-PAGE under 
SDS conditions. 
Figure 4.6: The formation of the CDTb oligomer in solution. Lane 1 – MIB pH 
4.0, 2 – MMT pH 4.0, 3 – SPG pH 4.0, 4 – Na-acetate pH 4.0, 5 – Bis-Tris pH 5.5, 
6 – Bis-tris pH 6.5, 7- Tris-HCl pH 7.5, 8 – Tris-HCl pH 8.5 
A faint protein band was observed well above the 188 kDa marker 
protein band for activated CDTb oligomer. Intensity of this protein band varied 
in different lanes. However, it was clearly visible in Na-Acetate buffer, pH 4.0 
test condition (Figure 4.6, lane 4). This observation agrees with results 
reported by Blocker and co-workers (Blocker et al., 2001) for the 
oligomerisation of iota toxin transport component (Ib). The formation of the 
CDTb oligomer could not be tested under non-SDS conditions. 
Concentration and Crystallisation of CDTa′ 
The protein was concentrated to 10 mg/ml without any difficulty. 
Figure 4.7 below, shows the concentrated CDTa′ protein on a 10% Tris-glycine 
SDS-PAGE. 
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Figure 4.7: The concentrated CDTa′ protein on Tris-glycine SDS-PAGE (lane 1)

Figure 4.8: Some of the primary CDTa′ crystals. CSS – Clear strategy Screen, 
PPS- Pact Premier Screen. JCSG – JCSG plus screen. 
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At least 20 out of 480 screened crystallisation conditions resulted in 
thin plate like crystals of similar morphology within 24 hours. This number 
went up to over 50 within a week’s time (Figure 4.8). 
Eight conditions were then chosen and these thin plate crystals were 
reproduced by the hanging drop vapour diffusion method. Crystals from two 
different conditions were chosen to test in the X-ray beam at Station I03 of 
Diamond Light Source, United Kingdom. These crystals were protein crystals 
but diffracted poorly to 5Å resolution. 
Figure 4.9: The effect of seeding on CDTa′ crystal morphology.

Figure 4.10: The CDTa′ crystals in complex with NAD (left) and NADPH (right) 
grown by streak seeding. 
Both of the tested conditions were selected for final crystal optimisation 
by employing the streak seeding technique. Seeding improved crystal 
morphology significantly and consequently the diffraction quality of crystals 
was improved. Figure 4.9 illustrates the effect of streak seeding on crystal 
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morphology. Co-crystallisations of the protein with its donor substrates were 
also set up. Seeding resulted in diffraction quality crystals of good morphology 
in co-crystallisations also (Figure 4.10). X-ray diffraction data collection and 
structure determination of CDTa′ are discussed in the chapter 5. 
Concentration and Crystallisation of CDTb′ and CDTb″ 
CDTb′ protein was concentrated successfully up to 7 mg/ml. A small 
amount of precipitate was observed in CDTb″ samples during the 
concentration process. The concentrated protein samples were centrifuged at 
10,000 rpm for 10 minutes at 40C prior to setting up crystallisation in order to 
remove the precipitated protein. 
Figure 4.11: Some of the primary crystallisation hits obtained for CDTb′ in the 
presence of 0.2% tween-20. SS – Structure screens 1 and 2, CSS – Clear 
strategy Screen, PPS- Pact Premier Screen. JCSG – JCSG plus screen. 
In the presence of Tween-20 several crystallisation conditions (Table 
4.3) produced very thin needle crystals which were not suitable for data 
collection. These crystals of similar morphology were grown for CDTb′ as well 
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as for CDTb″ (Figures 4.11 and 4.12). Optimisation of these conditions in 24 
well plates also did not result in any significant improvement. 
Figure 4.12: Some of the primary crystallisation hits obtained for CDTb″ in the 
presence of 0.2% tween-20. SS – Structure screens 1 and 2, CSS – Clear 
strategy Screen, PPS- Pact Premier Screen. JCSG – JCSG plus screen. 
However, in the absence of Tween-20, much better diamond shaped 
crystals for CDTb′ were grown in few conditions (Table 4.3 and Figure 4.13). 
These crystals were not big in size but they appeared to be better than the 
crystals grown in the presence of Tween-20 (Figure 4.11). 
Figure 4.13: Some of the primary crystallisation hits obtained for CDTb′ in the 
absence of tween-20. SS – Structure screens 1 and 2, CSS – Clear strategy 
Screen, PPS- Pact Premier Screen. JCSG – JCSG plus screen. 
In the absence of Tween-20, the Pact premier screen condition number 
E10 produced the best looking crystals for CDTb′ (Figure 4.13, right most 
panel). These crystals could be reproduced in 24 well plates by varying the 
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concentration of salt and precipitant in the reservoir solution as well as the 
protein to reservoir solution ratio in the drop (Table 4.5 and Figure 4.14). 
Optimisation of these conditions so far has not improved the size of crystals 
significantly. None of these crystals showed diffraction spots at Diamond Light 
Source. 
Table 4.5: Variation of condition for the optimisation of CDTb′ crystals in a 24 
well plate in the absence of Tween-20. 
Basic condition – 0.2 M K thiocyanate, 20% PEG 3350 
Parameter Variation 
Protein concentration (in drop) 3 mg/ml – 4 mg/ml 
Precipitant (PEG) concentration) 16% – 20% 
Salt concentration 0.0 M to 0.2 M 
Protein : reservoir solution in drop 1:1, 1:2, 2:1 
Figure 4.14: CDTb′ crystals grown in 24 well plates in hanging drop vapour 
diffusion method in the absence of Tween-20. (1) – 16% PEG3350, protein (3 
mg/ml) : reservoir solution =1:2; (2) - 20% PEG3350, protein (3 mg/ml) : reservoir 
solution =1:2 
These crystals (Figure 4.14), however, could be reproduced in a wide 
range of concentrations of salt and precipitating agent (Table 4.5). Further 
optimisation of these crystals using the additive screen from Hampton 
research was carried out. Figure 4.15 displays some of the crystals grown in 
the crystallisation conditions from the additive screen. Unfortunately, the size 
of crystals still could not be improved. Further optimisation of different 
conditions in order to grow large diffraction quality crystals is underway. 
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Figure 4.15: The CDTb′ crystals grown in the absence of tween-20 using 
additive screen with basic condition – 20% PEG 3350 
SUMMARY 
Chymotrypsin mediated activation of precursor CDTb (i. e. CDTb′) 
resulted in a fully functional activated protein fragment (CDTb′#). Results of 
the cell cytotoxicity experiments proved that the expressed and purified 
proteins (CDTa′, CDTb′ and CDTb″) were active and correctly folded. In 
addition to that, the cell cytotoxicity tests indicated that complete CDT has the 
potential to kill cells in isolation and hence should have a definite role in C. 
difficile infection. 
The preliminary experimental results showed the formation of 
oligomeric CDTb complex in solution under acidic conditions. However, the 
intensity of the protein band was very low on an SDS-PAGE and these 
conditions need to be optimised further. 
Crystallisation trials for CDTa′ resulted in diffraction quality crystals of 
CDTa in its native form as well as in complex with the ADP-ribose donor 
substrate i. e. NAD and NADPH (discussed in chapter 5 in details). Preliminary 
success was achieved for CDTb′ and CDTb″ crystallisations. Small but good 
morphology crystals for CDTb′ were grown in the absence of Tweeen-20. 
Optimisation of these preliminary crystallisation hits is underway. 
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CHAPTER – V 
CRYSTAL STRUCTURE OF ENZYMATIC

COMPONENT OF

C. DIFFICILE BINARY TOXIN: CDTa
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Structural Analysis of Known ADPRTs 
ADP ribosylating toxins (ADPRTs) are a large superfamily that has been 
divided into four different classes based on their substrate specificity (Table 
2.2). All ADPRTs share a common active site fold (Han and Tainer, 2002; 
Domenighini and Rappuoli, 1996). Three dimensional structures for 
representative members of each of the 4 classes of ADPRTs have been 
determined. These include - Diphtheria toxin (1TOX) from Corynebacterium 
diphtheriae (Bell and Eisenberg, 1996), Pseudomonas exotoxin A (1AER) from 
Pseudomonas aeruginosa (Li et al., 1996), Pertussis toxin (1PRT) from 
Bordetella pertussis (Stein et al., 1994), Cholera toxin (1XTC) from Vibrio 
cholerae (Zhang et al., 1995), Escherichia coli heat labile enterotoxin (1LTS) 
(Sixma et al., 1993), Clostridium perfringens Iota toxin (1GIQ) (Tsuge et al., 
2003), Clostridium botulinum C2 toxin (2J3V) (Schleberger et al., 2006), 
Vegetative insecticidal protein (1QS1) from Bacillus cereus (Han et al., 1999) 
and the C3-like toxins, C3Bot (1G24) from Clostridium botulinum (Han et al., 
2001) and C3stau (1OJZ) from Staphylococcus aureus (Evans et al., 2003). 
Based on the ADP-ribose donor substrate binding pattern, ADPRTs have been 
classified into two classes: 
1- DT type, which is based on active site architecture and NAD binding 
features that are present in diphtheria toxin (Bell and Eisenberg, 1996). And, 
2- CT type, where the NAD binding features are similar to that is 
observed in cholera toxin (Zhang et al., 1995). The CT type toxins include 
C3Bot, VIP2, pertussis toxin, Iota toxin and CDT from C. difficile. 
The ADP-ribose donor (i. e. NAD) binds to the catalytic cleft in a high 
energy, closed conformation in all ADPRTs irrespective of their class and 
interacting residues. The NAD binding cleft in all ADPRTs comprises of a 
similar mixed α/β core structure. The cleft is positioned between a β-stranded 
framework and either an α-helix (examples - C3Bot, C3stau, VIP2 and Iota) or 
a variable length active site loop (such as in pertussis, cholera, diphtheria and 
exotoxin A). A sequence alignment of different ADPRTs reveals the presence of 
several conserved residues that form catalytically important motifs in the 3-
dimensional structures (Figure 5.1). 
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Figure 5.1: The sequence alignment of different classes of ADPRTs showing 
conserved catalytically important motifs (adopted from Holbourn et al., 2006). 
Pert. = Pertussis toxin, Diphth. = diphtheria toxin. 
An aromatic residue followed by a conserved Arg/His has been found in 
all ADPRTs till date (Domenigini and Rappuoli, 1996). The DT class is 
characterised by a Tyr-His whereas the motif present in the CT class is 
Val/Leu-X-Arg (Figure 5.1, where X is an aromatic residue). This particular 
motif is designated as the Arg/His motif and is found to be involved in the 
ligand binding but not in catalysis (Holbourn et al., 2006). However, 
mutational studies suggest that the loss of this conserved residue results in 
almost complete loss of transferase activity in several ADPRTs (Lobet et al., 
1991; Cieplak et al., 1988; Burnette et al., 1988; Burnette et al., 1991; Tsuge 
et al., 2003; Wilde et al., 2002). 
The STS motif of ADPRTs is supposed to act as an anchor to hold the 
NAD binding site together. In C3Bot, the first Ser residues of the motif forms 
hydrogen bond with the catalytic Glu beneath the cleft to hold it in the correct 
position to mediate NAD cleavage (Holbourn et al., 2006). However, mutational 
studies on iota toxin and dipththeria toxin (Bell and Eisenberg, 1996; 
Nagahama et al., 2000) suggest that while the STS motif stabilises the 
catalytic site, it is not essential in all ADPRTs. In diphtheria toxin the STS 
motif is replaced with the YTS motif where the Tyr residue is shown to be 
crucial for activity of the toxin (Carroll and Collier, 1988; Carroll and Collier, 
1984; Carroll and Collier, 1987). 
A loop of varying length known as the ARTT (ADP-ribosylating turn 
turn) loop is common in all CT type ADPRTs. The ARTT loop contains key 
catalytic residues in the form of an EXE or QXE motif which have been 
suggested to play a decisive role in ligand binding as well as in the transfer of 
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ADP-ribose to the substrate (Han et al., 2001; Han and Tainer, 2002; 
Domenighini and Rappuoli, 1996). An aromatic residue at the centre of the 
ARTT loop in class 3 and class 4 ADPRTs is another conserved residue. In 
C3Bot, this residue (Phe) has been shown to be essential for substrate binding 
(Wilde et al., 2002). However, an aromatic residue (Tyr) at an equivalent 
position in actin-ADPRTs such as iota toxin has not been assigned any such 
function to date (Tsuge et al., 2003; Tsuge et al., 2008). 
The PN loop forms an essential part of the ligand binding machinery of 
ADPRTs. In C3Bot, the PN loop has been reported to undergo a large 
movement upon NAD binding. A similar movement of the loop, however, has 
not been observed in iota toxin. The PN loop of two different classes of ADPRTs 
(class 3 and class 4) has been found to contribute to the NAD binding with an 
Arg residue that interacts with NAD directly. An aromatic residue (Phe) in both 
classes has been suggested to stabilise ligand binding by stacking interactions 
(Tsuge et al., 2003; Menetrey et al., 2002; Holbourn et al., 2006). 
A 15 residue active site loop that is present in class 1 and class 2 of 
ADPRTs has been found missing in class 3 and class 4 (Bell and Eisenberg, 
1996, Sixma et al., 1991). This loop has been suggested to be involved in 
substrate recognition (O’Neal et al., 2005). In class 3 and class 4 of ADPRTs, 
this loop has been replaced by an α-helix (named as α-3 helix) which packs 
itself tightly against the NAD binding cleft (Tsuge et al., 2003; Han et al., 1999; 
Han et al., 2001; Evans et al., 2003). This helix contains 3 conserved 
catalytically important residues amongst all class 3 and class 4 ADPRTs. This 
part of the NAD binding cleft is thought to be involved in holding the ADP-
ribose component of NAD after cleavage of the N-glycosidic bond until it is 
transferred to the acceptor molecule (Holbourn et al., 2006). 
C. difficile binary toxin (CDT) along with C. perfringens iota toxin and C. 
botulinum C2 toxin belongs to the class 4 of ADPRTs. In this chapter, high 
resolution crystal structures of the enzymatic component of CDT in its native 
form under three different pH conditions as well as in complex with its donor 
substrates, i. e. NAD and NADPH are presented. The mode of donor substrate 
recognition by CDTa is compared with that of Iota A with a possible 
explanation of the ARTT loop stability upon ligand binding in CDTa. Based on 
the structural data presented, it seems that the ADP-ribosylation reaction by 
CDTa prefers to proceed via an SN1 mechanism of catalysis rather than SN2. 
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MATERIALS AND METHODS 
Data Collection and Data Processing 
A single crystal was mounted in a nylon loop and flash frozen at 100K 
temperature in a stream of nitrogen gas. Diffraction data sets for native CDTa 
crystals (Figures 4.9 and 4.10) grown in three different crystallisation 
conditions (Table 4.2) were collected at Stations I02 and I04 of Diamond Light 
Source, Didcot, UK. Single crystal diffraction data sets for CDTa in complex 
with its donor substrates, NAD and NADPH were also collected in similar 
fashion at Station I02. Each of the stations was equipped with a Quantum-4 
CCD detector (Area Detector Systems Corp.). X-ray wavelengths used for data 
collection are provided in Table 5.1. Twenty percent glycerol was used as 
cryoprotectant for CDTa-NAD and CDTa-NADPH complex crystals. All native 
crystals were mounted without any cryoprotectant. Two hundred images for 
each crystal were collected using the rotation method of data collection with 
an oscillation range ∆Φ = 10. Raw data images were indexed and scaled with 
the HKL2000 package (Otwinowski et al., 1997) and the scaled intensities were 
truncated to amplitudes using TRUNCATE (French et al., 1978) from the CCP4 
suite (CCP4, 1994). Detailed data collection and data processing statistics are 
given in table 5.1. 
Structure Solution and Refinement 
To solve phases for the CDTa-8.5 structure, the search model was 
derived from the coordinates of enzymatic component of iota toxin (Tsuge et 
al., 2003) (PDB entry-1GIQ and 1GIR). Initial phases for structure solution 
were obtained using the molecular replacement routines of the MOLREP 
program (Vagin et al., 1997). Data in the range of 50.0 to 3.0 Å was used for 
the molecular replacement step. The resultant model was refined using 
REFMAC5 (Murshudov et al., 1997) of the CCP4 suite. Five percent of 
reflections were separated as Rfree set and used for cross validation (Brunger, 
1992). After an initial round of rigid-body refinement, iterative rounds of 
restrained refinement with electron density map calculations and manual 
adjustments of the model using COOT (Emsley and Cowtan, 2004) were 
carried out. On the basis of 2Fo–Fc electron density, side-chain atoms were 
omitted at some positions. Water molecules were added at positions where Fo– 
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Fc electron density peaks exceeded 3σ and potential hydrogen bonds could be 
made. 
A similar approach was adopted to solve other CDTa structures. The 
refined CDTa-8.5 structure was used as phasing model to obtain initial phases 
for all other structures. The atomic coordinates for NAD and NADPH were 
obtained from studies of Tsuge and co-workers (Tsuge et al., 2003). 
Model validation was conducted with the aid of programs PROCHECK 
(Laskowski et al., 1993) and MOLPROBITY (Davis et al., 2007). Estimations of 
main chain Φ-Ψ torsion angles were obtained from Ramachandran plot 
(Ramachandran et al., 1963). Figures were drawn with PyMOL (DeLano 
Scientific, San Carlos, CA, USA). Validated structure coordinates for all five 
structures were deposited with the Protein Data Bank (PDB) under entries – 
2WN4, 2WN5, 2WN6, 2WN7 and 2WN8 (Sundriyal et al., 2009). 
RESULTS AND DISCUSSION 
Data Collection and Data Processing 
CDTa without its signal peptide (CDTa′) was crystallised in its native 
form in three different crystallisation conditions (Table 4.2). Two of the 
conditions were virtually identical except for the pH (9.0 and 4.0 respectively) 
(Table 4.2). Crystals of CDTa′ in complex with NAD and NADPH were grown in 
high pH condition at pH 9.0 (Table 4.2). 
Figure 5.2 displays a typical X-ray diffraction image for native CDTa. 
Indexing of data sets suggested that all of the crystals belong to monoclinic 
system. All data sets were indexed and scaled in both, P2 and P21 space 
groups. However, a clear molecular replacement solution was obtained in P21 
space group (Table 5.2). Hence, P21 was the correct space group with slight 
variations in cell parameters for different crystals (Table 5.1). Calculation of 
Matthew’s coefficient (Matthews, 1968) indicated that all of the crystals 
contained one protein molecule per asymmetric unit with about 40-50 % 
solvent content in different crystals (Table 5.1). 
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Figure 5.2: A typical X-ray diffraction image for native CDTa crystal (CDTa-8.5). 
Structure Solution and Refinement 
The CDTa-8.5 structure was determined at 1.85 Å resolution whereas 
CDTa-4.0, CDTa-9.0, CDTa-NAD and CDTa-NADPH structures were 
determined at 2.0 Å, 1.9 Å, 2.25 Å and 1.95 Å respectively. The molecular 
replacement process for CDTa-8.5 structure determination yielded one unique 
solution (Table 5.2.) in P21 space group. Molecular packing in the unit cell for 
this solution was free of any unfavourable intermolecular contacts confirming 
it to be the correct solution. Figure 5.3 shows the packing of CDTa molecules 
in the unit cell. 
The resulting model was subjected to 20 cycles of rigid body refinement 
followed by 10 cycles of restrained refinement. A marked reduction in Rcryst 
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(from 49.41 to 31.78 %) and Rfree (from 47.93 to 36.41 %) values and a 
significant increase in the figure of merit (from 39.8 to 70.1 %) were observed 
indicating the success of refinement steps (Table 5.3). 
Figure 5.3: The arrangement of CDTa molecules in the crystal unit cell (for 
CDTa-8.5 crystal). The two fold axis is perpendicular to the plane of the paper. 
The presence of bound ligand was confirmed in the electron density 
maps of respective structures immediately after the first round of restrained 
refinement. Figure 5.4 displays the observed electron density for unmodelled 
NAD in the CDTa-NAD structure at an initial stage of refinement. 
The N terminal of CDTa was found to be highly disordered and electron 
density for few of the N terminal residues (1-27 for CDTa-8.5; 1-24 for CDTa 
4.0; 1-23 for CDTa-9.0; 1-26 for CDTa-NAD and 1-16 for CDTa-NADPH) was 
not visible in any of the structures. However, the modelled length of the N-
terminal varied among different structures which indicated the presence of 
these residues in the protein as all five crystals were grown from the same 
batch of the protein. 
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Figure 5.4: Electron density for the bound NAD (unmodelled) seen after the first 
cycle of restrained refinement. The continuous density with green pieces of 
positive density corresponds to the bound NAD molecule. The 2Fo-Fc and Fo-Fc 
maps are shown at 1σ and 3σ contour level respectively. 
The loop regions -178-181, 382-384 for CDTa 4.0; 383-384 for CDTa-
9.0 and 179-181 for CDTa-NAD, could also not be modelled. Figure 5.5 shows 
the final electron density for the ARTT loop (discussed in a later section) and 
the bound NAD in the CDTa-NAD structure. 
There were no residues in the disallowed region of the Ramachandran 
plot for any of the structures (Figures 5.6 to 5.10). Table 5.4 summarises 
important structure refinement statistics for all five structures. A tight 
geometry for all molecules was maintained throughout the process of 
refinement and model building (Table 5.4). 
122

Figure 5.4: The final electron density for (A) – the ARTT loop from CDTa-NAD 
structure, and (B) – the bound NAD in CDTa-NAD structure at 2.25 Å resolution. 
The chemical structure of NAD is given in Figure 2.7 (page 47). 2Fo-Fc and Fo-Fc 
maps are shown at 1σ and 3σ contour level respectively. 
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Table 5.1: The data collection and processing statistics for all five crystals.

All crystals belong to P21 
space group 
CDTa-8.5 
(pH = 8.5) 
CDTa-4.0 
(pH = 4.0) 
CDTa-9.0 
(pH = 9.0) 
CDTa-NAD 
complex 
CDTa-NADPH 
complex 
Wavelength of X-ray (Å) 0.9795 1.3625 1.3625 0.9795 0.9795 
Exposure time per image 2 Seconds 4 Seconds 3 Seconds 
Ligand / Substrate - - - NAD NADPH 
Cell parameters 57.9, 44.5, 
78.0Å, β=102.8º 
57.1, 42.7, 
77.1Å, β=102.5 º 
57.4, 44.0, 
78.5Å, β=102.5 º 
62.1, 46.8, 
77.7Å, β=97.7 º 
60.8, 46.4, 
77.5Å, β=98.4 º 
Maximum Resolution (Å) 1.85 2.0 1.90 2.25 1.95 
Matthew’s coefficient 2.18 2.04 2.12 2.48 2.40 
Solvent content (%) 43.60 39.70 42.11 50.51 48.86 
Rsymm (%) 
Overall/ outermost shell 8.1 / 24.8 8.5 / 31.8 11.1 / 33.1 11.1 / 27.3 7.3 / 21.3 
Completeness (%) 
Overall/ outermost shell 96.0 / 76.3 94.0 / 75.3 96.3 / 75.5 95.8 / 74.9 96.3 / 74.0 
I / σI 
Overall / outermost shell 13.12 / 3.86 11.90 / 1.94 9.11 / 3.31 10.85 / 3.0 13.60 / 4.18 
Data Multiplicity 
Overall / outermost shell 3.7 / 2.5 3.5 / 1.8 3.7 /2.7 3.7 / 2.1 3.8 / 2.6 
No. of reflections 
Total / Unique 317439 / 33361 364537 / 24824 325716 / 29974 209467 / 21369 359671 / 30820 
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Table 5.2: The molecular replacement solution statistics for CDTa-8.5 structure. The best solution is highlighted.

S_ RF TF theta phi chi tx ty tz TFcnt Rfac Scor 
S___1__1 83.22 -91.80 5.07 0.071 0.000 0.268 31.88 0.485 0.392 
S___2__1 0.00 0.00 0.71 0.082 0.000 0.255 3.21 0.581 0.142 
S___3__1 6.95 5.39 179.23 0.156 0.000 0.205 5.69 0.590 0.099 
S___9__2 160.22 -5.33 128.87 0.769 0.000 0.306 1.53 0.595 0.092 
S___4__5 34.23 102.54 174.58 0.798 0.000 0.289 2.41 0.598 0.083 
S__12_13 52.98 26.26 90.42 0.156 0.000 0.284 2.02 0.586 0.081 
S___7__5 157.78 133.21 160.85 0.407 0.000 0.171 1.54 0.598 0.075 
S__10__7 48.00 -1.11 112.91 0.367 0.000 0.278 1.07 0.595 0.069 
S__11__9 137.44 -5.69 56.61 0.055 0.000 0.244 1.58 0.591 0.062 
S___5__4 10 60.41 -176.68 53.70 0.098 0.000 0.308 1.89 0.594 0.061 
S___8__4 11 40.89 39.47 177.22 0.443 0.000 0.254 2.07 0.597 0.060 
S___6__5 12 41.12 43.55 165.57 0.220 0.000 0.268 1.38 0.600 0.050 
Table 5.3: Refinement statistics for the first round of restrained refinement (10 cycles) for CDTa-8.5 structure. The 
starting and ending values are highlighted in cyan and yellow colours respectively. 
Ncyc Rfact      Rfree  FOM -LL -LLfree  rmsBOND  zBOND  rmsANGL  zANGL  rmsCHIRAL
 0    0.4941     0.4793    0.398     177378.  9471.3     0.0050        0.208      1.230       0.507      0.094
 1    0.4341     0.4565    0.482     173289.  9318.0     0.0215        0.965      1.473       0.704      0.101
 2    0.4005     0.4328    0.553     170723.  9224.7     0.0169        0.723      1.561       0.718      0.103
 3    0.3796     0.4161    0.592     168959.  9156.3     0.0166        0.689      1.654       0.760      0.108
 4    0.3646     0.4017    0.621     167647.  9102.5     0.0172        0.720      1.739       0.799      0.116
 5    0.3525     0.3914    0.643     166603.  9061.2     0.0178        0.740      1.805       0.825      0.123
 6    0.3426     0.3827    0.660     165762.  9028.1     0.0186        0.772      1.865       0.850      0.130
 7    0.3347     0.3753    0.674     165047.  9002.4     0.0193        0.800      1.907       0.870      0.135
 8    0.3281     0.3704    0.685     164467.  8980.2     0.0199        0.824      1.955       0.894      0.140
 9    0.3224     0.3662    0.694     163974.  8963.4     0.0205        0.851      2.002       0.917      0.145
 10    0.3178     0.3640    0.701     163593.  8949.3     0.0211        0.870      2.040       0.934      0.149 
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Table5.4: The structure refinement statistics for all five CDTa structures.

CDTa-8.5 CDTa-4.0 CDTa-9.0 CDTa-NAD CDTa-NADPH 
Rcryst / Rfree (%) 19.97 / 23.91 21.98 / 27.96 20.97 / 25.95 20.46 / 26.50 20.46 / 25.99 
Ramachandran plot (%) 
Allowed / Generously allowed 
99.70 / 0.30 99.40 / 0.60 
RMSD bond angles (º) 0.94 1.08 1.00 1.15 1.06 
RMSD bond length (Å) 0.007 0.008 0.007 
Number of Protein atoms 3135 3137 3178 3157 3247 
Number of Water molecules 424 154 231 156 259 
Average B factor (Å2)-
protein atoms 
main chain / side-chain 
Water 
Ligand (NAD/NADPH) 
Glycerol 
19.39 
18.95 / 19.84 
28.99 
--
--
34.15 
33.55 / 34.74 
39.39 
--
--
25.35 
24.67 / 26.02 
32.58 
--
--
32.35 
31.91 / 32.78 
41.07 
43.10 
58.70 
30.99 
30.50 / 31.49 
39.86 
44.10 
53.60 
PDB ID 2WN4 2WN8 2WN5 2WN7 2WN6 
•	 Rsymm = ΣhΣi[|Ii(h) – <I(h)>| / ΣhΣiIi(h)], where Ii is the ith measurement and <I(h)> is the weighted mean of all 
measurements of I(h). Rcryst = Σh|Fo – Fc| / ΣhFo, where Fo and Fc are the observed and calculated structure 
factor amplitudes of reflection h, respectively. Rfree is equal to Rcryst for a randomly selected 5% of reflections not 
used in the refinement. 
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Figure 5.6: The Ramachandran plot for CDTa-8.5 structure.
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Figure 5.7: The Ramachandran plot for CDTa-9.0 structure.
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Figure 5.8: The Ramachandran plot for CDTa-4.0 structure.
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Figure 5.9: The Ramachandran plot for CDTa-NAD structure.

130

Figure 5.10: The Ramachandran plot for CDTa-NADPH structure.
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Overall Structure of CDTa 
C. difficile binary toxin (CDT) belongs to the class 4 of ADPRT 
superfamily. Toxins from this class target monomeric actin molecules in 
the target cell and are known as Actin-ADPRTs (Popoff and Boquet, 
1988). CDTa is the enzymatic component of CDT and ADP-ribosylates all 
three isoforms of actin. CDTa shares about 84% sequence identity with 
the enzymatic component of C. perfringens Iota toxin (Ia). The sequence 
identity between CDTa and the enzymatic component of C. botulinum C2 
toxin (C2I) is about 40% (Barth 2004). 
The crystal structure of Ia in complex with NAD and NADPH but 
not in its native form has been reported by Tsuge and co-workers (Tsuge 
et al., 2003). The crystal structure of C2I in its native form but not in 
ligand bound forms has recently been determined by Schleberger and co-
workers (Schleberger et al., 2006). Since both of these toxins belong to 
two different classes (Table 2.1) of Clostridial actin-ADPRTs (Mauss, 
1990), it is not possible to compare them at the atomic level. 
Irrespective of the variable sequence homology between different 
Actin-ADPRTs, they all possess similar three dimensional fold (Holbourn 
et al., 2006). A high degree of sequence conservation is reflected at the 
structural level when the three dimensional structure of CDTa is 
compared with those of previously reported crystallographic results on Ia 
from C. perfringens (Tsuget et al., 2003), C2I from C. botulinum 
(Schleberger et al., 2006) and the ADPRT component of vegetative 
insecticidal protein, VIP2 from Bacillus cereus (Han et al., 1999) (Table 
5.5 and Figure 5.11). 
Table 5.5: The structural comparison of CDTa with the known homologues 
(The r.m.s.d. values are shown in Å). The aligned length of the protein 
(number of Cα atoms) is shown in brackets. 
CDTa-NAD Ia-NAD C2I 
CDTa-NAD -- -- --
Ia-NAD (1GIQ) 1.02 (392) -- --
C2I (2J3X) 2.75 (382) 2.86 (401) --
VIP2-NAD (1QS2) 2.79 (378) 2.96 (390) 3.90 (386) 
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Figure 5.11: Crystal structures of the enzymatic component of different 
Actin-ADPRT binary toxins indicating overall three-dimensional fold of the 
molecule. (A) – CDTa (PDB ID - 2WN7) (Sundriyal et al., 2009), (B) – Ia (PDB 
ID - 1GIQ) (Tsuge et al., 2003), (C) – VIP2 (PDB ID - 1QS2) (Han et al., 
1999), and (D) – C2I (PDB ID - 2J3X) (Schleberger et al., 2006). Bound NAD 
is shown in sticks. 
However, substrate specificity (Table 2.1) of these toxins can not 
be explained from their structures. Perhaps the answer lies in the way 
these toxins interact with their ADP-ribose acceptor substrate i. e. actin. 
γ smooth muscle actin differs from the other two isoforms (α and β) of 
actin at the N-terminal only and therefore it was suspected that perhaps 
this region is primarily responsible for substrate recognition by different 
Clostridial binary toxins (Vendekerckhove and Weber, 1979). The crystal 
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structure of Ia in complex with actin has been determined (Tsuge et al., 
2008) but no structure for C2I-actin complex is available to compare with 
it. 
All five CDTa structures superimpose well on Ia, C21 and VIP2 
(Table 5.5). The overall structure of CDTa matches extremely well with 
that of Ia (Table 5.5, r.m.s.d. = 1.02 Å) except the ADP ribosyl turn turn 
(ARTT) loop region (discussed in detail later). Enzymatic components of 
Clostridial binary toxins (Figure 5.11 A, B and D) are composed of two 
mixed alpha-beta globular domains (Han et al., 1999; Tsuge et al., 2003; 
Schleberger et al., 2006). In CDTa, the N terminal domain extends from 1 
to 215 residues whereas the C terminal domain is from 224-420. The two 
domains of the protein are linked by a loop that stretches from residue 
216 to 223 (Figure 5.12). 
Figure 5.12: Overall structure of CDTa (cartoon representation) with NAD 
bound to the catalytic cleft (shown in sticks) 
The N-terminal domain of CDTa consists of 5 alpha helices and 8 
beta strands and is believed to interact with its translocation partner (i. 
e. CDTb in this case) during the process of translocation (Tsuge et al., 
2003). The C-terminal domain of the protein also comprises of 5 alpha 
helices and 8 beta strands and accommodates catalytic machinery of the 
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protein (Figure 5.12). Both domains are arranged almost perpendicular to 
each other but facing their clefts towards the same face of the protein 
similar to their organisation in VIP2, Ia or C2I (Han et al., 1999; Tsuge et 
al., 2003; Schleberger et al., 2006). Numbering of secondary structure 
elements in CDTa (Figure 5.12) follow the secondary structure 
assignment as in Ia (Tsuge et al., 2003). 
As in other Actin-ADPRTs, both domains of the protein adopt a 
similar fold despite very low sequence identity (18% in case of CDTa) 
between them and this has been suggested to be a result of a gene 
duplication effect (Han et al., 1999). In CDTa, both domains superimpose 
onto each other with an r.m.s.d. of 2.62 Å (Figure 5.13). 
Figure 5.13: Superimposition of the N-terminal (Green) and the C-terminal 
(Cyan) domains of CDTa on each other with bound NAD to the C-terminal 
domain. 
Catalytic Cleft and Binding of NAD and NADPH 
The enzymatic component of C. perfringens iota toxin (Ia) is the 
closest homologue of CDTa, sharing about 84% sequence identity 
between them. Amino acid residues that have been suggested essential 
for the ADP ribosylating activity of Ia (Arg-295, Arg-296, Arg-352, Gln-
300, Asn-335, Glu-378 and Glu-380) (van Damme et al., 1996) are well 
conserved in CDTa (Arg-302, Arg-303, Arg-359, Gln-307, Asn-342, Glu-
385 and Glu-387) (Table 5.6). 
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Our present structural analysis has shown that both, NAD and 
NADPH bind to the catalytic cleft of CDTa in a ‘closed conformation’ 
interacting with residues Arg-302, Arg-303, Arg-359, Gln-307, Asn-342 
and Ser-345 (Figure 5.14). This is analogous to the structural 
observations made with Ia (Figure 5.14) with the NAD molecule 
interacting with residues Glu-380, Arg-295, Arg-296, Arg-352, Gln-300, 
and Asn-335 (Tsuge et al., 2003). 
Table 5.6: The positional conservation of catalytically important residues 
in Ia and CDTa. Blue – residues directly interacting with NAD/ NADPH, 
Red – suggested residues to interact with Actin, Black – other important 
residues in the active site. 
Based on these observations (Figure 5.14 and Table 5.6) it is 
interesting to note that in CDTa, Glu-387, which corresponds to Glu-380 
in Ia does not seem to interact either with NAD or with NADPH (Table 
5.6, Figures 5.14 and 5.15). However, Ser-345 in CDTa seems to be an 
important residue in the catalytic site and makes direct interactions with 
the ligand in both NAD and NADPH complex structures. These 
observations point out that even between these two close homologues 
(CDTa and Ia), the mode of ligand recognition is significantly different 
(Table 5.6 and Figure 5.14). 
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Figure 5.14: A schematic representation of Hydrogen bonding of NAD to CDTa (top) and Ia (bottom). 
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Gln-307 is an important residue in the catalytic cleft and makes 
direct interactions with both ligands i. e. NAD and NADPH in their 
respective complex structures. Gln-307 adopts similar orientation in all 
native CDTa structures with its side chain leaning towards the catalytic 
cleft. Dual conformation of Gln-307 was observed in the CDTa-NAD 
complex (Figures 5.14 and 5.15 A). 
Figure 5.15: Binding of (A) – the NAD and (B) – the NADPH to CDTa. The 
broken black lines show possible hydrogen bonds (based on distances). 
It seems that Gln-307 moves towards and away from the cleft and 
that its interaction with NAD in CDTa is not static but dynamic in nature 
(Figure 5.15 A). In CDTa-NADPH complex, Gln-307 has been pushed 
permanently away from the cleft by the phosphate group of NADPH 
which accommodates itself but still making direct interaction with it to 
stabilise the complex (Figure 5.15 B). Thus, Gln-307 seems to be one of 
the key residues for ligand-enzyme complex stability. A similar 
displacement of equivalent Gln residue (Gln-300) side chain has been 
reported in Ia-NADPH structure but its dual conformation has not been 
observed in Ia-NAD structure (Tsuge et al., 2003). Authors could not 
compare this movement of Gln-300 with native Ia because of non-
availability of crystals of Ia in its native form. Table 5.7 lists all hydrogen 
bond interactions to compare the binding of NAD and NADPH to CDTa. 
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Table 5.7: The hydrogen bond interactions of CDTa with NAD and 
NADPH. 
CDTa-NAD CDTa-NADPH 
Bonded residues (Atoms) Length 
(Ǻ) 
Angle 
(0) 
Length 
(Ǻ) 
Angle 
(0) 
R302 (NH1) – NADPH (O1A) - - 3.38 149.2 
R302 (NH2) – NAD / NADPH (O1A) 2.92 158.7 3.34 151.5 
R303 (N) – NAD / NADPH (O7N) 2.67 150.9 2.68 161.8 
R303 (O) – NAD / NADPH (N7N) 3.09 - 3.08 -
S345 (OG) – NAD / NADPH(O2D) 3.12 139.1 3.0 148.9 
N342 (OD1) – NAD / NADPH (N6A) 3.06 - 2.98 -
R359 (NH1)– NAD / NADPH (O1N) 2.71 164.1 2.40 154 
R359 (NH2) – NAD / NADPH (O2N) 2.82 154.0 2.89 127.8 
Q307 (N) – NAD / NADPH (O3X) - - 2.48 160.9 
Q307 (NE2) – NAD (O3B) / NADPH 
(O1X) 
2.60 94.1 2.71 103.5 
Ligand Binding and ARTT Loop 
It has been well established that in ADPRTs the ADP-ribosyl turn-
turn (ARTT) loop is important for substrate binding and ADP-ribosylation 
even though the length of the loop varies among these proteins (Holbourn 
et al., 2006). The ARTT loop in Ia spans from residue 370 to 380 (Tsuge 
et al., 2003). In CDTa, this loop (connecting strands β13 and β14) spans 
from residues 377 to 387 and consists of two sharp turns as in Ia or 
C3Bot (Tsuge et al., 2003; Han et al., 2001). 
Conformational changes in the ARTT loop induced by NAD binding 
have been reported for C3Bot toxin (Menetery et al., 2002). These 
conformational changes in the loop, however, have not been claimed with 
confidence in Ia due to the non-availability of the same crystal form for 
native Ia. Authors (Tsuge et al., 2003) suggested that in Ia, it was 
possible to have similar conformational changes in the ARTT loop as a 
result of NAD binding and that these conformational changes in the loop 
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possibly disturbed the molecular packing in the crystal and prevented 
the authors from having native Ia and Ia-NAD crystals in the same form. 
With CDTa, we have overcome this problem and have determined 
the crystal structure of CDTa in its native form as well as in complex 
with NAD and NADPH in the same crystal forms (Tables 4.2 and 5.1). 
Hence, a direct comparison between native CDTa structures at acidic 
(CDTa-4.0) as well as at basic pH (CDTa-9.0) with ligand bound 
structures was possible. 
The ARTT loop in CDTa is found to be associated with significant 
disorder and high conformational flexibility in all three native structures 
as observed from their electron density maps. However, upon ligand 
(NAD/NADPH) binding, the loop adopts a highly ordered structure 
(Figure 5.16) associated with some critical changes in the orientation of 
side-chains in the catalytic site when compared with Ia. 
Electron density for both of the proposed catalytically important 
residues (Glu-385 and Glu-387) of the EXE motif in the ARTT loop was 
well defined in all five structures. The EXE motif adopts similar 
orientation in all structures (Figure 5.17). Ligand binding seems to 
stabilise the loop and electron density for the whole loop was clearly 
visible (Figure 5.16). This finding from two different ligand bound 
structures (CDTa-NAD and CDTa-NADPH) suggests that although the 
ligand binding stabilises the loop, it does not induce any specific large 
conformational changes in the loop as suggested for C3Bot (Menetrey et 
al., 2002) or proposed for Ia (Tsuge et al., 2003). 
C3Bot belongs to the Rho-ADPRT superfamily that targets Rho 
proteins. Phe-209, the conserved aromatic residue in the ARTT loop of 
C3Bot has been shown to be essential for substrate binding (Han et al., 
2001). This residue corresponds to Tyr-375 in Ia, Tyr-382 in CDTa, Phe-
423 in VIP and Phe-384 in C2I but its functional implications have not 
been discussed for any of these structures. 
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Figure 5.16: Electron density around the ARTT loop in (A) – CDTa 9.0, and (B) – CDTa-NAD structure. Disorder in the loop region 
can be seen clearly in the form of breaks in the electron density and the noise (red coloured density). 2Fo-Fc and Fo-Fc maps are 
shown at 1σ and 3 σ contour level respectively. 
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Han and co-workers (Han et al., 2001) have suggested that the 
solvent exposed side chain of Phe-209 in C3Bot may have a possible role 
in Rho protein binding to the enzyme. They further suggested that the 
absence of any other hydrophobic residue near Phe-209 in the protein 3-
dimensional structure will lead to significant conformational changes in 
the protein in order to bury Phe-209. In the crystal structure, the 
authors have reported that Phe-209 of the protein interacts 
hydropobically with Phe-49, Trp-58 and Ile-124 of the non-
crystallographic symmetry related molecule in the crystal in order to 
stabilise the structure. 
The side chain of Tyr-382 (a conserved critical aromatic residue 
known to be important in ADPRTs) in the ARTT loop was not visible in 
the CDTa-8.5 and CDTa-4.0 structures. It could be modelled in the 
CDTa-9.0, CDTa-NAD and CDTa-NADPH structures. However, 
interestingly, it adopts a different orientation in the native (CDTa-9.0) 
and ligand bound forms (Figures 5.17 and 5.18) which seems to be 
crucial for stabilisation of the protein-ligand complex. In the native CDTa 
structure, Tyr-382 stacks itself with Phe-126 of the symmetry related 
molecule similar to that seen in C3Bot. In the ligand bound structures, 
Tyr-382 flips inside towards the catalytic cleft and adopts a similar 
orientation in both of the complexes (CDTa-NAD and CDTa-NADPH) and 
interacts with Glu-387 (of EXE motif) which is considered an important 
catalytic residue (Figure 5.17). 
This movement of Tyr-382 would make it unavailable for an 
interaction with the substrate molecule unlike in C3Bot. Tyr-375 of Ia 
was also found in an inward flipped orientation in Ia-NAD structure 
(Figure 5.18). However, a recent report on Ia-Actin complex structure 
reveals that Tyr-375 of Ia in the complex adopts a similar inward flipped 
side chain orientation and does not interact with its substrate i. e. Actin 
(Tsuge et al., 2008). 
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Figure 5.17: A stereo view of the orientation of ARTT loop in CDTa in 
native and NAD bound form. Green – CDTa-8.5, Yellow – CDTa-9.0, 
Magenta – CDTa-4.0, Cyan – CDTa-NAD. Green – CDTa-8.5, Yellow – 
CDTa-9.0, Cyan – CDTa-NAD, Magenta – Ia-NAD. (The residue numbering 
is according to CDTa. The corresponding residues in Ia are Tyr-375, Glu-
378 and Glu-380. 
Figure 5.18: A stereo view of the ARTT loop in CDTa (native and NAD 
bound form) and Ia (NAD bound form). Green – CDTa-8.5, Yellow – CDTa-
9.0, Cyan – CDTa-NAD, Magenta – Ia-NAD. (The residue numbering is 
according to CDTa. The corresponding residues in Ia are Tyr-375, Glu-378 
and Glu-380. 
EXE Motif and STS Motif 
The EXE motif present in the ARTT loop has been considered 
important for ligand binding (Han et al., 2001; Han and Tainer, 2002). 
Glu-378 and Glu-380 form the EXE motif in Ia and correspond to Glu-
385 and Glu-387 in CDTa. 
Site-directed mutagenesis of Glu-378 and other catalytically 
important residues in Ia have been studied in detail by Nagahama and 
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co-workers (Nagahama et al., 2000). Results of their study suggest that 
Glu-378 plays a crucial role in stabilising substrate-enzyme complexes 
and catalysis. Its mutation to Ala resulted in the complete loss of 
NADase, ARTase, cytotoxic and lethal activity of Ia indicating that the 
carboxylic group of Glu-378 is essential for these activities. However, the 
kinetic analysis suggests that Glu-378 is essential for catalytic activity of 
Ia but not required for binding to NAD. Mutagenesis data from the same 
study suggests that Glu-380 is also not required for NAD binding in Ia. 
Glu-380 has been shown to interact directly with NAD in the Ia-
NAD complex whereas both residues (Glu-378 and Glu-380) are at 
hydrogen-bonding distance from NADPH in the Ia-NADPH complex 
(Tsuge et al., 2003). The binding of NADPH to Ia has not been discussed 
by the authors. In CDTa, however, the structurally equivalent Glu 
residues (Glu-385 and Glu-387) are not involved in direct interaction 
with either NAD or NADPH. (Figures 5.14 and 5.15, Tables 5.6 and 5.7). 
Figure 5.19: A stereo representation of superimposition of the catalytic 
machinery of CDTa and Ia with bound NAD. Green – CDTa-NAD, Cyan – Ia-
NAD. The residues numbering is according to CDTa. 
In addition, Glu-385 (corresponding to Glu-378 in Ia) adopts 
different orientation all together in CDTa (Figure 5.18). In Ia, the side 
chain of Glu-378 points towards the ligand binding cleft whereas in all 
five CDTa structures determined so far, it points away from the cleft 
eliminating possibilities of its interaction with any of the two studied 
ligands (Figure 5.19). No interaction of these two residues of CDTa (Glu-
385 and Glu-387) with NAD or NADPH still resulting in stable complex 
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formation suggests that the EXE motif is perhaps not necessary for the 
ligand binding and stabilisation of the complex in CDTa. This finding 
agrees with the results of mutational studies by Nagahama and co-
workers (Nagahama et al., 2000) on Ia. 
Ser-345, Thr-346 and Ser-347 together constitute the STS motif in 
CDTa. This motif corresponds to Ser-338, Thr-339 and Ser-340 in Iota 
toxin (Ia). Replacement of Ser-338 to Ala or Cys in Ia did not result in the 
complete loss of activity and suggests that the hydroxyl group of Ser-338 
is not essential for catalytic activity (Nagahama et al., 2000). However, its 
replacement to amino acids with a larger side chains such as Phe results 
in complete loss of ADPase activity (Nagahama et al., 2000). Ser-345 in 
CDTa occupies the equivalent position of Ser-338 in Ia. In CDTa Ser-345 
is situated very close to the active site cleft. Based on the structural 
observation it is clear that (as in Ia) the replacement of Ser-345 with a 
larger residue would abrogate substrate binding by not allowing the ADP-
ribose donor to sit into the cleft properly. 
Furthermore, in all CDTa structures, Ser-345 and Glu-387 sit in 
close proximity to each other and form a strong hydrogen bond (2.4-
2.7Å). Ser-345 makes a direct hydrogen bond with both NAD/NADPH in 
their respective complex structures. This is a significant difference 
observed based on the structural data from Ia where Glu-380 makes 
direct interaction with the ligand rather than Ser-338 (Tsuge et al., 
2003). However, in Ia-NAD structure, Ser-338 of the STS motif is also 
positioned at a hydrogen bonding distance from the NAD molecule 
(Figure 5.19) but its implications have not been discussed by the authors 
(Tsuge et al., 2003). Based on these structural results and in the light of 
results from the study of Nagahama and co-workers (Nagahama et al., 
2000) on Ia, it is tempting to suggest that Ser-345 in CDTa appears to 
have a crucial role in ligand binding and perhaps in catalysis as 
speculated by Tsuge et al. (Tsuge et al., 2003). 
Effect of Ligand Binding on ARTT loop Stability 
A crucial difference between the ligand binding pattern of Ia and 
CDTa is the involvement of Ser-345 of CDTa in ligand binding. In CDTa, 
OG atom of Ser-345 makes a hydrogen bond interaction with O2D atom 
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of NAD/ NADPH (Table 5.7) whereas, in Ia, Glu-380 interacts with the 
same atom of the ligand (Figure 5.14). 
Ser-345 and Glu-387 of CDTa (Ser-338 and Glu-380 of Ia) are 
positioned at close proximity with a strong hydrogen bond between them 
in all five CDTa structures (Figure 5.20). Thus the side chain of Glu-387 
of ARTT loop is held from one end by Ser-345 in all native as well as 
ligand bound CDTa structures (Figure 5.20). However, in this situation, 
the side chain of Glu-387 is still free to move in the ligand binding cleft in 
a hinge-like motion in all native structures. This freedom is perhaps 
translated throughout the loop exhibiting the observed flexibility in the 
loop region (Figure 5.16 A) in the absence of ligand. 
On ligand binding, Try-382, a conserved aromatic residue at the 
centre of the ARTT loop, flips towards the catalytic cleft to form a 
hydrogen bond with Glu-387 from the other side of its side chain (Figure 
5.20). Fixing the side chain of Glu-387 from both sides restricts its 
movement in the cleft which otherwise could have abrogated the ligand 
binding. This restricted movement of Glu-387 could be the possible 
reason for the improved stability in the ARTT loop region upon ligand 
binding (Figure 5.16 B). 
Other Important Residues 
Glu-301, Tyr-246, Asn-255 and Phe-349 have also been suggested 
to play an important role in the enzymatic activity of Ia (Tsuge et al., 
2003). In CDTa, Glu-308 (Glu-301 in Ia) does not seem to participate in 
ligand binding directly but stays close to Arg-302 (Arg-295 in Ia) which 
interacts with the ligand directly (Figure 5.15). Replacement of Glu-301 
to Ala in Ia resulted in the complete loss of NADase and ARTase activity 
of enzyme (Nagahama et al., 2000). 
Our structural analysis shows that Glu-308 holds Arg-302 in 
position by hydrogen bonding to form an optimal interaction with the 
ligand (Figure 5.20). A similar role can be attributed for residues Tyr-253 
and Asn-262 (Tyr-246 and Asn-255 in Ia). Tyr-253 forms a hydrogen 
bond with Asn-262 and thus restricts its movement. Asn-262 further 
restricts the movement of Asn-342 (Asn-335 in Ia) and places it optimally 
for interaction with NAD/NADPH (Figures 5.15 and 5.20). 
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Figure 5.20: The arrangement of residues in the CDTa catalytic cleft. 
Green – CDTa-9.0, Cyan – CDTa, Magenta – CDTa-NADPH. The residues 
numbering is according to CDTa. 
Phe-356 (Phe-349 in Ia) adopts similar orientation in all five CDTa 
structures. The side-chain of Phe-356 is relatively mobile in the three 
native structures. However, in the ligand bound structures its orientation 
is rearranged and provides stacking interactions against the nicotinamide 
ring of the ligand thus preventing its (nicotinamide ring’s) rotation in the 
plane. This fixed rotation of nicotinamide ring is further stabilised by 
Arg-303 through hydrogen bonding similar to the observations made with 
Ia (Figure 5.15). This network of interactions facilitates tight binding of 
the ligand at the active site. 
pH Induced Catalytic Site Flexibility 
In order to understand the active site flexibility in CDTa, the native 
structures were determined at three different pH levels- 4.0, 8.5 and 9.0. 
It is suggested that the highly acidic pH of the endosomal compartment 
(~4.0) induces a drastic conformational change in CDTa which facilitates 
its translocation into the cytosol through the heptameric CDTb pore 
(Barth et al. 2000; Simpson, 1989). It was thought that the crystal 
structure at low and high pH levels (CDTa-9.0 and CDTa-4.0) under the 
identical conditions of crystal growth would help in analysing the pH 
induced conformational changes within the protein. 
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All native CDTa structures superimpose well with an rmsd of 
0.63Å (Table 5.8). However, clear ‘conformational flexibility’ was observed 
among these structures in the active site (i. e., functionally important 
part). This was confined to the ARTT loop between strands β13 and β14 
(Figure 5.17) and the loop between strand β9 and helix α10 named ‘loop 
304’ (Figure 5.21). 
Table 5.8: The structural comparison of all different CDTa structures. 
Protein/Protein CDTa-8.5 CDTa-4.0 CDTa-9.0 CDTa-NAD 
CDTa-8.5 -- -- -- --
CDTa-4.0 0.63 (386) -- -- --
CDTa-9.0 0.35 (389) 0.54 (389) -- --
CDTa-NAD 0.71 (391) 0.85 (387) 0.65 (390) --
CDTa-NADPH 0.62 (391) 0.88 (389) 0.74 (394) 0.37 (392) 
Figure 5.21: The orientation of loop 304 which shows differences 
between CDTa-4.0 and other CDTa structures. Yellow – CDTa-9.0, 
Magenta – CDTa-4.0, Cyan – CDTa-NAD. 
This flexibility was more pronounced in the CDTa-4.0 structure 
and was consistent with the analysis of crystallographic temperature 
factors (Table 5.9) which provides an opportunity to obtain a relatively 
unbiased picture of the mobility of different parts of the structure. Indeed, 
these regions adopt a more stable structure at a higher pH (e. g. 8.5 and 
9.0) and NAD/NADPH complex structures of CDTa. Although this region 
is clearly influenced by the conditions required to obtain crystals (which 
are identical for the CDTa-4.0 and CDTa-9.0 structures except for the pH 
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of the crystallisation buffers) the innate flexibility may be important in the 
translocation of the enzymatic component (CDTa) of the toxin into the 
cytosol via receptor mediated early endosomal pathway. 
Table 5.9: Average B factors for the two flexible loop regions in different 
CDTa structures. 
Region (residue number) Average B factor 
CDTa-
8.5 
CDTa-
9.0 
CDTa-
4.0 
CDTa-
NAD 
CDTa-
NADPH 
Whole protein 19.39 25.35 34.15 32.35 30.99 
ARTT loop* (377-387) 
[Atoms] 
25.88 
[74] 
30.56 
[68] 
40.37 
[60] 
40.53 
[81] 
40.49 
[81] 
Loop 304 (304-325) 
[Atoms] 
21.05 
[175] 
34.02 
[175] 
41.61 
[171] 
34.41 
[175] 
35.77 
[175] 
* The modelled length of ARTT loop varies in different structures 
However, no appreciable conformational changes could be 
observed as a result of pH change in different structures and all three 
CDTa structures- CDTa-4.0, CDTa-8.5 and CDTa-9.0 superimpose well. 
Similar studies with the enzymatic component of C. botulinum C2 toxin 
(C2I) also did not show any such pH induced conformational changes 
(Schleberger et al., 2006). It is possible that these changes take place at 
acidic pH and it is quite likely that the presence of the translocation 
partner may be required to facilitate these conformational changes. 
Mechanistic Implications 
Currently available structural and biochemical data on ADPRTs, i. 
e., the conservation of catalytic site apparatus and NAD binding suggest 
a common catalytic mechanism based on nuclephilic substitution (SN) – 
either an SN1 or SN2 type reaction (Tsuge et al., 2003; Tsuge et al., 2008). 
A nucleophilic substitution reaction involves an electron pair 
donor (the nucleophile, Nu) with an electron pair acceptor (the 
electrophile) where a sp3-hybridised electrophile must have a leaving 
group (X) in order for the reaction to take place. The nucleophilic 
substitution reactions can proceed via two mechanisms – 
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An SN1 (substitution nucleophilic order 1) reaction is a first order 
chemical reaction where the attack by the nucleophile and the departure 
of the leaving group occurs in two separate steps. An SN1 reaction 
proceeds via formation of a planar carbenium ion in the first step, which 
is then, in second step, attacked by the nucleophile (Figure 5.22 A). The 
rate limiting step in an SN1 reaction is the first step i. e. the formation of 
carbenium ion. A higher stability of carbenium ion is a favourable 
condition for a reaction to take place via the SN1 mechanism. 
Figure 5.22: A schematic representation of the progression of an SN1 
reaction (A) and an SN2 reaction (B). 
On the other hand, an SN2 (substitution nucleophilic order 2) 
reaction is a second order reaction where the departure of the leaving 
group (formation of carbenium ion) takes place simultaneously with the 
backside attack by the nucleophile (Figure 5.22 B) and hence the 
reaction completes in one step. The rate of the SN2 reaction is determined 
by the ease of simultaneous nucleophilic attack and the departure of the 
leaving group. However, these are not the only factors determining the 
rate of the reaction. 
The SN2 reaction mechanism in class 4 ADPRTs has been 
proposed based on the structural analysis of VIP2 (Han et al., 1999). In 
the case of Ia, progression of the SN2 reaction has been postulated via 
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two possible ways. In the first hypothesis, guanidium group of Arg-177 of 
actin has been suggested to act as the nucleophile following its 
deprotonation by Glu-378 of the toxin. 
However, in the structure of Ia-Actin complex, it has been shown 
that Arg-177 of actin is positioned at a considerably long distance (7.0 Å) 
from Glu-378 of the toxin or the nicotinamide ring of NAD (Tsuge et al., 
2008). This eliminates the possibility of both – deprotonation of Arg-177 
by Glu-378 and a direct nucleophilic attack on ADP-ribose+ 
oxocarbenium ion by Arg-177 (Figure 5.23). Formation of the ADP-
ribose+ oxocarbenium ion has been suggested to be a spontaneous 
process driven by the specific highly folded conformation of NAD (Figure 
5. 4 B) in the catalytic cleft (Tsuge et al., 2003; Tsuge et al., 2008). 
Figure 5.23: A stereo representation of distances between the catalytic 
centre (C1D of NAD) and deprotonting Glu (Glu-385 in CDTa, Glu-378 in Ia). 
Green – CDTa-NAD, Cyan – Ia-NAD, Magenta – Ia of Ia-Actin, Orange – 
Actin of Ia-Actin. All distances shown are in Å units. 
Superimposition of CDTa-NAD and Ia-NAD complexes on Ia-Actin 
complex reveals that the toxin (Ia) does not undergo any large 
conformational change upon actin binding. It indicates that in the case of 
CDTa also, the SN2 reaction via direct nucleophilic attack by Arg-177 of 
actin would not be possible (Figure 5.23). 
Alternatively, for Ia, it was suggested that a water molecule that 
was present near the NMN (Nicotinamide mono nucleotide) ring (~4.0 Å) 
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could be a possible nucleophile. However, this water molecule could be 
modelled only in one of the two molecules in the asymmetric unit with a 
high temperature factor (Tsuge et al., 2003). These findings rule out its 
role in mediating the SN2 reaction for Ia. 
In CDTa, in complex with either NAD or NADPH, there are at least 
two water molecules with reasonably low temperature factors near the 
nicotinamide ring. One of the water molecules seems to be important as 
it bridges NAD, Ser-345 and Tyr-253 in the complex (Figure 5.24). 
However, this water molecule which is closest to the reaction centre (C1D 
of NAD/NADPH) is present at a considerably large distance of 5.45 Å in 
the CDTa-NAD (Figure 5.24) and at 4.25 Å in the CDTa-NADPH complex 
structure. These observations make the SN2 mechanism of catalysis less 
preferred in the case of CDTa. 
Figure 5.24: The position of nearest water molecule in the catalytic centre 
and hydrogen bonding network. The bound NAD is shown in green colour. 
The water molecule is shown as sphere. Hydrogen bonds are shown using 
black broken lines. Distance of the catalytic centre (C1D of NAD) from the 
water molecule (5.50 Å) is shown using red broken line. 
For the ADP-ribosylation reaction to proceed via an SN1 mechanism, 
the formed oxocarbenium ion (ADP-ribose+) must be highly stable. In the 
case of Actin-ADPRTs, the SN1 reaction mechanism would involve 
formation of an isolated positively charged oxocarbenium intermediate 
with the direct stabilising electrostatic interactions from the negatively 
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charged carboxylate group of catalytic glutamate (Glu-380 in Ia) or 
hydroxyl group of serine (Ser-345 in CDTa). 
In Ia, the SN1 reaction mechanism has been proposed via two 
reaction intermediates where rotation of the primary oxocarbanium ion, 
resulting in the formation of a secondary cation has been suggested 
(Tsuge et al., 2008). In Ia-actin complex structure, loop II of Ia (between 
α7 and α8) undergoes significant conformational changes. As a result, 
Gly-249 of the loop seems to interact directly with Arg-177 (acceptor 
residue) of actin. These changes in the loop rearrange Tyr-246 and Tyr-
251 in Ia (Tyr-253 and Tyr-258 in CDTa) also. Tyr-251 in Ia is suggested 
to play a role in transferring the rotated positively charged ADP-ribose 
intermediate cation to the substrate (Tsuge et al., 2008). Previous 
mutational studies on both of these residues (Tyr-246 and Tyr-251) in Ia 
have been shown to have adverse effects on NADase as well as ARTase 
activity of the protein (Tsuge et al., 2003). 
Figure 5.25: A stereo representation of negatively charged residues 
surrounding the catalytic centre (C1D) of NAD. These residues probably 
contribute towards the stability of formed oxocarbenium ion. 
In CDTa, a similar SN1 mechanism could be followed. Based on our 
structural data it is clear that Ser-345 interacts with both of the ligands 
(NAD or NADPH) directly which is further surrounded by Glu-387, Tyr-
253, Tyr-258 and Tyr-382. The negatively charged environment created 
by these residues could play a crucial role in stabilising the formed 
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positively charged oxocarbenium ion, which is a favourable condition for 
an SN1 reaction to take place (Figure 5.25). 
We propose that in CDTa it is Ser-345 that stabilises the 
oxocarbenium ion (Figure 5.26, step A) by direct interactions and 
facilitates its transfer to Tyr-258 following its rotation (Figure 5.26, step 
B and C) in a similar way as it has been proposed for Ia (Tsuge et al., 
2008). 
Figure 5.26: The proposed SN1 mechanism of ADP-ribosylation of actin by 
CDTa (Adopted from Tsuge et al., 2008). Colour coding – Black-NAD, Red-
CDTa, Blue-Actin. 
Suggested rotation of the primary oxocarbenium ion (Figure 5.26 
step B to step C) overcomes two difficulties. Firstly, NAD binds in the 
catalytic cleft in a highly compact conformation which is a high energy 
state. By rotation around the P-O bond, the formed primary 
oxocabanium ion moves to a relaxed, low energy state and thus becomes 
more stable. Secondly, rotation of the primary oxocarbenium ion would 
bring it closer to the surrounding negatively charged residues (Figure 
5.25) and thus the stability of the secondary cation would be enhanced 
resulting in the SN1 mechanism favouring conditions. 
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In Ia, an SN1 mechanism is further proposed to be progressed via 
rearrangement in Arg-177 of actin (Tsuge et al., 2008). This 
rearrangement in actin would bring Arg-177 of actin very near to Glu-
378 (another conserved Glu of EXE motif) of Ia (Figures 5.26 and 5.27) 
(Tsuge et al., 2008). Glu-378 thus participates in the ADP-ribose transfer 
reaction by deprotonating the guanidium group of Arg-177. In addition to 
that, Glu-378 holds Arg-177 of actin in the catalytic centre. 
When compared with Ia, Glu-385 of CDTa (equivalent to Glu-378 in 
Ia), adopts a different orientation and sticks away from the catalytic cleft 
(Figures 5.18 and 5.27). In this orientation, rearrangement of Arg-177 of 
actin would still leave both of the residues at a considerable distance of 
about 7.0 Å from each other (Figure 5.27). How this different orientation 
of Glu-385 still mediates the catalysis is an open question to investigate. 
Figure 5.27: The representation of distances between catalytic Glu-385 
(378) of CDTa (Ia) and Arg-177 of Actin before and after the proposed 
rearrangement of Arg-177 (Tsuge et al., 2008). The figure was produced by 
superimposing CDTA-NAD structure on Ia-Actin complex structure. Cyan – 
Ia (Gul-378), Green – CDTa (Gul-385), Magenta – Actin (Arg-177) before 
rearrangement), Orange – Actin (Arg-177) after rearrangement. Distances 
(in Å units) are shown using broken lines. 
Our structural data shows that the ARTT loop is not directly 
involved in the ligand binding in any of the complex CDTa structures 
(Figures 5.14 and 5.15), and is free to rearrange itself further. It is 
tempting to suggest based on two different complex crystal structures 
(CDTa-NAD and CDTa-NADPH) that once the donor substrate (NAD/ 
NADPH) is cleaved followed by the formation of oxocarbenium ion, further 
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rearrangement of the ARTT loop can not be ruled out considering its high 
flexibility. 
The presence of a large open cavity near the active site cleft as 
observed in the Ia-actin complex (Tsuge et al., 2008) also supports the 
hypothesis of ARTT loop rearrangements upon actin binding. This 
rearrangement in the ARTT loop would bring Glu-385 of CDTa into the 
reaction centre to proceed with the transfer of ADP-ribose moiety to Arg-
177 of actin from Ser-345 via Tyr-258 (Figure 5.22, step C). However, this 
hypothesis needs to be validated by direct structural evidence of CDTa in 
complex with actin, in combination with functional dissection of key 
residues by site-directed mutagenesis. 
SUMMARY 
CDTa and Ia belong to the actin-ADPRT family that irreversibly 
modify monomeric actin molecules by transferring the ADP ribose moiety 
of NAD/NADPH to Arg-177 of actin. Based on our structural data, 
despite high homology at primary sequence, structural as well as 
functional level, the mode of donor substrate recognition in Ia and CDTa 
appears to be different. 
The enzymatic components of Actin-ADPRTs have been suggested 
to undergo a low pH induced conformational changes during the process 
of translocation from the early endosome to the cytosol. The observed 
conformational flexibility and enhanced level of disorder in two of the 
catalytically important loop regions of CDTa at low pH state provide 
preliminary evidence for these conformational changes. However, to 
understand the exact mechanism of translocation of CDTa as well as the 
transfer of ADP-ribose to actin by CDTa, additional input in terms of 
mutational studies and structures (such as CDTa-actin complex) are 
required. 
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Understanding of C. difficile binary toxin (CDT) is still in the 
initial stage. This thesis is a step towards the structural, functional 
and biological characterisation of C. difficile binary toxin. 
In this thesis, we report cloning, expression and purification 
methods for both of the components (enzymatic as well as 
transport) of CDT. Purification methods described (Chapter III) 
resulted in milligram quantities of proteins of high purity. The cell 
cytotoxicity effect of CDT were shown on Vero cells (Chapter IV). 
Various combinations of CDTa and CDTb concentrations were 
tested including two different versions of recombinantly expressed 
CDTb (named as CDTb′ and CDTb′′) and their chymotrypsin 
activated fragments. It is clear from the results that both of the 
purified components are active and the complete CDT has a 
definite cell killing potential. However, there are at least two 
questions yet to be answered. 
1- Variation in the concentrations of CDTa or CDTb did not yield 
in any observable changes in the number of dead cells. It is 
still not clear whether the concentration of CDTa or the 
chymotrypsin activated CDTb is the key step in the process of 
cell death by CDT. 
2- Recombinantly expressed mature fragment of CDTb (CDTb′′) 
resulted in relatively poor cell death (in combination of CDTa) 
when compared with its chemotrypsin activated fragment. The 
length of CDTb′′ during the expression was decided based on 
a report by Perelle and co-workers (1997). Our experimental 
data does not reveal why CDTb′′ is less active. It may possible 
that the N terminal part of active CDTb is important for its 
function. Furthermore, CDTb′′ was expressed as GST-CDTb′′ 
fusion protein and cleavage of the tag would still leave 4 to 5 
undesired residues from the PreScission protease recognition 
sequence at the N terminal of the mature protein. Could these 
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residues interfere with the activity of the protein, bearing in 
mind that chymotrypsin activation of CDTb′′ improves the 
number of dead cells significantly (Chapter IV). Another 
possibility could be that the activation site predicted by 
Perelle and co-workers may not be precise and we have, in 
reality, expressed a larger fragment than the required. This 
issue can however be resolved by the N terminal sequencing 
of CDTb′′ and chymotrypsin activated CDTb′ and then aligning 
both of the sequences against each other. The expressed 
CDTb′′ can not be shorter than the required mature fragment 
due to the fact that chymotrypsin activation of CDTb′′ 
improves cell death count. 
High resolution crystal structure of CDTa has been 
determined in its native from at low and high pH states as well as 
in ligand bound forms (Chapter V). The CDTa structure shows 
crucial differences in the donor substrate recognition pattern 
when compared with the closest homologue i. e. the enzymatic 
component of iota toxin (Ia) from C. perfringens. In CDTa, the 
crystallographic data suggests that it is Ser-345 and not Glu-387 
that plays a key role in the protein-ligand complex stabilisation. 
On the other hand, in Ia, the analysis of crystallographic data 
(Tsuge et al., 2003) indicates that Ser-338 and Glu-380 may play 
interchangeable roles in the protein-ligand complex stabilisation 
as both of these residues seem to interact directly with ligand. 
However, the authors have not discussed the binding of Ser-338 
with NAD. 
In CDTa, mutational studies are required to assign definitive 
functional roles to Ser-345 or Glu-387 in the ligand binding. 
Several sets of primers for point mutations in CDTa have been 
designed for this purpose (S345A, S345R, S345Y, S345F, E387A, 
E387R, E387F and E387D). Positive clones for S345A and S345F 
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have been constructed successfully. These primers can be used to 
produce double mutants as well (such as S345A/E387A) which 
would be advantageous to study the interchangeable role of S-345 
and E-387 in the ligand binding. 
NAD and NADPH are the donor substrates for CDTa and 
other similar toxins. The ADP-ribose part of NAD/NADPH is 
transferred to monomeric Actin by the action of these ADPRTs. The 
crystal structure of Ia in complex with actin at 2.8 Å has been 
reported by Tsuge and co-workers in 2008. Ia does not seem to 
undergo any significant conformational changes except in one of 
the loops which brings G-249 of Ia at a hydrogen bonding distance 
from R-177 of actin. It has been postulated that E-378 residue in 
the ARTT loop of Ia mediates transfer of the ADP-ribose to R-177 of 
actin. The corresponding residue in CDTa is E-385. However, when 
compared, we see that the side chain of E-385 of CDTa adopts 
entirely different orientation and points away from the catalytic 
cleft unlike in Ia (Chapter V). This difference in orientation leaves 
E-385 of CDTa at a longer distance from R-177 of actin when 
superimposed on the Ia-Actin structure. Though, owing to the 
flexibility in the ARTT loop, rearrangement/s in the loop can not be 
ruled out. 
The crystal structure of CDTa in complex with actin could 
provide a definitive answer regarding how this side chain 
orientation of E-385 still carries out an identical function in CDTa. 
Preliminary experiments towards achieving this goal are in 
progress. In addition, site directed mutagenesis studies of E-385 
could throw some light on this issue. Different sets of primers 
(E385A, E385R, E385F and E385D) have been designed for this 
purpose. 
CDTb, like the transport components of other binary toxins 
is believed to form a homo-heptameric complex upon activation by 
chymotrypsin. The crystal structure of the transport component of 
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C2 toxin from C. botulinum in monomeric form (Schleberger et al., 
2006) has been reported. However, at present, structural 
information about any of the Clostridial binary toxin transport 
components in the heptameric form is not available. In this regard, 
a well established protocol for the expression and purification of 
CDTb has been developed. Preliminary crystallisation hits for 
CDTb′ have produced crystals which are currently being optimised. 
In the long term, it would be exciting to be able to 
characterise the CDTb homo-heptameric complex alone and the 
CDTb homo-heptamer in complex with the bound CDTa. Till date 
there is no information available about the amino acid residues of 
CDTb which play a role in the heptamer formation as well as about 
the residues of CDTb and CDTa which facilitate the binding of 
CDTa to the CDTb heptamer. However, when the chymotrypsin 
activated CDTb′ was incubated overnight at 40C at low pH 
condition, a faint but clearly visible protein band corresponding to 
the oligomeric form was visible on the SDS-PAGE (Chapter IV). 
Further, the structure of CDTa-CDTb complex could be useful to 
understand the pH induced conformational changes in CDTa 
which have been considered important for the translocation of 
CDTa from the endosome to the cytosol. 
Further research on all thesis topics at the molecular level 
will be of great academic, therapeutic as well as industrial interest 
towards the development of treatments against C. difficile infection. 
Answers to these questions will enhance our understanding of C. 
diffiicile binary toxin which will be helpful in the elucidation of 
general principles in protein-protein recognition involving similar 
binary toxins such as C. perfringens iota toxin and C. botulinum C2 
toxin. 
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APPENDIX I 
AMINO ACID SEQUENCES OF C.

DIFFICILE BINARY TOXIN

COMPONENTS
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Amino Acid Sequence of Full Length Enzymatic Component (CDTa) 
of C. difficile Binary Toxin (CDTa) (Refer to Figure 2.5) 
MKKFRKHKRISNCISILLILYLTLGGLLPNNIYAQDLQSYSEKVCNTTY 
KAPIESFLKDKEKAKEWERKEAERIEQKLERSEKEALESYKKDSVEIS 
KYSQTRNYFYDYQIEANSREKEYKELRNAISKNKIDKPMYVYYFESPE 
KFAFNKVIRTENQNEISLEKFNEFKETIQNKLFKQDGFKDISLYEPGK 
GDEKPTPLLMHLKLPRNTGMLPYTNTNNVSTLIEQGYSIKIDKIVRIVI 
DGKHYIKAEASVVNSLDFKDDVSKGDSWGKANYNDWSNKLTPNELA 
DVNDYMRGGYTAINNYLISNGPVNNPNPELDSKITNIENALKREPIPTN 
LTVYRRSGPQEFGLTLTSPEYDFNKLENIDAFKSKWEGQALSYPNFIS 
TSIGSVNMSAFAKRKIVLRITIPKGSPGAYLSAIPGYAGEYEVLLNHGS 
KFKINKIDSYKDGTITKLIVDATLIP 
Amino Acid Sequence of Functionally Mature Fragment of 
Enzymatic Component (CDTa’) of C. difficile Binary Toxin (Refer to 
Figure 2.5) 
KVCNTTYKAPIESFLKDKEKAKEWERKEAERIEQKLERSEKEALESY 
KKDSVEISKYSQTRNYFYDYQIEANSREKEYKELRNAISKNKIDKPMY 
VYYFESPEKFAFNKVIRTENQNEISLEKFNEFKETIQNKLFKQDGFKD 
ISLYEPGKGDEKPTPLLMHLKLPRNTGMLPYTNTNNVSTLIEQGYSIKI 
DKIVRIVIDGKHYIKAEASVVNSLDFKDDVSKGDSWGKANYNDWSN 
KLTPNELADVNDYMRGGYTAINNYLISNGPVNNPNPELDSKITNIENA 
LKREPIPTNLTVYRRSGPQEFGLTLTSPEYDFNKLENIDAFKSKWEGQ 
ALSYPNFISTSIGSVNMSAFAKRKIVLRITIPKGSPGAYLSAIPGYAGEY 
EVLLNHGSKFKINKIDSYKDGTITKLIVDATLIP 
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Amino Acid Sequence of Full Length Transport Component (CDTb) of 
C. difficile Binary Toxin (Refer to Figure 2.5) 
MKIQMRNKKVLSFLTLTAIVSQALVYPVYAQTSTSNHSNKKKEIVNED 
ILPNNGLMGYYFSDEHFKDLKLMAPIKDGNLKFEEKKVDKLLDKDKS 
DVKSIRWTGRIIPSKDGEYTLSTDRDDVLMQVNTESTISNTLKVNMK 
KGKEYKVRIELQDKNLGSIDNLSSPNLYWELDGMKKIIPEENLFLRDY 
SNIEKDDPFIPNNNFFDPKLMSDWEDEDLDTDNDNIPDSYERNGYTI 
KDLIAVKWEDSFAEQGYKKYVSNYLESNTAGDPYTDYEKASGSFDK 
AIKTEARDPLVAAYPIVGVGMEKLIISTNEHASTDQGKTVSRATTNSKT 
ESNTAGVSVNVGYQNGFTANVTTNYSHTTDNSTAVQDSNGESWNTG 
LSINKGESAYINANVRYYNTGTAPMYKVTPTTNLVLDGDTLSTIKAQE 
NQIGNNLSPGDTYPKKGLSPLALNTMDQFSSRLIPINYDQLKKLDAGK 
QIKLETTQVSGNFGTKNSSGQIVTEGNSWSDYISQIDSISASIILDTEN 
ESYERRVTAKNLQDPEDKTPELTIGEAIEKAFGATKKDGLLYFNDIPID 
ESCVELIFDDNTANKIKDSLKTLSDKKIYNVKLERGMNILIKTPTYFTN 
FDDYNNYPSTWSNVNTTNQDGLQGSANKLNGETKIKIPMSELKPYKR 
YVFSGYSKDPLTSNSIIVKIKAKEEKTDYLVPEQGYTKFSYEFETTEKD 
SSNIEITLIGSGTTYLDNLSITELNSTPEILDEPEVKIPTDQEIMDAHKIY 
FADLNFNPSTGNTYINGMYFAPTQTNKEALDYIQKYRVEATLQYSGFK 
DIGTKDKEMRNYLGDPNQPKTNYVNLRSYFTGGENIMTYKKLRIYAIT 
PDDRELLVLSVD 
Amino Acid Sequence of Signal Peptide less Fragment of Transport 
Component (CDTb’) of C. difficile Binary Toxin (Refer to Figure 2.5) 
EIVNEDILPNNGLMGYYFSDEHFKDLKLMAPIKDGNLKFEEKKVDKL 
LDKDKSDVKSIRWTGRIIPSKDGEYTLSTDRDDVLMQVNTESTISNTL 
KVNMKKGKEYKVRIELQDKNLGSIDNLSSPNLYWELDGMKKIIPEEN 
LFLRDYSNIEKDDPFIPNNNFFDPKLMSDWEDEDLDTDNDNIPDSYE 
RNGYTIKDLIAVKWEDSFAEQGYKKYVSNYLESNTAGDPYTDYEKAS 
GSFDKAIKTEARDPLVAAYPIVGVGMEKLIISTNEHASTDQGKTVSRA 
TTNSKTESNTAGVSVNVGYQNGFTANVTTNYSHTTDNSTAVQDSNG 
ESWNTGLSINKGESAYINANVRYYNTGTAPMYKVTPTTNLVLDGDTLS 
TIKAQENQIGNNLSPGDTYPKKGLSPLALNTMDQFSSRLIPINYDQLK 
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KLDAGKQIKLETTQVSGNFGTKNSSGQIVTEGNSWSDYISQIDSISASI 
ILDTENESYERRVTAKNLQDPEDKTPELTIGEAIEKAFGATKKDGLLY 
FNDIPIDESCVELIFDDNTANKIKDSLKTLSDKKIYNVKLERGMNILIKT 
PTYFTNFDDYNNYPSTWSNVNTTNQDGLQGSANKLNGETKIKIPMSE 
LKPYKRYVFSGYSKDPLTSNSIIVKIKAKEEKTDYLVPEQGYTKFSYEF 
ETTEKDSSNIEITLIGSGTTYLDNLSITELNSTPEILDEPEVKIPTDQEIM 
DAHKIYFADLNFNPSTGNTYINGMYFAPTQTNKEALDYIQKYRVEATL 
QYSGFKDIGTKDKEMRNYLGDPNQPKTNYVNLRSYFTGGENIMTYK 
KLRIYAITPDDRELLVLSVD 
Amino Acid Sequence of Functionally Mature Fragment of Transport 
Component (CDTb’’) of C. difficile Binary Toxin (Refer to Figure 2.5) 
LMSDWEDEDLDTDNDNIPDSYERNGYTIKDLIAVKWEDSFAEQGYK 
KYVSNYLESNTAGDPYTDYEKASGSFDKAIKTEARDPLVAAYPIVGVG 
MEKLIISTNEHASTDQGKTVSRATTNSKTESNTAGVSVNVGYQNGFT 
ANVTTNYSHTTDNSTAVQDSNGESWNTGLSINKGESAYINANVRYYN 
TGTAPMYKVTPTTNLVLDGDTLSTIKAQENQIGNNLSPGDTYPKKGLS 
PLALNTMDQFSSRLIPINYDQLKKLDAGKQIKLETTQVSGNFGTKNSS 
GQIVTEGNSWSDYISQIDSISASIILDTENESYERRVTAKNLQDPEDKT 
PELTIGEAIEKAFGATKKDGLLYFNDIPIDESCVELIFDDNTANKIKDSL 
KTLSDKKIYNVKLERGMNILIKTPTYFTNFDDYNNYPSTWSNVNTTNQ 
DGLQGSANKLNGETKIKIPMSELKPYKRYVFSGYSKDPLTSNSIIVKIK 
AKEEKTDYLVPEQGYTKFSYEFETTEKDSSNIEITLIGSGTTYLDNLSI 
TELNSTPEILDEPEVKIPTDQEIMDAHKIYFADLNFNPSTGNTYINGMY 
FAPTQTNKEALDYIQKYRVEATLQYSGFKDIGTKDKEMRNYLGDPNQ 
PKTNYVNLRSYFTGGENIMTYKKLRIYAITPDDRELLVLSVD 
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